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Abstract !
! Programmable*site.speci1ic*endonucleases*are*useful*tools*for*genome*editing*and*may*lead*to*novel*therapeutics*to*treat*genetic*diseases.**TALENs*can*be*designed*to*cleave*chosen*DNA*sequences.**To*better*understand*TALEN*speci1icity*and*engineer*TALENs*with*improved*speci1icity,*we*pro1iled*30*unique*TALENs*with*varying*target*sites,*array*length,*and*domain*sequences*for*their*ability*to*cleave*any*of*1012*potential*off.target*DNA*sequences*using*in#vitro*selection*and*high.throughput*sequencing.**Computational*analysis*of*the*selection*results*predicted*76*off.target*substrates*in*the*human*genome,*16*of*which*were*accessible*and*modi1ied*by*TALENs*in*human*cells.**The*results*collectively*suggest*that*(i)*TALE*repeats*bind*DNA*relatively*independently;*(ii)*longer*TALENs*are*more*tolerant*of*mismatches,*yet*are*more*speci1ic*in*a*genomic*context;*and*(iii)*excessive*DNA.binding*energy*can*lead*to*reduced*TALEN*speci1icity*in*cells.**We*engineered*a*TALEN*variant,*Q3,*that*exhibits*equal*on.target*cleavage*activity*but*10.fold*lower*average*off.target*activity*in*human*cells.**Our*results*demonstrate*that*identifying*and*mutating*residues*that*contribute*to*non.speci1ic*DNA.binding*can*yield*genome*engineering*agents*with*improved*DNA*speci1icities.*
 Cas9 cleaves double-stranded DNA in cells at a sequence targeted by a short guide RNA 
(gRNA).  We used in vitro selection to determine the abilities of eight Cas9:guide RNA 
complexes to cleave off-target DNA sequences.  The selection results predicted five off-target 
substrates in the human genome that were confirmed to undergo genome cleavage in cells treated  
iii
Dissertation Advisor: Professor David R. Liu John Paul Guilinger
with Cas9:guide RNA complexes.  To improve the specificity of Cas9:guided RNA complexes 
we describe the development of a FokI nuclease fusion to a catalytically dead Cas9 that requires 
simultaneous DNA binding and association of two FokI-dCas9 monomers to cleave DNA.  Off-
target DNA cleavage of the engineered FokI-dCas9 is further reduced by the requirement that 
only sites flanked by two gRNAs ~15 or 25 base pairs apart are cleaved.  In human cells, fCas9 
modified target and off-target DNA sites with comparable efficiency to wild-type Cas9 nucleases 
but with > 140-fold higher specificity.  
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I.1  Introduction to site-specific nucleases for genome modification 
Site-specific nucleases that can be designed to target any sequence of DNA in a cell are 
powerful research tools with significant therapeutic implications.  In cells, site-specific nucleases 
bind a target DNA sequence.  A site-specific nucleases will then cleave both strands of DNA 
either within or nearby the targeted DNA resulting in double strand breaks.1,2  Double-strand 
breaks can be repaired through the cellular process of non-homologous end joining (NHEJ).  
Erroneous repair by NHEJ can cause stochastic DNA insertions or deletions that will likely shift 
the coding frame of a gene!effectively!resulting!in!targeted!gene!knockout.3–6  Alternatively, 
the double-strand break can efficiently recombine with exogenous DNA template homologous to 
the target site through homology-directed repair (HDR) for precise alterations to a target 
genomic sequence.7–10    Indeed, site-specific nucleases have already been used to modify 
targeted sequences in the genomes of a variety of organisms11–17 and human cell lines.18–20,8,4–6   
In addition to engineering the genomes of cells or organisms for direct biological 
interrogation, genetic screens have recently been performed with site-specific nucleases to 
uncover genetic factors underlying specific cellular processes in an unbiased manner21,22. Site-
specific nucleases could also serve as the basis of a new generation of human therapeutics and 
are currently in clinical trials as a potential cure for HIV.18  In this therapy,23 the CCR5 gene is 
knocked out with site-specific nuclease in a patients own T-cells, resulting in T-cells that lack the 
co-receptor encoded by CCR5 that is required for HIV infection.  Thus, site-specific nucleases 
represent an effective tool for clinically relevant genetic manipulation. 
In order to effectively modify a given DNA sequence, an optimal site-specific nuclease 
will be easily programmed to target many different DNA sequences, highly efficient at cleaving 
the target DNA and specifically cleave only the target DNA.  First, an ideal site-specific nuclease 
can be easily designed to target any DNA sequence with as little sequence constraints as 
possible.  Maximizing the targetable sequence space increases the number of potential genomic 
loci that can be modified for use in both basic science and therapeutics. Second, a site-specific 
nuclease should be able to efficiently and effectively cleave the target DNA sequence to 
maximize the amount of genetic modification.  Third, a site-specific nuclease should be as 
specific as possible cleaving only the target DNA sequence and not cleaving other sequences 
(Figure I.1).  
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Figure I.1.  Site-specific genome modification.  A programmable site-specific nuclease is 
shown that cleaves genomic DNA resulting in modification.  Modification of the target site and a 
potential off-target site is shown. 
 
The specificity of site-specific nucleases is imperative since the DNA-binding specificity 
of endonucleases has been inversely correlated with their cellular toxicity.24   The specificity of a 
site-specific nuclease is also critical because cleavage at unintended, off-target sites could 
confound any biological inquiry21 or worse introduce genetic malefactors in human therapies.  
Previous reports of gene therapies relying on viruses to deliver genes that integrate randomly into 
the genome highlight the need for more specific and precise genome modification.  Retroviral 
delivery and resulting random integration of a gene to express interleukin receptor gamma chain 
in children with severe combined immunodeficiency-X1 (SCID-X1) effectively cured nine out of 
ten children treated.25  However, two of the children developed leukemia likely from retroviral 
integration near the promoter of the LMO2 oncogene.26  Given the potential for integration into 
oncogenic loci, it is imperative that genes integrate at specific sequences known to be safe for 
integration.  Apart from directing integration of exogenous genes into defined genomic loci, it is 
also important that site-specific nucleases do not modify tumor suppressor genes potentiating 
malignant cells.  
Identifying genuine off-target sites cleaved by site-specific nucleases is challenging given 
the shear size of the human genome.  There will be at least ~3x109 potential “off-target” sites for 
every target site in the human genome, although the vast majority of these “off-target” sites will 
be very different from the target site, a fraction of these off-target sites will be similar to the on-
target site to some degree.  To identify off-target modification caused by a site-specific nuclease, 
ideally one would high-throughput sequence genomic DNA from cells or organisms treated with 
the site-specific nuclease searching for any off-target modification across the entire genome in an 
  
 
Disrupt problematic gene?!
     Off-target modification? On-target modification    
Disruption of target gene  
Programmable site-specific nuclease XGenomic DNA 
! 4!
unbiased study.  However, to sequence enough genomes to detect rare off-target modification 
events on the order of 1/10,000, it would cost a prohibitive amount of well over $300,000.27  
Unbiased high-throughput sequencing of the exome of human cells expanded from a single cell 
treated with a site-specific nuclease revealed that at least some site-specific nucleases do not 
cause widespread or highly abundant off-target cleavage.28,29  Another method to interrogate the 
specificity of site-specific nucleases in cells uses integrase-deficient lentiviral vectors 
(IDLVs),30,31 which can integrate at double-strand breaks caused by site-specific nucleases in 
cells.  While IDLV can be used to identify off-target cleavage in cells, it could be complicated by 
cellular factors such as DNA accessibility, which varies from site to site and between cell 
types,32 or DNA repair and integration pathways after cleavage that could obscure the 
determination of nuclease specificity.  IDLV may also suffer from high-background integration 
at double-strand breaks that arise naturally, independent of nuclease activity.  Purely cellular 
studies are also inherently limited to the stochastic handful of off-target sites in a given genome 
that are similar to the target sequence. 
Studies measuring the nuclease activity of a handful of closely related off-target 
substrates can yield useful information but cannot cover the number of potential off-target sites 
in genomes, which for some site-specific nucleases number more than 10,000.33,34   In order to 
evaluate the ability of site-specific nucleases to cleave a very large number of off-target sites 
required to estimate, predict and reliably identify off-target cleavage in cells, a broad and in-
depth study of specificity is necessary.  Sequential enrichment of ligands by exponential 
(SELEX) is a method used to identify numerous off-target sequences resulting in a more 
comprehensive specificity profile.4,8  Off-target DNAs are uncovered from interrogating an 
immense library potential off-target DNAs (~1014) for those members that bind to an 
immobilized DNA-binding domain of the site-specific nuclease. Alternatively, a high-throughput 
study of DNA-binding domains fused to a transcriptional activator domain (in place of the 
nuclease domain) can also describe specificity of the monomeric DNA-binding domains of site-
specific nucleases.35  While both the above activator and SELEX experiments can describe the 
DNA-binding specificities of the monomeric DNA-binding domains of some site-specific 
nucleases, the DNA cleavage specificities of active, dimeric nucleases can differ from the 
specificities of their component monomeric DNA-binding domains.36  Thus, the Liu lab has 
previously developed an in vitro selection to interrogate site-specific nucleases for their abilities 
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to cleave 1012 potential off-target DNA substrates.36   While the selection is preformed in vitro 
and not in cells, it does report on the specificity of active nucleases on a large number (~1012) of 
potential off-target sites and can be used to identify cellular off-target sites.36  Chapters 1 and 2 
apply this in vitro selection to profile the specificity of two different types of designer site-
specific nucleases, transcription activator-like effector nucleases (TALENs) and RNA-guided 
Cas9 nucleases. 
There are three major types of programmable site-specific nucleases: zinc finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and RNA-guided 
Cas9 nucleases (Cas9:gRNA).  ZFNs are fusions of the non-specific FokI restriction 
endonuclease cleavage domain with a zinc finger DNA-binding domain.  Zinc finger DNA-
binding domains consist of three to four individual zinc fingers in tandem repeats. Since each 
individual zinc finger specifically recognizing three base pairs,37 a zinc finger DNA-binding 
domain in total recognizes 9 bp or 12 bp.  ZFNs can be engineered to be active only as 
heterodimers through the use of obligate heterodimeric FokI variants.38,39  In this configuration, 
two distinct ZFN monomers are each designed to bind one target half-site resulting in cleavage 
within the DNA spacer sequence between the two half-sites.   While sophisticated methods32,40 
have been developed to generate zinc finger DNA-binding domains, the ease of designer zinc 
finger construction and the targetable sequence space of ZFNs remains limited.  More troubling 
for the use of ZFNs as genome editing agents, reports demonstrate potential widespread off-
target activity of ZFNs in cells.30,33,36   
TALENs are another type of designer site-specific nuclease which are fusions of the FokI 
restriction endonuclease cleavage domain with a DNA-binding TALE repeat array (Figure 
I.2).41   
! 6!
!
Figure I.2.  TALEN architecture.  A TALEN monomer contains an N-terminal domain (blue) 
followed by an array of TALE repeats (brown), a C-terminal domain (green), and a FokI 
nuclease cleavage domain (purple).  The 12th and 13th amino acids (the RVD, red) of each TALE 
repeat recognize a specific DNA base pair.  Two different TALENs bind their corresponding 
half-sites, allowing FokI dimerization and DNA cleavage.  
 
These arrays consist of multiple 34-amino acid TALE repeat sequences, each of which uses a 
repeat-variable di-residue (RVD), the amino acids at positions 12 and 13, to recognize a single 
DNA nucleotide.42,43  Examples of RVDs that recognize each of the four DNA base pairs are 
known, enabling arrays of TALE repeats to be constructed that can bind virtually any DNA 
sequence.  Like ZFNs, TALENs can be engineered to be active only as heterodimers through the 
use of obligate heterodimeric FokI variants.  In this configuration, two distinct TALEN 
monomers are each designed to bind one target half-site resulting in cleavage within the DNA 
spacer sequence between the two half-sites.    
Numerous studies have reported on the specificities of individual TALE repeats.44–48 The 
specificity of individual repeats determines the specificity of the array of repeats, but it is not 
clear exactly how repeats may interact with each other or if there is interedepence between the 
specific binding of TALE repeats.  Chapter 1 demonstrates that individual TALE repeats bind 
their respective DNA base pairs relatively independently.  Other studies8,31,49,50 and Chapter 1 
demonstrate that TALENs can induce off-target modification in cells.  Chapter 1 also broadly 
profiles the specificity of TALENs using the specificity profiles to predict and estimate off-target 
cleavage in cells.  Chapter 1 also discusses a model of excess DNA-binding energy derived from 
the specificity profiling of TALENs, which is then used to engineer TALEN variants with 
improved specificity in cells. 
5’ TTCATTACACCTGCAGCT     N10-24     AGTATCAATTCTGGAAGA!
3’ AAGTAATGTGGACGTCGA     N10-24     TCATAGTTAAGACCTTCT!
TALE repeats FokI 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG!
RVD 
RVD code 
!
NI = A!
HD = C!
NN = G!
NG = T !
!
A 
N-terminus 
                              
!
SIVAQLSRPDPALAALTNDHLVALACLGGGRPALDAVKKGLPHAPALIKRTNRRIPERTSHRVA!
SIVAQLSRPDPALAALTNDHLV LACLGGGRPALDAVKKGLPHAPALIQRTNQRIPERTSHQVA !
SIVAQLSRPDPALAALTNDHLVALACLGGGRPALDAVQQGLPHAPALIQQTNQQIPERTSHQVA!
SIVAQLSRPDPALAALTNDHLVALACLG------------------------------------!
           !
!
C-terminal domain!
Canonical 
Q3 
Q7 
28-aa 
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RNA-guided Cas9 nucleases are another type of site-specific nucleases with powerful 
genome-modifying capability.  Cas9 protein in complex with a guide RNA uses simple 
RNA:DNA hybridization to direct nuclease activity to a target DNA sequence (Figure I.3).2   
 
Figure'I.3.''RNA.guided'Cas9'architecture.'!Cas9!protein!(yellow)!binds!to!target!DNA!in!complex!with!a!guide!RNA!(gRNA,!green).!!The!S.#pyogenes!Cas9!protein!recognizes!the!PAM!sequence!NGG!(blue),!initiating!unwinding!of!dsDNA!and!gRNA:DNA!base!pairing.!!Black!triangles!indicate!the!cleavage!points!three!bases!from!the!PAM!on!both!top!and!bottom!strands.!
 
Because the guide RNA (gRNA) is short, ~100 bases, distinct gRNAs each targeting a different 
DNA site can easily be designed and constructed.  Thus, Cas9:gRNA genome editing agents are 
especially easy to generate compared to generating much larger sequences coding for ZFNs or 
TALENs proteins.  Chapter 2 and other studies29,51–53 demonstrate that Cas9:gRNA is capable of 
significant off-target activity.  While a dimeric, Cas9 nickase strategy can drastically improve 
specificity,15,29,35 Chapter 3 reports an alternative strategy improving the specificity of genome 
modification by fusing a dimeric FokI domain to catalytically inactive Cas9.  Future avenues of 
research into the specificity of site-specific nucleases should focus on a comparison between 
TALENs and the more specific dimeric RNA-guided Cas9 nuclease strategies. 
  
a Cas9 
gRNA 
PAM 
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1.1  Introduction to TALEN specificity  
The ability to engineer site-specific changes in genomes is a powerful research capability 
with significant therapeutic implications.  Transcription activator-like effector nucleases 
(TALENs) are fusions of the FokI restriction endonuclease cleavage domain with a DNA-
binding TALE repeat array (Figure 1.1).   
5’ TTCATTACACCTGCAGCT     N10-24     AGTATCAATTCTGGAAGA!
3’ AAGTAATGTGGACGTCGA     N10-24     TCATAGTTAAGACCTTCT!
TALE repeats FokI 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG!
RVD 
RVD code 
!
NI = A!
HD = C!
NN = G!
NG = T !
!
A 
N-terminus 
                              
!
SIVAQLSRPDPALAALTNDHLVALACLGGGRPALDAVKKGLPHAPALIKRTNRRIPERTSHRVA!
SIVAQLSRPDPALAALTNDHLVALACLGGGRPALDAVKKGLPHAPALIQRTNQRIPERTSHQVA !
SIVAQLSRPDPALAALTNDHLVALACLGGGRPALDAVQQGLPHAPALIQQTNQQIPERTSHQVA!
SIVAQLSRPDPALAALTNDHLVALACLG------------------------------------!
            !
!
C-terminal domain!
Canonical 
Q3 
Q7 
28-aa 
!
Figure 1.1.  TALEN architecture.  A T LEN monomer contains an -terminal domain (blue) 
followed by an array of TALE repeats (brown), a C-terminal domain (green), and a FokI 
nuclease cleavage domain (purple).  The 12th and 13th amino acids (the RVD, red) of each TALE 
repeat recognize a specific DNA base pair.  Two different TALENs bind their corresponding 
half-sites, allowing FokI dimerization and DNA cleavage.  
 
These arrays consist of multiple 34-amino acid TALE repeat sequences, each of which uses a 
repeat-variable di-residue (RVD), the amino acids at positions 12 and 13, to recognize a single 
DNA nucleotide.1, 2  Examples of RVDs that recognize each of the four DNA base pairs are 
known, enabling arrays of TALE repeats to be constructed that can bind virtually any DNA 
sequence.  TALENs can be engineered to be active only as heterodimers through the use of 
obligate heterodimeric FokI variants.3, 4  In this configuration, two distinct TALEN monomers 
are each designed to bind one target half-site resulting in cleavage within the DNA spacer 
sequence between the two half-sites.  In cells, TALEN-induced double-strand breaks can result 
in targeted gene knockout through non-homologous end joining (NHEJ)5 or precise targeted 
genomic sequence alteration through homology-directed repair (HDR) using an exogenous DNA 
template.6, 7  TALENs have been successfully used to manipulate genomes in a variety of 
organisms6, 8-11 and cell lines.5, 7, 12, 13 
Although TALENs are sufficiently specific to show activity against their intended target 
sites without causing widespread and highly abundant genomic off-target modification,4, 14-16 
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TALEN-mediated DNA cleavage at off-target sites can result in unintended mutations at 
genomic loci.  While recent studies identify closely related off-target substrates containing two 
or fewer mismatches in zebrafish17 and in human cell lines,13 more distant off-target substrates 
are of particular interest since one would expect a typical 36-bp target site to be approximately 
eight or more mutations away from any sequence in the human genome.  Two distant genomic 
off-target sites were identified from 19 potential off-target sites predicted using SELEX,7 an in 
vitro method to identify binding sites of DNA-binding domains in isolation.  Only a single 
heterodimeric off-target site was identified through the use of integrase-deficient lentiviral 
vectors (IDLVs)18, 19 to capture off-target double-strand break sites in cells.  The limited number 
of off-target TALEN sites previously characterized in studies performed to date suggest that 
further research is needed both to better understand the extent of TALEN-induced genomic off-
target mutations and to improve TALEN specificity to minimize these unwanted effects. 
The underlying principles that determine the specificities of TALEN proteins remain 
poorly characterized.  While SELEX experiments and a high-throughput study of TALE 
activator specificity have described the DNA-binding specificities of monomeric TALE 
proteins5, 7, 9 and a single TALE activator,20 respectively, the DNA cleavage specificities of 
active, dimeric nucleases can differ from the specificities of their component monomeric DNA-
binding domains.21  For example, zinc finger nucleases (ZFNs), another type of engineered 
dimeric nuclease, demonstrate compensation effects between monomers.21  Cellular methods to 
study off-target genomic modification such as whole-genome sequencing or IDLV capture could 
be complicated by cellular factors such as DNA accessibility, which varies from site to site and 
between cell types,22 or DNA repair and integration pathways after cleavage that could obscure 
the determination of intrinsic TALEN protein specificity.  Purely cellular studies are also 
inherently limited to the stochastic handful of off-target sites in a given genome that are similar 
to the target sequence and thus are unable to evaluate the ability of TALENs to cleave a very 
large number of off-target sites necessary for a broad and in-depth study of TALEN specificity.  
Using a previously described in vitro selection method,21, 23 we interrogated TALENs for 
their abilities to each cleave 1012 potential off-target DNA substrates related to their intended 
target sequences.  The resulting data provide the first comprehensive profiles of TALEN 
cleavage specificities in a manner that is not limited to the small number of typical target-related 
sites in a genome.  The selection results suggest a model in which excess non-specific DNA-
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binding energy gives rise to greater off-target cleavage relative to on-target cleavage.  Based on 
this model, we engineered TALENs with substantially improved DNA cleavage specificity in 
vitro.  In human cells, these engineered TALENs exhibit 24- to > 120-fold greater specificity for 
the most readily cleaved off-target site than currently used TALEN constructs.   
 
1.2  Specificity profiling of TALENs targeting human genes 
We profiled the specificities of 30 unique heterodimeric TALEN pairs (hereafter referred 
to as TALENs) harboring different C-terminal, N-terminal and FokI domain variants and 
targeted to sites with half-sites of various lengths.   Throughout this report, the number of base 
pairs recognized by each half site is listed to include the 5’ T nucleotide recognized by the N-
terminal domain.  Most of the TALENs tested contained the obligate heterodimeric EL/KK FokI 
domain, although the more active heterodimeric ELD/KKR and homodimeric FokI nuclease 
domain were also used, as specified below.3, 24  TALENs were constructed as previously 
reported12 and designed to target one of three distinct sequences, which we refer to as CCR5A, 
CCR5B, or ATM, in two different human genes, CCR5 and ATM (Figure 1.2).   
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TALEN monomer 
ATM L18  5’-TGAATTGGGATGCTGTTT          "
         "
            TGAATTGGGATGCTGTTTTTAGGTATTCTATTCAAATTTATTTTACTGTCTTTA"
            ACTTAACCCTACGACAAAAATCCATAAGATAAGTTTAAATAAAATGACAGAAAT"
"
ATM R18                                         AAATAAAATGACAGAAAT-5’"
TALEN monomer 
CCR5A L18     5’-TTCATTACACCTGCAGCT"
CCR5B L16   5’-TCTTCATTACACCTGC             "
CCR5B L13      5’-TCATTACACCTGC               "
CCR5B L10         5’-TTACACCTGC          "
"
               TCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGA"
               AGAAGTAATGTGGACGTCGAGAGTAAAAGGTATGTCAGTCATAGTTAAGACCTTCT"
 "
CCR5A R18                                            TCATAGTTAAGACCTTCT-5’ "
CCR5B R16                                   GTATGTCAGTCATAGT-5’"
CCR5B R13                                   GTATGTCAGTCAT-5’"
CCR5B R10                                   GTATGTCAGT-5’"
  "
"
CCR5 target sites 
A 
B 
ATM target site 
 
Figure 1.2.  Target DNA sequences in human CCR5 and ATM genes.  The target DNA 
sequences for the TALENs used in this study are shown in black.  The N-terminal TALEN end 
recognizing the 5´ T for each half-site target is noted (5´) and TALENs are named according to 
number of base pairs targeted.  TALENs targeting the CCR5 L18 and R18 shown are referred to 
as CCR5A TALENs while TALENs targeting the L10, L13, L16, R10, R13 or R16 half-sites 
shown are referred to as CCR5B TALENs. 
 
The specificity profiles were generated using a previously described in vitro selection 
method.21, 23  Briefly, pre-selection libraries of > 1012 DNA sequences each were digested with 
3 nM to 40 nM of an in vitro-translated TALEN.  TALEN concentrations in the selection were 
empirically determined to avoid overdigestion, since the selection isolates DNA products 1.5 
target sites in length.  For example, CCR5A TALEN digestion of concatemerized repeats of the 
CCR5 DNA target sites under the conditions used in the selection yielded the expected ladder of 
integral units of target sites (Figure 1.3).   
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Figure'1.3.''TALEN and restriction enzyme digestion of concatemerized on-target or 
mutant DNA sites.  A single-stranded discrete DNA oligonucleotide containing a left half-site 
(L), spacer (S), right half-site (R), and constant region (represented by a thick black line) was 
circularized, then concatemerized by rolling circle amplification.  The protocol for In Vitro 
Selection for DNA Cleavage (Online Methods) was preformed using CCR5Aon-Circ oligos 
(CCR5 on-target DNA sites) or CCR5Amut-Circ oligos (CCR5 mutant DNA sites) except after 
TALEN digestion samples were analyzed by PAGE gel.  For lanes 1, 2, and 4 the DNA target 
site was the CCR5 on-target sequence but for lane 3 the DNA sequence contained a completely 
randomized right half-site.  For lanes 1, 2, and 3 the resulting concatemerized DNAs were 
incubated with in vitro-translated CCR5A TALENs and the samples were purified by M-column 
(Qiagen) and analyzed by PAGE.  Lane 1 shows digestion of concatemerized on-target DNA 
sites with a restriction enzyme (Tsp45I); lane 2 shows digestion of concatemerized on-target 
DNA sites with a CCR5A TALEN; lane 3 shows digestion of concatemerized mutant DNA sites 
with a CCR5A TALEN; and lane 4 shows the concatemerized DNA substrate before digestion or 
column purification.  
'
Under these conditions, there is little cleavage to monomeric target sites compared to digestion 
of the same concatemerized DNA with a restriction enzyme that yields mostly monomeric sites.   
TALEN concentrations used in the selection (3 nM to 40 nM) correspond to ~20 to ~200 dimeric 
TALEN molecules per human cell nucleus,25 which is in the lower range of cellular protein 
expression26, 27  and therefore approaches the lower limit of TALEN concentration possible in a 
cell.  
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A completely random library of 25% of each base pair at each position would not yield 
sufficient library coverage of potential target sites with relatively few mutations relative to the 
on-target site.  Therefore, a partially randomized library of 79% on-target base pair at each 
position was used.  At this randomization frequency, 0.021% of the library contains an on-target 
site (no mutations), based on the expected binomial distribution of 79% on-target base pairs 
across the 36-bp target site.  14% of the library will have six mutations, with ~100 copies on 
average of all possible six-mutation sequences possible in a 36-bp site.  (In theory, the library 
will have 1.0 x1012 molecules with exactly six mutations which is ~100-fold more than the 1.4 
x109 different six-mutation sequences possible in a 36-bp site.)  Thus, pre-selection DNA 
libraries were sufficiently large that they each contain, in theory, at least ten copies of all 
possible DNA sequences with six or fewer mutations relative to the on-target sequence.   
Incubation of the pre-selection DNA libraries with TALENs results in cleavage of 
preferred sequences.  Cleaved library members harbored a free 5’ monophosphate that enabled 
them to be captured by adapter ligation (Figure 1.4).   
L    S    R 
L´"  S´"  R´" 
L    S    R 
L´"  S´"  R´" 
L    S    R 
L´"  S´"  R´" 
DNA library of ~1012 target sites 
L    S    R 
R 
S 
L 
L    S    R 
L´"  S´"  R´" 
      S    R 
 "  S´"  R´" 
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G
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!
Figure 1.4.  Selection scheme.  (A) A single-stranded library of DNA oligonucleotides 
containing partially randomized left half-site (L), spacer (S), right half-site (R) and constant 
region (thick black line) was circularized, then concatemerized by rolling circle amplification.  
The concatemerized double stranded DNA (double arrows) contained repeated target sites with 
L’ S’ R’ representing the reverse sequence complement of L S R.  (B) The concatemerized DNA 
libraries of mutant target sites were incubated with an in vitro-translated TALEN of interest.  
Cleaved library members were blunted and ligated to adapter #1.  The ligation products were 
amplified by PCR using one primer consisting of adapter #1 and the other primer consisting of 
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adapter #2–constant sequence, which anneals to the constant regions.  From the resulting ladder 
of amplicons containing a half-site with an integral number (n) of repeats of a target site 
(represented by brackets), amplicons corresponding to 1.5 target-sites in length were isolated by 
gel purification and subjected to high-throughput DNA sequencing and computational analysis. !
DNA fragments of length corresponding to 1.5 target sites (an intact target site and a 
repeated half-site up to the point of TALEN-induced DNA cleavage) were isolated by gel 
purification.  High-throughput sequencing and computational analysis of TALEN-treated or 
control samples surviving this selection process revealed the abundance of all TALEN-cleaved 
sequences as well as the abundance of the corresponding sequences before selection.  In the 
control sample, all members of the pre-selection library were cleaved by a restriction 
endonuclease at a constant sequence to enable them to be captured by adapter ligation and 
isolated by gel purification.  The enrichment value for each library member surviving selection 
was calculated by dividing its post-selection sequence abundance by its pre-selection abundance.  
For ATM and CCR5A TALEN variants, the DNA that survived the selection contained 
significantly fewer mean mutations in the targeted half-sites than were present in the pre-
selection libraries (Figure 1.5).   
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Figure 1.5.  In vitro selection results.  The fraction of sequences surviving selection (green) and 
before selection (black) are shown for CCR5A TALENs (A) and ATM TALENs (B) with 
EL/KK FokI domains as a function of the number of mutations in both half-sites (left and right 
half-sites combined excluding the spacer).  !
For example, the mean number of combined mutations in the 18-bp left half-site and 18-bp right 
half-site among DNA sequences surviving selection after treatment with TALENs was 4.06 for 
CCR5A and 3.18 for ATM sequences, respectively, compared to 7.54 and 6.82 mutations in the 
corresponding pre-selection libraries (Figure 1.5).  For all selections, the on-target sequences 
were enriched by 8- to 640-fold with an average enrichment value of 110-fold (Supplementary 
 19 
Table S4).  To validate our selection results in vitro, we assayed the ability of the CCR5B 
TALEN targeting 13-bp left and right half-sites (L13+R13) to cleave each of 16 diverse off-
target substrates (Figure 1.6).   
!!!DNA   Enrichment      Left half-site             Right half-site 
!
  OnB   1.0     TCATTACACCTGC   CATACAGTCAGTA!
  B1    0.47    TCATTACACCTGt   CATACAGTCAGTA!
  B2    0.46    TCATaACACCTGC   CATACAGTCAGTA!
  B3    0.13    TCATTACACCcGC   CATACAGTCAGTA !
  B4    1.1     TCATTACACCTGC   CATACAGTaAGTA!
  B5    0.84    TCATTACACCTGC   gATACAGTCAGTA !
  B6    0.21    TCATTACACCTGC   CATtCAGTCAGTA!
  B7    0.03    TCATTACACCTGC   CATACAGTCgGTA!
  B8    0.25    TCATaACACCTGt   CATACAGTCAGTA!
  B9    0.25    TCATTAtACCTaC   CATACAGTCAGTA!
  B10   0.00    TCATTgCACCcGC   CATACAGTCAGTA !
  B11   0.55    TCATTACACCTGC   gATACAGTaAGTA!
  B12   0.04    TCATTACACCTGC   CAcACAtTCAGTA!
  B13   0.03    TCATTACACCTGC   CATACtaTCAGTA!
  B14   0.30    TCATTACACCTGt   CATACAGTaAGTA!
  B15   0.18    TCATaACACCTGC   gATACAGTCAGTA!
  B16   0.04    TCATTACACCTGt   CATtCAGTCAGTA!
  !
  !
  !
 !
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Figure 1.6.  In vitro selection results.  (A) Enrichment values from the selection of L13+R13 
CCR5B TALEN for 16 mutant DNA sequences (mutations in red) relative to on-target DNA 
(OnB). (B) Discrete assays of on-target and off-target sequences from (A) as analyzed by PAGE.  
(C) Correspondence between discrete in vitro TALEN cleavage efficiency (cleaved DNA as a 
fraction of total DNA) for the sequences listed in (B) normalized to on-target cleavage (= 1) 
versus their enrichment values in the selection normalized to the on-target enrichment value 
(= 1).  The Pearson’s r coefficient of correlation between normalized cleavage efficiency and 
normalized enrichment value is 0.90.   !
The efficiencies with which each of these 16 putative off-target substrates were cleaved by the 
TALEN in these discrete in vitro assays correlated well (r = 0.90) with the observed enrichment 
values from the selection (Figure 1.6). 
To quantify the DNA cleavage specificity at each position in the TALEN target site for 
all four possible base pairs, a specificity score was calculated as the difference between pre-
selection and post-selection base pair frequencies, normalized to the maximum possible change 
of the pre-selection frequency from complete specificity (defined as 1.0) to complete anti-
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specificity (defined as –1.0).  For ATM and CCR5A TALENs tested, the targeted base pair at 
every position in both half-sites is preferred, with the sole exception of the base pair closest to 
the spacer for some ATM TALENs at the right-half site (Figure 1.7).   
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Figure 1.7.  In vitro selection results. (A) Specificity scores for the CCR5A TALENs at all 
positions in the target half-sites plus a single flanking position.  The colors range from dark blue 
(maximum specificity score of 1.0) to white (no specificity, score of 0) to dark red (maximum 
negative score of –1.0); see the main text for details.  Boxed bases represent the intended target 
base.  Note for the right half-site, the R18 TALENs, the sense strand is shown.  (B) Same as (A) 
for the ATM TALENs.  
 
The 5’ T recognized by the N-terminal domain is highly specified, and the 3’ DNA end (targeted 
by the C-terminal TALEN end) generally tolerates more mutations than the 5’ DNA end; both of 
these observations are consistent with previous reports.33, 34  All 12 of the positions targeted by 
the NN RVDs in the ATM and CCR5A TALENs were enriched for G, confirming previous 
reports5, 7, 33, 35 that the NN RVD specifies G.  Taken together, these results show that the 
selection data accurately predicts the efficiency of off-target TALEN cleavage in vitro, and that 
TALENs are overall quite specific across the entire target sequence.   
Selection results for all TALEN variants and under all tested conditions demonstrated 
similar trends for the initial for selection results for ATM and CCR5A TALENs. The on-target 
sequences were enriched by 8- to 640-fold with an average enrichment value of 110-fold 
(Figures 1.8 - 1.10 and Tables 1.1-1.10). 
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Figure 1.8 (Continued).  Specificity profiles from all CCR5A TALEN selections as heat 
maps.   
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Figure 1.8 (Continued).  Specificity profiles from all CCR5A TALEN selections as heat 
maps. Specificity scores for every targeted base pair in selections of CCR5A TALENs are 
shown. Specificity scores for the L18+R18 CCR5A TALEN at all positions in the target half-
sites plus a single flanking position.  The colors range from dark blue (maximum specificity 
score of 1.0) to white (score of 0, no specificity) to dark red (maximum negative score of -1.0); 
see the main text for details.  Boxed bases represent the intended target base. The titles to the 
right indicate if the TALEN used in the selection differs from the canonical TALEN architecture, 
which contains a canonical C-terminal domain, wild-type N-terminal domain, and EL/KK FokI 
variant. (A) Specificity profiles of canonical, Q3, Q7, 28-aa, 32 nM canonical, 8 nM canonical, 4 
nM canonical, 32 nM Q7 and 8 nM Q7 CCR5A TALEN selections.  (B) Specificity profiles of 4 
nM Q7, N1, N2, N3, canonical ELD/KKR, Q3 ELD/KKR, Q7 ELD/KKR and N2 ELD/KKR 
CCR5A TALEN selections.  When not specified, TALEN concentration was 16 nM. 
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Figure 1.9 (Continued).  Specificity profiles from all ATM TALEN selections as heat maps.   
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Figure'1.9'(Continued).'''Specificity profiles from all ATM TALEN selections as heat 
maps.  Specificity scores for every targeted base pair in selections of ATM TALENs are shown. 
Specificity scores for the L18+R18 ATM TALEN at all positions in the target half-sites plus a 
single flanking position.  The colors range from dark blue (maximum specificity score of 1.0) to 
white (score of 0, no specificity) to dark red (maximum negative score of -1.0); see the main text 
for details.  Boxed bases represent the intended target base. The titles to the right indicate if the 
TALEN used in the selection differs from the canonical TALEN architecture, which contains a 
canonical C-terminal domain, wild-type N-terminal domain, and EL/KK FokI variant.  
Selections correspond to conditions listed in Supplementary Table S1. (A) Specificity profiles of 
(12 nM) canonical, Q3, (12 nM) Q7, 24 nM canonical, 6 nM canonical, 3 nM canonical, 24 nM 
Q7, and 6 nM Q7 ATM TALEN selections.  (B) Specificity profiles of N1, N2, N3, canonical 
ELD/KKR, Q3 ELD/KKR, Q7 ELD/KKR, and N2 ELD/KKR ATM TALEN selections.  When 
not specified, TALEN concentration was 12 nM. 
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Figure 1.10.  Specificity profiles from all CCR5B TALEN selections as heat maps. 
Specificity scores for every targeted base pair in selections of CCR5B TALENs are shown. 
Specificity scores for CCR5B TALENs targeting all possible combinations of the left (L10, L13, 
L16) and right (R10, R13, R16) half-sites at all positions in the target half-sites plus a single 
flanking position.  The colors range from dark blue (maximum specificity score of 1.0) to white 
(score of 0, no specificity) to dark red (maximum negative score of -1.0); see the main text for 
details.  Boxed bases represent the intended target base 
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Selection name 
 
Target  
site 
Left+Right 
half-site 
Site 
length 
N-terminal 
domain 
C-terminal  
domain 
FokI 
domain 
TALEN  
conc. (nM) 
CCR5A 32 nM 
canonical CCR5A L18+R18 36 canonical Canonical EL/KK 32 
CCR5A 16 nM 
canonical 
(or CCR5A 
canonical) CCR5A L18+R18 36 canonical Canonical EL/KK 16 
CCR5A 8 nM 
canonical CCR5A L18+R18 36 canonical Canonical EL/KK 8 
CCR5A 4 nM 
canonical CCR5A L18+R18 36 canonical Canonical EL/KK 4 
CCR5A Q3 CCR5A L18+R18 36 canonical Q3 EL/KK 16 
CCR5A 32 nM Q7 CCR5A L18+R18 36 canonical Q7 EL/KK 32 
CCR5A 16 nM Q7 
(or CCR5A Q7) CCR5A L18+R18 36 canonical Q7 EL/KK 16 
CCR5A 8 nM Q7 CCR5A L18+R18 36 canonical Q7 EL/KK 8 
CCR5A 4 nM Q7 CCR5A L18+R18 36 canonical Q7 EL/KK 4 
CCR5A 28-aa CCR5A L18+R18 36 canonical 28-aa EL/KK 16 
CCR5A N1 CCR5A L18+R18 36 N1 Canonical EL/KK 16 
CCR5A N2 CCR5A L18+R18 36 N2 Canonical EL/KK 16 
CCR5A N3 CCR5A L18+R18 36 N3 Canonical EL/KK 16 
CCR5A canonical 
ELD/KKR CCR5A L18+R18 36 canonical Canonical ELD/KKR 16 
CCR5A Q3 
ELD/KKR CCR5A L18+R18 36 canonical Q3 ELD/KKR 16 
CCR5A Q7 
ELD/KKR CCR5A L18+R18 36 canonical Q7 ELD/KKR 16 
CCR5A N2 
ELD/KKR CCR5A L18+R18 36 N2 Canonical ELD/KKR 16 
Table 1.1.  CCR5A TALEN constructs and concentrations used in the selections.  For each 
selection using TALENs targeting the CCR5A target sequence, the selection name, the target 
DNA site, the TALEN N-terminal domain, the TALEN C-terminal domain, the TALEN FokI 
domain, and the TALEN concentration (conc.) are shown. 
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Selection name 
 
Target  
site 
Left + Right 
half-site 
Site 
length 
N-terminal 
domain 
C-terminal  
domain 
FokI 
domain 
TALEN  
conc. (nM) 
ATM 24 nM 
canonical ATM L18+R18 36 canonical Canonical EL/KK 24 
ATM 12 nM 
canonical 
(or ATM 
canonical) ATM L18+R18 36 canonical Canonical EL/KK 12 
ATM 6 nM 
canonical ATM L18+R18 36 canonical Canonical EL/KK 6 
ATM 3 nM 
canonical ATM L18+R18 36 canonical Canonical EL/KK 3 
ATM Q3 ATM L18+R18 36 canonical Q3 EL/KK 12 
ATM 24 nM Q7 ATM L18+R18 36 canonical Q7 EL/KK 24 
ATM 12 nM Q7 
(or ATM Q7) ATM L18+R18 36 canonical Q7 EL/KK 12 
ATM 6 nM Q7 ATM L18+R18 36 canonical Q7 EL/KK 6 
ATM N1 ATM L18+R18 36 N1 Canonical EL/KK 12 
ATM N2 ATM L18+R18 36 N2 Canonical EL/KK 12 
ATM N3 ATM L18+R18 36 N3 Canonical EL/KK 12 
ATM canonical 
ELD/KKR ATM L18+R18 36 canonical Canonical ELD/KKR 12 
ATM Q3 
ELD/KKR ATM L18+R18 36 canonical Q3 ELD/KKR 12 
ATM Q7 
ELD/KKR ATM L18+R18 36 canonical Q7 ELD/KKR 12 
ATM N2 
ELD/KKR ATM L18+R18 36 N2 Canonical ELD/KKR 12 
Table 1.2. ATM TALEN constructs and concentrations used in the selections.  For each 
selection using TALENs targeting the ATM target sequence, the selection name, the target DNA 
site, the TALEN N-terminal domain, the TALEN C-terminal domain, the TALEN FokI domain, 
and the TALEN concentration (conc.) are shown. 
 
 
Selection name  
 
Target  
site 
Left + Right 
half-site 
Site 
length 
N-terminal 
domain 
C-terminal  
domain 
FokI 
domain 
TALEN  
conc. (nM) 
L16+R16 CCR5B CCR5B L16+R16 32 canonical Canonical EL/KK 10 
L16+R13 CCR5B CCR5B L16+R13 29 canonical Canonical EL/KK 10 
L16+R10 CCR5B CCR5B L16+R10 26 canonical Canonical EL/KK 10 
L13+R16 CCR5B CCR5B L13+R16 29 canonical Canonical EL/KK 10 
L13+R13 CCR5B CCR5B L13+R13 26 canonical Canonical EL/KK 10 
L13+R10 CCR5B CCR5B L13+R10 23 canonical Canonical EL/KK 10 
L10+R16 CCR5B CCR5B L10+R16 26 canonical Canonical EL/KK 10 
L10+R13 CCR5B CCR5B L10+R13 23 canonical Canonical EL/KK 10 
L10+R10 CCR5B CCR5B L10+R10 20 canonical Canonical EL/KK 10 
Table 1.3.  CCR5B TALEN constructs and concentrations used in the selections.  For each 
selection using TALENs targeting the CCR5B target sequence, the selection name, the target 
DNA site, the TALEN N-terminal domain, the TALEN C-terminal domain, the TALEN FokI 
domain, and the TALEN concentration (conc.) are shown. 
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Selection name 
 
Seq. 
count 
Mean 
mut. 
Stdev 
mut. 
Mut./bp 
 
P-value 
vs. library 
P-value 
vs. other TALENs 
CCR5A 32 nM 
canonical 53883 4.327 1.483 0.120 3.3E-10 
vs. CCR5A canonical 
ELD/KKR = 0.26 
CCR5A 16 nM 
canonical 28940 4.061 1.438 0.113 5.4E-10 
vs. CCR5A Q3 
ELD/KKR = 0.028 
CCR5A 8 nM 
canonical 29568 3.751 1.394 0.104 3.3E-10  
CCR5A 4 nM 
canonical 34355 3.347 1.355 0.093 1.5E-10  
CCR5A Q3 51694 3.841 1.380 0.107 1.7E-10  
CCR5A 32 nM Q7 48473 2.718 1.197 0.076 4.4E-11  
CCR5A 16 nM Q7 56593 2.559 1.154 0.071 3.1E-11  
CCR5A 8 nM Q7 43895 2.303 1.157 0.064 3.0E-11  
CCR5A 4 nM Q7 43737 2.018 1.234 0.056 2.1E-11  
CCR5A 28-aa 47395 2.614 1.203 0.073 4.0E-11  
CCR5A N1 64257 3.721 1.379 0.103 1.1E-10 
vs. CCR5A 8 nM 
canonical  =0.039 
CCR5A N2 45467 3.148 1.306 0.087 8.2E-11  
CCR5A N3 24064 2.474 1.493 0.069 8.1E-11  
CCR5A canonical 
ELD/KKR 46998 4.336 1.491 0.120 4.0E-10  
CCR5A Q3 ELD/KKR 56978 4.098 1.415 0.114 2.2E-10  
CCR5A Q7 ELD/KKR 54903 3.234 1.330 0.090 7.3E-11  
CCR5A N2 ELD/KKR 79632 3.286 1.341 0.091 5.2E-11  
Table 1.4. Statistics of sequences selected by CCR5A TALEN digestion.  Statistics are shown 
for each TALEN selection on the CCR5A target sequence .  Seq. counts: total counts of high-
throughput sequenced and computationally filtered selection sequences. Mean mut.: mean 
mutations in selected sequences.  Stdev. mut.:  standard deviation of mutations in selected 
sequences. Mut./bp: mean mutation normalized to target site length (bp).  P-value vs. library: P-
values between the TALEN selection sequence distributions to the corresponding pre-selection 
library sequence distributions were determined as previously reported14 using a (left) one-sided t-
test.  P-value vs. other TALENs: all pairwise comparisons between each distribution of TALEN-
digested sequences were calculated (e.g., comparing CCR5A 16 nM canonical and CCR5A 32 
nM canonical).  All P-values above the lower P-value limits are shown.  Lower P-values limits 
were based on multiple comparison correction and thus any P-value below the lower value is 
considered significant.  For CCR5A lower P-value limits were 0.0125 based on multiple 
comparisons correction using the Bonferroni method.  All post-selection sequences were 
assumed to be binomially distributed. 
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Selection name 
 Seq. count 
Mean 
mut. 
Stdev 
mut. 
Mut./bp 
 
P-value 
vs. library 
P-value 
vs. other TALENs 
ATM 24 nM 
canonical 89571 3.262 1.360 0.091 6.54E-11 
vs. ATM canonical 
ELD/KKR =0.046 
ATM 12 nM 
canonical 
(or ATM canonical) 96703 3.181 1.307 0.088 5.36E-11  
ATM 6 nM 
canonical 78852 2.736 1.259 0.076 3.63E-11  
ATM 3 nM 
canonical 82527 2.552 1.258 0.071 2.71E-11  
ATM Q3 96582 2.551 1.248 0.071 2.31E-11  
ATM 24 nM Q7 10166 1.885 2.125 0.052 2.06E-10  
ATM 12 nM Q7 
(or ATM Q7) 4662 1.626 2.083 0.045 5.31E-10 
vs. ATM 6 nM Q7 
=0.069 
ATM 6 nM Q7 1290 1.700 2.376 0.047 7.16E-09  
ATM N1 84402 2.627 1.318 0.073 2.92E-11 vs. ATM N3 =0.039 
ATM N2 62470 2.317 1.516 0.064 2.69E-11  
ATM N3 1605 2.720 2.363 0.076 2.69E-08 
vs. ATM 6 nM 
canonical =0.36 
vs. Q3 ELD/KKR 
=0.017 
ATM canonical 
ELD/KKR 107970 3.279 1.329 0.091 5.48E-11  
ATM Q3 ELD/KKR 104099 2.846 1.244 0.079 3.15E-11  
ATM Q7 ELD/KKR 21108 1.444 1.56 0.040 3.02E-11  
ATM N2 ELD/KKR 70185 2.45 1.444 0.06805 2.82E-11  
Table 1.5. Statistics of sequences selected by ATM TALEN digestion.  Statistics are shown 
for each TALEN selection on the ATM target sequence.  Seq. counts: total counts of high-
throughput sequenced and computationally filtered selection sequences. Mean mut.: mean 
mutations in selected sequences.  Stdev. mut.:  standard deviation of mutations in selected 
sequences. Mut./bp: mean mutation normalized to target site length (bp).  P-value vs. library: P-
values between the TALEN selection sequence distributions to the corresponding pre-selection 
library sequence distributions) were determined as previously reported14 using a (left) one-sided 
t-test.  P-value vs. other TALENs: all pairwise comparisons between each distribution of 
TALEN-digested sequences were calculated.  All P-values above the lower P-value limits are 
shown.  Lower P-values limits were based on multiple comparison correction and thus any P-
value below the lower value is considered significant.  For ATM lower P-value limits were 
0.0125 based on multiple comparisons correction using the Bonferroni method.  All post-
selection sequences were assumed to be binomially distributed.  Note that for the 3 nM Q7 ATM 
and the 28-aa ATM selection not enough sequences were obtained to interpret, although these 
selections were performed. 
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Selection name 
Seq. 
count 
Mean 
mut. 
Stdev 
mut. 
Mut./bp 
 
P-value 
vs. library 
P-value 
vs. other TALENs  
L16+R16 CCR5B 34904 2.134 1.168 0.067 4.7E-11  
L16+R13 CCR5B 38229 1.581 1.142 0.055 2.7E-11  
L16+R10 CCR5B 37801 1.187 0.949 0.046 2.2E-11  
L13+R16 CCR5B 46608 1.505 1.090 0.052 1.7E-11  
L13+R13 CCR5B 53973 0.996 1.025 0.038 8.8E-12  
L13+R10 CCR5B 60550 0.737 0.884 0.032 7.4E-12  
L10+R16 CCR5B 36927 1.387 0.971 0.053 3.0E-11  
L10+R13 CCR5B 58170 0.839 0.882 0.036 9.1E-12  
L10+R10 CCR5B 57331 0.646 0.779 0.032 1.0E-11  
Table 1.6. Statistics of sequences selected by CCR5B TALEN digestion.   Statistics are 
shown for each TALEN selection on the CCR5B target sequences.  Seq. counts: total counts of 
high-throughput sequenced and computationally filtered selection sequences. Mean mut.: mean 
mutations in selected sequences.  Stdev. mut.:  standard deviation of mutations in selected 
sequences. Mut./bp: mean mutation normalized to target site length (bp).  P-value vs. library: P-
values between the TALEN selection sequence distributions to the corresponding pre-selection 
library sequence distributions) were determined as previously reported14 using a (left) one-sided 
t-test.  P-value vs. other TALENs: all pairwise comparisons between each distribution of 
TALEN-digested sequences were calculated.  All P-values above the lower P-value limits are 
shown.  Lower P-values limits were based on multiple comparison correction and thus any P-
value below the lower value is considered significant.  For CCR5B lower P-value limits were 
0.0055 based on multiple comparisons correction using the Bonferroni method.  All post-
selection sequences were assumed to be binomially distributed.   
 
 
Library name 
Target  
site 
Left + Right 
half-site 
Site 
length 
Seq. 
count  
Mean 
mut. 
Stdev 
mut. 
Mut./bp 
 
CCR5A Library CCR5A L18+R18 36 158643 7.539 2.475 0.209 
ATM Library ATM L18+R18 36 212661 6.820 2.327 0.189 
CCR5B Library CCR5B L16+R16 32 280223 6.500 2.441 0.203 
CCR5B Library CCR5B L16+R13 29 280223 5.914 2.336 0.204 
CCR5B Library CCR5B L16+R10 26 280223 5.273 2.218 0.203 
CCR5B Library CCR5B L13+R16 29 280223 5.969 2.340 0.206 
CCR5B Library CCR5B L13+R13 26 280223 5.383 2.230 0.207 
CCR5B Library CCR5B L13+R10 23 280223 4.742 2.106 0.206 
CCR5B Library CCR5B L10+R16 26 280223 5.396 2.217 0.208 
CCR5B Library CCR5B L10+R13 23 280223 4.810 2.100 0.209 
CCR5B Library CCR5B L10+R10 20 280223 4.169 1.971 0.208 
Table 1.7.  Statistics of sequences from pre-selection libraries.  For each pre-selection library 
containing a distribution of mutant sequences of the CCR5A target sequence, ATM target 
sequence and CCR5B target sequences. Seq. counts: total counts of high-throughput sequenced 
and the computationally filtered selection sequences. Mean mut.: mean mutations of sequences.  
Stdev. mut.: standard deviation of sequences.  All pre-selection sequences were assumed to be 
binomially distributed.  Mut./bp: mean mutation normalized to target site length (bp).   
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Selection  Enrichment value 
 0 Mut. 1 Mut. 2 Mut. 3 Mut. 4 Mut. 5 Mut. 6 Mut. 7 Mut. 
CCR5A 32 nM 
canonical 9.879 9.191 8.335 6.149 4.205 2.269 1.005 0.325 
CCR5A 16 nM 
canonical 12.182 13.200 10.322 7.195 4.442 2.127 0.748 0.216 
CCR5A 8 nM 
canonical 19.673 17.935 13.731 8.505 4.512 1.756 0.531 0.116 
CCR5A 4 nM 
canonical 36.737 29.407 19.224 9.958 4.047 1.242 0.302 0.058 
CCR5A Q3 18.550 16.466 12.024 8.070 4.632 1.938 0.572 0.126 
CCR5A 32 nM Q7 60.583 54.117 31.082 11.031 2.640 0.469 0.073 0.013 
CCR5A 16 nM Q7 62.294 64.689 35.036 10.538 2.183 0.322 0.046 0.010 
CCR5A 8 nM Q7 97.020 91.633 38.634 8.974 1.485 0.189 0.029 0.010 
CCR5A 4 nM Q7 197.239 130.497 38.361 6.535 0.896 0.120 0.025 0.019 
CCR5A 28-aa 70.441 62.213 33.481 10.488 2.317 0.402 0.064 0.012 
CCR5A N1 19.038 18.052 13.858 8.788 4.546 1.697 0.499 0.115 
CCR5A N2 41.715 35.752 22.638 10.424 3.777 0.989 0.194 0.038 
CCR5A N3 173.897 88.392 31.503 8.770 1.853 0.350 0.089 0.036 
CCR5A canonical 
ELD/KKR 8.101 10.012 8.220 6.147 4.119 2.291 1.019 0.330 
CCR5A Q3 
ELD/KKR 14.664 12.975 9.409 6.819 4.544 2.235 0.797 0.198 
CCR5A Q7 
ELD/KKR 37.435 32.922 21.033 10.397 3.867 1.087 0.238 0.046 
CCR5A N2 
ELD/KKR  35.860 31.469 20.135 10.189 3.983 1.155 0.260 0.050 
Table 1.8. CCR5A enrichment values of sequences as a function of number of mutations.  
For each TALEN selection on the CCR5A target sequence, enrichment values calculated by 
dividing the fractional abundance of post-selection sequences from a TALEN digestion by the 
fractional abundance of pre-selection sequences as a function of total mutations (Mut.) in the 
half-sites.   
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Selection  Enrichment value 
 0 Mut. 1 Mut. 2 Mut. 3 Mut. 4 Mut. 5 Mut. 6 Mut. 7 Mut. 
ATM 24 nM 
canonical 19.900 16.881 12.162 6.318 2.629 0.884 0.228 0.057 
ATM 12 nM 
canonical 20.472 17.645 12.724 6.549 2.606 0.803 0.189 0.039 
ATM 6 nM 
canonical 41.141 29.522 17.153 6.551 1.872 0.431 0.082 0.017 
ATM 3 nM 
canonical 56.152 37.152 18.530 6.196 1.562 0.308 0.058 0.015 
ATM Q3 50.403 36.687 19.031 6.245 1.513 0.294 0.057 0.016 
ATM 24 nM Q7 353.148 90.350 13.475 1.531 0.186 0.128 0.116 0.118 
ATM 12 nM Q7 513.385 89.962 11.310 0.860 0.190 0.093 0.115 0.092 
ATM 6 nM Q7 644.427 82.074 7.650 0.677 0.170 0.205 0.163 0.164 
ATM N1 57.218 35.388 17.808 6.124 1.644 0.383 0.076 0.023 
ATM N2 119.240 53.618 18.977 4.742 0.992 0.233 0.076 0.044 
ATM N3 201.158 55.468 15.244 3.187 0.764 0.307 0.154 0.173 
ATM canonical 
ELD/KKR 19.356 15.692 11.855 6.403 2.706 0.899 0.224 0.054 
ATM Q3 ELD/KKR 32.816 25.151 16.172 6.727 2.095 0.506 0.095 0.018 
ATM Q7 ELD/KKR 447.509 93.166 13.505 1.543 0.170 0.053 0.049 0.045 
ATM N2 ELD/KKR 90.625 45.525 18.683 5.369 1.267 0.274 0.076 0.035 
Table 1.9. ATM Enrichment values of sequences as a function of number of mutations.  For 
each TALEN selection on the ATM target sequence enrichment values calculated by dividing the 
fractional abundance of post-selection sequences from a TALEN digestion by the fractional 
abundance of pre-selection sequences as a function of total mutations (Mut.) in the half-sites.   
 
 
Selection  Enrichment value 
 0 Mut. 1 Mut. 2 Mut. 3 Mut. 4 Mut. 5 Mut. 6 Mut. 7 Mut. 
L16+R16 
CCR5B 59.422 35.499 13.719 3.770 0.737 0.132 0.024 0.011 
L16+R13 
CCR5B 80.852 31.434 7.754 1.380 0.218 0.040 0.022 0.016 
L16+R10 
CCR5B 64.944 20.056 3.867 0.515 0.056 0.010 0.006 0.006 
L13+R16 
CCR5B 101.929 34.255 8.131 1.299 0.167 0.033 0.016 0.011 
L13+R13 
CCR5B 113.102 22.582 3.037 0.315 0.044 0.022 0.017 0.017 
L13+R10 
CCR5B 74.085 11.483 1.270 0.121 0.022 0.013 0.011 0.013 
L10+R16 
CCR5B 60.186 22.393 5.286 0.777 0.084 0.012 0.006 0.006 
L10+R13 
CCR5B 74.204 13.696 1.673 0.152 0.021 0.011 0.010 0.009 
L10+R10 
CCR5B 43.983 7.018 0.740 0.061 0.013 0.007 0.007 0.008 
Table 1.10. CCR5B enrichment values of sequences as a function of number of mutations.  
For each TALEN selection on the CCR5B target sequence, enrichment values calculated by 
dividing the fractional abundance of post-selection sequences from a TALEN digestion by the 
fractional abundance of pre-selection sequences as a function of total mutations (Mut.) in the 
half-sites.   
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1.3  TALEN off-target cleavage in cells 
For TALENs targeting 36 total base pairs, potential off-target sites in the human genome 
are expected on the average to contain approximately eight or more mutations relative to the on-
target site (Table 1.11), more mutations than theoretically are covered in the in vitro selection.  
Mutations in site Off-target sites to CCR5A Statistically expected 
0 1 1 
1 0 0.0 
2 0 0.0 
3 0 0.0 
4 0 0.0 
5 0 0.0 
6 0 0.0 
7 0 0.3 
8 8 3.6 
9 70 34.1 
10 634 275.9 
11 4338 1956.3 
12 27114 12226.7 
13 149005 67716.9 
14 648230 333747.3 
15 2657598 1468488.3 
16 9783617 5782172.6 
Table 1.11.   Genomic off-target site abundance in the human genome.  Column 2 shows the 
number of sites in the human genome related to the CCR5A on-target sequence, allowing for a 
spacer length from 12 to 25 bps between the two half-sites.  Column 3 shows the statistically 
expected average numbers of off-target sites that would be found in a human-sized genome for a 
36-bp target sequence assuming a random distribution of an equal ratio of A:C:G:T across the 
genome utilizing the binomial distribution of mutant sites multiplied by the number of spacer 
lengths allowed (14). Number of sites with m mutations = genome size (2 x 3.1 x 109) x spacer 
length allowance (14) x binomial distribution of mutations in a 36-bp target site with a 0.75 
probability of a mutation occurring [(36! / (m! x (36 - m)!)) x (0.75)m x (0.25)36-m]. 
 
 Therefore, we used a machine-learning algorithm31 trained on the tens of thousands of off-target 
sites revealed by the in vitro selection to identify rare TALEN candidate off-target sites in the 
human genome.  The “classifier” algorithm calculates the posterior probability of each 
nucleotide in each position of a target to occur in a sequence that was cleaved by the TALENs in 
opposition to sequences from the target library that were not observed to be cleaved.28  These 
posterior probabilities were then used to score the likelihood that the TALEN used to train the 
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algorithm would cleave every possible target sequence in the human genome with monomer 
spacing of 10 to 30 bps.  Since sites containing the longest tested DNA spacers (24 bp) were 
productively cleaved during the in vitro selection, target sites with even longer spacers were 
considered for potential off-target modification in the genome.  
  Using this “classifier” algorithm, we identified the 36 best-scoring heterodimeric 
candidate off-target sites for the ATM TALENs and 48 of the best-scoring candidate off-target 
sites for the CCR5A TALENs (Table 1.12).  
A 
CCR5A 
Site Score Mut. Left half-site 
Spacer 
length Right half-site 
OnCCR5A 0.008 0 TTCATTACACCTGCAGCT 18 AGTATCAATTCTGGAAGA 
OffC-1 0.747 9 TaCATcACAtaTGCAaaT 29 tGTATCAtTTCTGGgAGA 
OffC-2 0.747 9 TaCATcACAtaTGCAaaT 29 tGTATCAtTTCTGGgAGA 
OffC-3 0.747 9 TaCATcACAtaTGCAaaT 29 tGTATCAtTTCTGGgAGA 
OffC-4 0.747 11 TcCATaACACaTctttCT 10 tGcATCAtTcCTGGAAGA 
OffC-5 0.804 11 TcCAaTACctCTGCcaCa 14 AGgAgCAAcTCTGGgAGA 
OffC-6 0.818 10 TTCAgTcCAtCTGaAaac 16 gGTATCAtTTCTGGAgGA 
OffC-7 0.834 14 TaCAaaACcCtTGCcaaa 27 taTATCAATTtgGGgAGA 
OffC-8 0.837 12 TcCAagACACCTGCttac 26 tcTATCAATTtgGGgAGA 
OffC-9 0.874 10 TTCATaACAtCTtaAaaT 27 AaTAcCAAcTCTGGAtGA 
OffC-10 0.89 12 TcCAaaACAtCTGaAaaT 25 tGgATCAAaTtgGGAAGA 
OffC-11 0.896 12 TTCAgaACACaTGactac 21 tGTATCAgTTaTGGAtGA 
OffC-12 0.904 13 TcCATaAtAtCTtCctCT 28 gGgATtAATTtgGGAgGA 
OffC-13 0.905 11 TgCAaTAtACCTGttGaT 16 ctcATCAATTCTGGgtGA 
OffC-14 0.906 12 TTCATaACACtccacctT 16 gGTATCAAaTCTGGggGA 
OffC-15 0.906 12 TcCATgACACaaaagaCT 26 gGTATCtATcCTGGAAtA 
OffC-16 0.906 9 TTCcTTcCACCaGtgtCc 28 AGcATCAATcCTGGAAGA 
OffC-17 0.907 10 TTaATaACAtCTcCAaCT 24 gGcAcCAAaTCTGGAtGA 
OffC-18 0.909 13 TcCATcACcCCTcCctCc 10 gGTgcCAgcTCTGGAgGA 
OffC-19 0.909 8 TTCATTACtCCTcCttCT 30 ctTATCAcTTtTGGAAGA 
OffC-20 0.912 10 TgCATTACACaTtatGtg 17 AGcAgCAcTTCTGGAAGA 
OffC-21 0.913 11 TTCAaaACACaTaCAtCT 28 AacAaCAtTcCTGtAAGA 
OffC-22 0.913 10 TcCATTACcaCTGCAGaT 25 gacATCAgTTaTGGAtGA 
OffC-23 0.925 13 TTCcagACcCCTtCctCa 13 gacATCAAaTCTGGgAGA 
OffC-24 0.927 12 TTCcaaACACCcGCttCc 26 taTATCctTTCTGGAAtA 
OffC-25 0.93 12 TgaAaTACACCTGCctaT 13 gGccTCAAggCTGGAtGA 
OffC-26 0.93 12 TgCcaaACctCTGtcaCc 22 AGgATCAcTTCTGGAAGA 
OffC-27 0.931 12 TgCcaaACctCTGtcaCc 22 AGgATCAcTTCTGGAAGA 
Table 1.12 (Conitinued).  Predicted ATM and CCR5A off-target sites in the human 
genome.   
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OffC-28 0.931 8 TTtATTACACtTcCAGaT 19 gaTATCctTTCTGGAAGA 
OffC-29 0.932 13 TaCAaaAaACtTtCtGag 27 tGTATCAATTtgGGgAGA 
OffC-30 0.932 11 TcCAaaACACCcaCAGac 19 gGTATagATTgTGGAAGA 
OffC-31 0.934 13 TTCATTcCACaTcCccac 25 gtTATCAAcatgGGAAGA 
OffC-32 0.934 11 TTCAaTAtgCCaaCAGCT 11 AGctTCAATctgGGAgGA 
OffC-33 0.934 12 TTCAaTACACtTGtctaT 12 tGTgTCAtTTCTGGgttA 
OffC-34 0.935 11 TTCAacACACCTtCAaaa 12 tGTgTCAtTaaTGGAAGA 
OffC-35 0.935 10 TTCAaaACAtCTGacatT 10 AaTAgaAATTCTGGAAGA 
OffC-36 0.935' 11 cTCcTaAtACCTGCAaaT 21 gaTATtAtTTCTGGAgGA 
OffC-38 0.939' 10 TTCATaACAaCTtaAaCa 16 tGgATCAATTgTGGAAtA 
OffC-39 0.941' 9 TTaATTAtAttTttAaCa 25 AGTAcCAATTCTGGAAGA 
OffC-40 0.941' 9 TTaATTAtAttTttAaCa 25 AGTAcCAATTCTGGAAGA 
OffC-42  0.941' 9 TcaATTAtACCTaCAtaT 24 AGTtTCAATTtaGGAAGA 
OffC-45 0.943' 10 aTCATTgCcCCTGCAGag 23 gGTATCttTcCTGGAtGA 
OffC-49 0.946' 9 TTCAaTACACCTaCAtCa 15 AGTcaCAtTTCTGGAAtt 
OffC-56 0.951' 9 TgCATTACAaCTGaAGac 19 AGcATtAcTTCaGGAAGA 
OffC-65  0.956' 9 TaCATTcCACCTaCttCc 22 AGTtTgAcTTCTGGAAGA 
OffC-69 0.958' 9 TTCATTACACCcaCtGCT 23 caTtTCtAgTCTGGAttA 
OffC-76 0.96' 9 TcCATaAtcCCatCAGCT 19 AGTgTCAtTTCTGGAAGg 
OffC-137 0.974' 9 TTCATTAtgCCTGCAGta 14 AGcATCAATTCatGAtGA 
OffC-150 0.975' 9 TTCATTgCACCTGataCT 16 gGaAcCtATTCTGGAAGt 
B  
OnATM 0.000' 0 TGAATTGGGATGCTGTTT     18 TTTATTTTACTGTCTTTA 
OffA-1 0.595' 7 TGAATaGGaAataTaTTT 20 TTTATTTTACTGTtTTTA 
OffA-2 0.697' 9 TGgATTcaGATaCTcTTT 10 TTTATTTTttTaTtTTTA 
OffA-3 0.697' 9 TGgATTcaGATaCTcTTT 10 TTTATTTTttTaTtTTTA 
OffA-4 0.697' 9 TGgATTcaGATaCTcTTT 10 TTTATTTTttTaTtTTTA 
OffA-5 0.697' 9 TGgATTcaGATaCTcTTT 10 TTTATTTTttTaTtTTTA 
OffA-6 0.697' 9 TGgATTcaGATaCTcTTT 10 TTTATTTTttTaTtTTTA 
OffA-7 0.697' 9 TGgATTcaGATaCTcTTT 10 TTTATTTTttTaTtTTTA 
OffA-8 0.7' 8 TGcATaGGaATGCTaaTT 10 TTTATTTTACTaTtTaTA 
OffA-9 0.708' 10 TGAATTaaaATcCTGcTT 19 gTTATaTgACTaTtTTTA 
OffA-10 0.711' 10 TccATTaaaATaCTaTTT 18 TTTATTTTAtTaTtTTTA 
OffA-11 0.715' 10 TGAATTGaGAgaagcaTT 16 TTTATTTTAtTaTtTTTA 
OffA-12 0.725' 10 TGAAgTGGGATaCTGTTa 29 ggTATaTTAtaaTtTTTA 
OffA-13 0.729' 9 TGAATTatGAaGCTacTT 17 TTTATTgTAaTaTtTTTA 
OffA-14 0.731' 9 TGAATaaGGATGCTaTTa 25 TTTATTTattTaTtTTTA 
OffA-15 0.744' 10 TGAATgGGGAcaCaGcca 29 TTTATTTTAtTaTtTTTA 
OffA-16 0.752' 9 TaAATgGaaATGCTGTTc 24 aTTATTTTAtTGTtTTTt 
OffA-17 0.761' 9 gGAAaTGGGATaCTGagT 15 TTTATgTTACTaTtTcTA 
OffA-18 0.781' 11 TGgATcGaagTGaTtaTT 23 TTTATTTTAtTaTtTTTA 
OffA-19 0.792' 11 TGAATTGaGATtCacagc 23 TTTATTTTttTaTtTTTA 
Table 1.12 (Continued).  Predicted ATM and CCR5A off-target sites in the human genome.   
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OffA-20 0.803' 8 TGAATTaGGAatCTGaTT 10 TTTATTTTAtTaTtaTTA 
OffA-21 0.807' 12 TaAATTaaaATaCTccag 23 aTTATTTTAaTGTtTTTA 
OffA-22 0.811' 10 TGAATaGGaATatTcTTT 12 TTTATTTattTaTtTTTA 
OffA-23 0.811' 9 TagATTGaaATGCTGTTT 15 TTTtTaTTAtTaTtTTTA 
OffA-24 0.816' 10 TGAcTaGaaATGaTGaTT 25 TTTATTTTctTaTtTTTA 
OffA-25 0.817' 12 TGAATTtaaAaaaTGTcc 13 aTTATTTTAtTaTtTTTA 
OffA-26 0.817' 12 TGAATTtaaAaaaTGTcc 13 aTTATTTTAtTaTtTTTA 
OffA-27 0.817' 10 TGgATccaGATaCTcTTT 10 TTTATTTTttTaTtTTTA 
OffA-28 0.819' 7 TGgAgTGaGATcCTGTTT 21 TTTATTTTAtTGTtaTTA 
OffA-29 0.824' 8 TGAAcTtGGATGaTaTaT 24 TTTATTTgAtTaTCTTTA 
OffA-30 0.832' 9 TGtATTGGGATaCcaTTT 26 TcTATTTTAtTaTtTTTt 
OffA-31 0.833' 9 TcAATTGGGATGaTcaTa 23 TTTATTcTAtTtTtTTTA 
OffA-32 0.835' 9 TGAAagGGaAaGtTGgaT 23 TTTATTTTACTaTtTTTA 
OffA-33 0.841' 9 TGgtTTGGGATcCTGTgT 27 TTTATgTTttTaTtTTTA 
OffA-34 0.841' 9 TGAAaTGGGATGagcTTg 28 TTTATTTTAtTaTtTTaA 
OffA-35 0.844' 10 TGAATTGGGATaCTGTag 29 cTTAaaTaAaTaTtTTTA 
OffA-36 0.844' 10 TGAATTGtGgTatTGccT 18 TTTATggTttTGTCTTTA 
Table 1.12 (Continued).  Predicted ATM and CCR5A off-target sites in the human genome.   
 (A) Using a machine-learning “classifier” algorithm trained on the output of the in vitro CCR5A 
TALEN selection,15 mutant sequences of the target site allowing for spacer lengths of 10 to 30 
base pairs were scored.  The resulting 36 predicted off-targets sites with the best scores for the 
CCR5A TALENs and the next 12 best-scoring off-target sites with nine or ten mutations are 
shown with their respective classifier scores, mutation numbers, left and right half-site sequences 
(mutations from on-target in lower case), and the length of the spacer between half-sites in base 
pairs.  (B) The 36 predicted off-targets sites with the best scores for the ATM TALENs for ATM 
TALENs (without the next 12 best-scoring off-target sites with nine or ten mutations) are listed 
as OffA.   
 
  These sites differ from the on-target sequence at seven to fourteen positions.  These 84 
predicted off-target sites for CCR5A and ATM TALENs were amplified from genomic DNA 
purified from human U2OS-EGFP cells expressing either CCR5A or ATM TALENs.12  
Sequences containing insertions or deletions of three or more base pairs in the DNA spacer of the 
potential genomic off-target sites and present in significantly greater numbers in the TALEN-
treated samples versus the untreated control sample were considered TALEN-induced 
modifications.  Consistent with a previous report3, CCR5A or ATM TALENs containing 
ELD/KKR and homodimeric FokI domains demonstrated increased on-target activity compared 
to EL/KK FokI domains.  Of the 45 CCR5A off-target sites that we successfully amplified, we 
identified nine off-target sites with TALEN-induced modifications; likewise, of the 31 ATM off-
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target sites that we successfully amplified, we observed seven off-target sites with TALEN-
induced modifications (Table 1.13).   
Site No TALEN 
ATM 
EL/KK FokI 
ATM 
ELD/KKR FokI 
ATM 
Homo FokI 
OnATM 0.007% 6.8% 16% 18% 
 
OffA-1  <0.006% <0.006% 0.026% 0.077% 
OffA-11  <0.006% <0.006% 0.036% 0.39% 
OffA-13 <0.006% 0.008% 0.025% <0.006% 
OffA-16 <0.006% <0.006% <0.006% 0.057% 
OffA-17 <0.051% <0.14% <0.17% 0.94% 
OffA-23 0.018% <0.006% 0.29% 0.23% 
OffA-35  <0.006% <0.006% <0.006% 0.070% 
Site No TALEN 
CCR5A 
EL/KK FokI 
 
CCR5A 
ELD/KKR FokI 
CCR5A 
Homo FokI 
OnCCR5A <0.006% 9.8% 28% 47% 
OffC-5 <0.006% 0.53% 2.3% 2.3% 
OffC-15 <0.020% <0.014% 0.23% 0.043% 
OffC-16 <0.006% <0.006% 0.031% <0.006% 
OffC-28 <0.009% 0.014% 0.16% 0.056% 
OffC-36 <0.006% <0.006% 0.15% 0.028% 
OffC-38 <0.006% ND ND 0.067% 
OffC-49 <0.006% ND ND 0.110% 
OffC-69 <0.010% ND ND 0.089% 
OffC-76 <0.006% ND ND 0.149% 
A
B
!
Table 1.13.   Cellular modification induced by ATM and CCR5A TALENs at on-target and 
predicted off-target genomic sites. (A) For cells treated with either no TALEN or CCR5A 
TALENs containing heterodimeric EL/KK, heterodimeric ELD/KKR, or the homodimeric 
(Homo) FokI variants, cellular modification rates are shown as the percentage of observed 
insertions or deletions (indels) consistent with TALEN cleavage relative to the total number of 
sequences for on-target (On) and predicted off-target sites (Off).  See the main text for details.  
ND refers to no data collected since the cellular modification of off-target sites OffC-38, OffC-
49, OffC-69 and OffC-76 was not assayed for CCR5A TALENs containing EL/KK and 
ELD/KKR FokI domains.  (B) Same as (A) for ATM TALENs. 
 
The inspection of modified on-target and off-target sites yielded a prevalence of deletions 
ranging from three to dozens of base pairs (Figure 1.11), consistent with previously described 
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characteristics of TALEN-induced genomic modification.36  
OnCCR5A 
TTCATTACACCTGCAGCTCTCATTTTCCATACAGTCAGTATCAATTCTGGAAGA (7267) ref!
TTCATTACACCTGCAGCTCTCAT-------ACAGTCAGTATCAATTCTGGAAGA (76)!
TTCATTACACCTGCAG------------------TCAGTATCAATTCTGGAAGA (63)!
TTCATTACACCTG------------------------------------GAAGA (61)!
!
OffC-2 
TACATCACATATGCAAATTGACTCAAAATGGATCATAGACCTAAATGTGTATCATTTCTGGGAGA (163332) ref!
TACATCACATATGCAAATTGACTCAAAATGGATCA---ACCTAAATGTGTATCATTTCTGGGAGA (6)!
TACATCACATATGCAAATTGACTCAAAATG-------GACCTAAATGTGTATCATTTCTGGGAGA (4)!
!
OffC-5 
TCCAATACCTCTGCCACACCCAGGCATTGGCCAGGAGCAACTCTGGGAGA (17045) ref!
TCCAATACCTCTGCCACAC-----------CCAGGAGCAACTCTGGGAGA (28)!
TCCAATACCTCTG----------GCATTGGCCAGGAGCAACTCTGGGAGA (12)!
TCCAATAC--------------------------------CTCTGGGAGA (10)!
!
OffC-15!
TCCATGACACAAAAGACTTCCCTGATTTCTTCTAAGGCATCACTGGTATCTATCCTGGAATA (6967) ref!
TCCATGACACAAAAGACTTCCCTGATTTCTTCTAAGG-----CTGGTATCTATCCTGGAATA (6)!
!
OffC-16!
TTCCTTCCACCAGTGTCCACAGTCTTCACACTGATCACCAAATCCCAGCATCAATCCTGGAAGA (38536) ref!
TTCCTTCCACCAGTGTCCACAGTC-----------CACCAAATCCCAGCATCAATCCTGGAAGA (4)!
!
OffC-28!
TTTATTACACTTCCAGATCTTTTATTTTAAGTTACCAGATATCCTTTCTGGAAGA (7379) ref!
TTTATTACACTT----------------------CCAGATATCCTTTCTGGAAGA (3)!
TTTATTACACTTCCAGATCTTTT---------------ATATCCTTTCTGGAAGA (2)!
TTTATTACACTTCCAGATCTTT-----------------TATCCTTTCTGGAAGA (2)!
!
OffC-36 
CTCCTAATACCTGCAAATTATAAGGACACTATTTGACTTGATATTATTTCTGGAGGA (12461) ref!
CTCCTAATACCTGCAAATTATAAGGACACT----GACTTGATATTATTTCTGGAGGA (11)! !
Figure 1.11.  Modifications induced by TALENs at on-target and predicted off-target 
genomic sites.  Examples of modified sequences at the on-target site and off-target sites for cells 
treated with CCR5A TALENs containing the ELD/KKR FokI domains.  For each example 
shown, the unmodified reference genomic site (ref) is the first sequence, followed by the top 
three sequences containing deletions.  The numbers in parentheses indicate sequencing counts 
and the half-sites are underlined and bolded. !
These results collectively indicate in vitro selection data processed through a machine-learning 
algorithm, can predict bona fide off-target substrates that undergo TALEN-induced modification 
in human cells.   
To better understand the likelihood of detecting genomic off-target sites using other 
methods, three previously reported TALENs targeting separate sites in the human HDAC1, 
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PMS2, and SDHD genes12 were constructed with ELD/KKR FokI domains.  These TALENs 
were chosen because their target sites are only three to five mutations away from potential off-
target sites in the human genome (Table 1.14).   
Site Mut. Left half-site 
Spacer 
length Right half-site 
OnHDAC  0 TGGCGCAGACGCAGGGC 17 TTACTACTACGACGGTGA 
OffHDAC-1 3 TGaCGCAGACaCAGGGC 17 TTACTACTACGACGGgGA 
     
OnPMS 0 TCGGGTGTTGCATCCATG 18 AGGTGAGCGGGGCTCGCA 
OffPMS-1 4 TCcGGTGTTGCATCCtTG 18 AGGTGAGCtGGGCTCGCg 
OffPMS-2 4 TCcGGTGTTGCATCCtTG 18 AGGTGAGCtGGGCTCGCg 
     
OnSDHD 0 TCAGGAACGAGATGGCGG 17 GCCGTTTGCGGTGCCCTA 
OffSDHD-1 1 TCAGGAACGAGATGGCGG 17 GCCGTTTGCGGTGCCCaA 
OffSDHD-3 3 TCAGGAACGAGATGGCGG 17 GCCcTTTGCaGTGCCCaA 
OffSDHD-4 3 TCAGGAACGAGATGGCGG 17 GCCcTTTaCGGTGCCCaA 
OffSDHD-5 5 TCAGGAAtGAGATGGCGG 17 aCCcTTcGCGGTGCCCaA 
Table 1.14.  Predicted HDAC1, PMS2, and SDHD off-target sites in the human genome.  
List of genomic on-target and off-targets sites with one to five mutations from the on-target site 
of the HDAC1, PMS2, and SDHD TALENs.  Sites were identified by a simple computational 
search for off-target sites closely related to the target site in the human genome.  Sites are shown 
with mutation numbers, left and right half-site sequences (with mutations from on-target in lower 
case), and the length of the spacer between half-sites in base pairs. 
    
The HDAC1, PMS2, and SDHD putative off-target and on-target sites were amplified from 
genomic DNA isolated from cells expressing the appropriate TALENs.  Since only three out of 
six of these more closely related off-target sites containing three to five mutations were 
significantly modified (Table 1.15), it is likely that more distant off-target sites with 8 to 12 
mutations would be very difficult to predict and detect, consistent with reports14-16, 38 that fail to 
identify TALEN-induced off-target site modification in cells.   
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Site No TALEN HDAC1 TALEN 
OnHDAC < 0.001% 5.22% 
OffHDAC-1 < 0.001% 0.052% 
Site No TALEN SHDD TALEN 
OnSDHD < 0.001% 33.10% 
OffSDHD-1 < 0.001% 0.246% 
OffSDHD-2 < 0.001% < 0.001% 
OffSDHD-3 < 0.001% 0.002% 
OffSDHD-4 < 0.001% < 0.001% 
Site No TALEN PMS2 TALEN 
OnPMS 0.006% 20.36% 
OffPMS-1 < 0.001% 1.439% 
OffPMS-2 0.002% 3.930%  
Table 1.15.   Cellular modification induced by HDAC1, PMS2, and SDHD TALENs at on-
target and predicted off-target genomic sites. (A) For cells treated with either no TALEN or 
HDAC1, PMS2, or SDHD TALENs containing heterodimeric ELD/KKR FokI variants, cellular 
modification rates are shown as the percentage of observed insertions or deletions (indels) 
consistent with TALEN cleavage relative to the total number of sequences for on-target (On) and 
predicted off-target sites (Off).  See the main text for details.   
 
Thus, the challenge of identifying bona fide genomic off-target sites is compounded by the 
presence of more than 10,000 potential genomic off-target sites containing 8 to 12 mismatches 
out of 36 recognized bases revealed by both computational identification and statistical modeling 
(Table 1.11). 
To compare genomic off-target site prediction by our classifier to a purely computational 
approach, we used a recently developed ab initio genomic off-target site prediction algorithm, 
TALENoffer,37 to identify the 32 best-scoring genomic off-target sites for the CCR5A TALEN.  
These TALENoffer-predicted off-target sites were amplified from genomic DNA purified from 
cells expressing the CCR5A TALEN with homodimeric FokI domains, and assayed for cellular 
modification (Table 1.16).   
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Site Score Mut. Left half-site 
Spacer 
length Right half-site Classifier 
CP_CCRoff-1 -1.503 9 aTaATTACACCTGCAaCT 24 AGTgTCAgTTtgGtAAGt  
CP_CCRoff-2 -1.524 9 TTCATTACAaaTaCAGaa 23 AGaATttATTCTGtAAGA  
CP_CCRoff-3 -1.53 10 TTCtTTAaACCTaaAaCT 21 AtTATtAtTTtTGGAAGt  
CP_CCRoff-4 -1.534 8 TTCATTACtCCTcCttCT 30 ctTATCAcTTtTGGAAGA OffC-19 
CP_CCRoff-5 -1.537 8 TTttTTACtCCTGtAaCa 21 AGTcTCAATTtTGGAAGA  
CP_CCRoff-6 -1.571 9 TTCATTcaACCTtCAaCT 21 AcagTgAATTtTGGAAGA  
CP_CCRoff-7 -1.583 9 TcaATTAtACCTaCAtaT 24 AGTtTCAATTtaGGAAGA OffC-42 
CP_CCRoff-8 -1.583 9 gcCAcTgCAaCTcCAGCc 30 AGTATCAtTTtTGGAAGA  
CP_CCRoff-9 -1.594 9 TaCATcACAtaTGCAaaT 29 tGTATCAtTTCTGGgAGA OffC-1 
CP_CCRoff-10 -1.594 9 TaCATcACAtaTGCAaaT 29 tGTATCAtTTCTGGgAGA OffC-2 
CP_CCRoff-11 -1.594 9 TaCATcACAtaTGCAaaT 29 tGTATCAtTTCTGGgAGA OffC-3 
CP_CCRoff-12 -1.594 9 TaCATTcCACCTaCttCc 22 AGTtTgAcTTCTGGAAGA  
CP_CCRoff-13 -1.606 11 TcCcTTcCACCcaCAaCT 26 AGTATtAgTTCTGGggtA  
CP_CCRoff-14 -1.606 9 TTCATTtCAtCTcaAaCT 13 AaTgTCAtTTCTGtAAGA  
CP_CCRoff-15 -1.611 9 TcCccTACctCTGCAGCT 28 AGTgTCAcTTCTGGgAGg  
CP_CCRoff-16 -1.611 8 TTCATcttcCCTGCAGCg 27 AGaATCAAaTCTGtAAGA  
CP_CCRoff-17 -1.617 9 TTCATTACAaaTGCAGta 29 tGTATgAATTtgaGAAGA  
CP_CCRoff-18 -1.62 8 TTtATTACACtTcCAGaT 19 gaTATCctTTCTGGAAGA OffC-28 
CP_CCRoff-19 -1.621 10 TTCtaTAaAaCTcCAaCT 11 AGTATgAATTCTttAAtA  
CP_CCRoff-20 -1.622 9 TTCtTTACACCTcCAGCT 22 AaaATCAAagtTtGAtGA  
CP_CCRoff-21 -1.635 10 TTCATTAtcaCTcCAaCT 10 AtTAggAgTcCTGGAAGA  
CP_CCRoff-22 -1.637 10 TTCtcTACACCTGaAaCc 12 AGcATtgtgTCTGGAAGA  
CP_CCRoff-23 -1.638 8 TTaATTAaACCTGCAGtT 24 tacATtAATTCTGGAAaA  
CP_CCRoff-24 -1.65 11 TTCATTACAaCcaaAatT 29 AGTAatAATgtTGGgAGA  
CP_CCRoff-25 -1.651 10 TTCcTTACcCCTGCAtCT 21 tGTtTCAtTTtTttgAGA  
CP_CCRoff-26 -1.653 8 TggAcTgCACCTGCAGCT 23 AGctTtgATTCTGGAAGA  
CP_CCRoff-27 -1.653 11 TTCATTtCACaTaCAcCc 20 AtTATgAAgTtTtGAtGA  
CP_CCRoff-28 -1.654 10 TTCATTAaACaTGaAaCT 16 AGTATgAgcTCatGgAGA  
CP_CCRoff-29 -1.655 9 TTCAcTACACCTGCAGCc 26 AtaATgAcTTCTGGctGg  
CP_CCRoff-30 -1.655 10 TTaATTcCACCTGCAGCT 29 gGTcaCAggTtTtGgAGA  
CP_CCRoff-31 -1.659 8 TTCtaaACACCTGtAGCT 27 AGgAaCAATaCTGGAtGA  
CP_CCRoff-32 -1.662 10 TTCATTtgACCTcCcaCT 17 tGTgggAATTCTGGgAGA  
Table 1.16.  Purely computationally predicted off-target sites in the human genome using 
TALENoffer program.  Computationally predicted genomic off-target sites from TALENoffer 
program9 allowing for spacer lengths of 10 to 30 base pairs and only searching for heterodimeric 
off-target sites.  The resulting 32 predicted off-targets sites with the best scores for the CCR5A 
TALENs are shown with their respective classifier scores, mutation numbers, left and right half-
site sequences (with mutations from on-target in lower case), and the length of the spacer 
between half-sites in base pairs. 
 
Since the TALENoffer sites were only eight to 11 mutations from the on-target site, they were on 
average less distant from the on-target sequence than the off-target sites predicted by our 
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classifier (9.2 versus 11.1 mean mutations in the off-target sites from the TALENoffer versus 
from our classifier, respectively).  Therefore, from our classifier prediction of genomic off-target 
sites for the CCR5A TALEN, only CCR5A genomic off-target sites containing eight to 11 
mutations were considered for comparison to TALENoffer sites.  Both sets of sites were assayed 
for cellular modification by the CCR5A TALEN with homodimeric FokI domains (Table 1.17 
and Table 1.18).   
C-terminal 
domain:  No TALEN Canonical 
FokI domain:  No TALEN Homo  
TALENoffer  
site 
Classifier  
site Indels Total Indels Total % Modified P-value 
OnCCR5A  0 9997 3006 9773 30.758% < 1.0E-250 
CP_CCRoff-1  0 9135 2 17468 0.011%  
CP_CCRoff-2  0 63390 0 36666 < 0.006%  
CP_CCRoff-3  14 11594 7 10460 0.067%  
CP_CCRoff-4 OffC-19 0 28732 0 26314 < 0.006%  
CP_CCRoff-5  0 21413 0 21538 < 0.006%  
CP_CCRoff-6  0 22764 0 28279 < 0.006%  
CP_CCRoff-8  2 24054 0 25702 < 0.006%  
CP_CCRoff-9 OffC-1 1 68283 6 59642 0.010%  
CP_CCRoff-10 OffC-2 0 68421 4 59558 0.007%  
CP_CCRoff-11 OffC-3 0 68421 4 59558 0.007%  
CP_CCRoff-12  0 14364 0 13806 < 0.007%  
CP_CCRoff-13  0 15016 0 24585 < 0.006%  
CP_CCRoff-14  0 28025 1 27546 < 0.006%  
CP_CCRoff-15  0 16105 8 13019 0.061% 1.59E-03 
CP_CCRoff-16  0 26453 1 29619 < 0.006%  
CP_CCRoff-17  0 21155 1 28839 < 0.006%  
CP_CCRoff-18 OffC-28 0 28111 52 12591 0.413% 2.34E-19 
CP_CCRoff-19  0 35891 0 33962 < 0.006%  
CP_CCRoff-20  0 64345 1 118954 < 0.006%  
CP_CCRoff-21  0 14857 0 11150 < 0.009%  
CP_CCRoff-22  0 14368 0 37008 < 0.006%  
CP_CCRoff-23  3 22876 7 20671 0.034%  
CP_CCRoff-24  4 129051 1 50695 < 0.006%  
CP_CCRoff-25  0 0 1 39845 < 0.006%  
CP_CCRoff-26  0 21677 0 24695 < 0.006%  
CP_CCRoff-27  0 24710 0 43452 < 0.006%  
Table 1.16.  Cellular modification induced by CCR5A TALENs at on-target and predicted 
off-target genomic sites generated by TALENoffer.   
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CP_CCRoff-28  0 10269 0 11496 < 0.009%  
CP_CCRoff-29  3 121960 2 100659 < 0.006%  
CP_CCRoff-30  0 18320 0 12945 < 0.008%  
CP_CCRoff-31  0 74541 1 89994 < 0.006%  
CP_CCRoff-32  0 29550 1 102087 < 0.006%  
 
Table 1.16 (Continued).  Cellular modification induced by CCR5A TALENs at on-target 
and predicted off-target genomic sites generated by TALENoffer.  Results from sequencing 
CCR5A on-target and each genomic off-target site predicted by TALENoffer that amplified from 
50 ng genomic DNA isolated from human cells treated with either no TALEN or TALENs 
containing canonical C-terminal domains and homodimeric (Homo) FokI domains.  Indels: the 
number of observed sequences containing insertions or deletions consistent with TALEN-
induced cleavage.  Total: total number of sequence counts.  Modified: number of indels divided 
by total number of sequences, expressed as percentages.  Upper limits of potential modification 
were calculated for sites with no observed indels by assuming there is less than one indel then 
dividing by the total sequence count to arrive at an upper limit modification percentage, or taking 
the theoretical limit of detection (1/16,400), whichever value was larger.  P-values: calculated as 
previously reported15 using a (right) one-sided Fisher’s exact test between each canonical C-
terminal domain TALEN-treated sample and the untreated control sample.  P-values of 
< 0.00161 were considered significant and are shown.  The significance cut off of 0.00161 was 
based on the multiple comparison correction from the Benjamini-Hochberg method.16, 17  
Specificity is the ratio of on-target to off-target genomic modification frequency for each site.  
 
 
 44 
 
 
C-terminal 
domain: No TALEN 
 
Canonical  
FokI 
domain: No TALEN 
 
Homo  
Classifier  
site Indels Total Indels Total 
 
% Modified P-value 
OffC-1 0 51248 1 87496 < 0.006%   
OffC-2 6 124356 0 163322 < 0.006%  
OffC-3 6 124356 0 163322 < 0.006%  
OffC-4 0 45377 0 40452 < 0.006%  
OffC-5 0 27009 395 17077 2.313% 1.20E-164 
OffC-6 0 10766 0 6560 < 0.015%  
OffC-9 0 40603 0 30771 < 0.006%  
OffC-13 0 65518 0 78546 < 0.006%  
OffC-16 0 36228 0 32636 < 0.006%  
OffC-17 0 32112 0 31299 < 0.006%  
OffC-19 1 22868 0 28478 < 0.006%  
OffC-20 0 23335 0 18972 < 0.006%  
OffC-21 0 34302 0 21161 < 0.006%  
OffC-22 1 81037 0 104857 < 0.006%  
OffC-28 0 28111 52 12591 0.056% 2.34E-19 
OffC-30 0 11840 0 6285 < 0.015%  
OffC-32 0 1944 0 19115 < 0.006%  
OffC-34 0 9052 0 9072 < 0.011%  
OffC-35 0 23839 0 11897 < 0.008%  
OffC-36 1 23412 5 18052 0.028%  
OffC-38 0 16396 9 13351 0.067% 7.38E-04 
OffC-39 0 51962 0 13562 < 0.007%  
OffC-40 0 3910 0 24711 < 0.006%  
OffC-49 0 26333 27 24497 0.110% 2.74E-09 
OffC-56 0 25357 0 26999 < 0.006%  
OffC-65 0 14364 0 13806 < 0.007%  
OffC-69 0 10407 25 27950 0.089% 4.90E-04 
OffC-76 0 61760 59 39617 0.149% 8.19E-25 
OffC-137 0 26470 0 23318 < 0.006%  
OffC-150 0 22058 5 20952 0.024%  
Table 1.17 (Continued).  Cellular modification induced by CCR5A TALENs at on-target 
and predicted off-target genomic sites generated by the classifier trained on selection 
results.   
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Table 1.17 (Continued).  Cellular modification induced by CCR5A TALENs at on-target 
and predicted off-target genomic sites generated by the classifier trained on selection 
results.  Results from sequencing CCR5A on-target and each genomic off-target site with eight 
to 11 mutations predicted by the classifier and the next 10 best-scoring amplified off-target sites 
with nine or ten mutations (OffC-38 to OffC-150) after the first 36 top-scoring genomic off-
target site predicted by the classifer.  Sites that amplified from 50 ng genomic DNA isolated 
from human cells treated with either no TALEN or TALENs containing canonical C-terminal 
domains and homodimeric (Homo) FokI domains.  Indels: the number of observed sequences 
containing insertions or deletions consistent with TALEN-induced cleavage.  Total: total number 
of sequence counts.  Modified: number of indels divided by total number of sequences, 
expressed as percentages.  Upper limits of potential modification were calculated for sites with 
no observed indels by assuming there is less than one indel then dividing by the total sequence 
count to arrive at an upper limit modification percentage, or taking the theoretical limit of 
detection (1/16,400), whichever value was larger.  P-values: calculated as previously reported15 
using a (right) one-sided Fisher’s exact test between each canonical C-terminal domain TALEN-
treated sample and the untreated control sample.  P-values < 0.0040 were considered significant 
and are shown.  The significance cut off 0.0040 was based on the multiple comparison correction 
from the Benjamini-Hochberg method.16, 17  Specificity is the ratio of on-target to off-target 
genomic modification frequency for each site.  
 
One genomic off-target site predicted by both TALENoffer and our classifier was modified in 
cells.  Of the remaining 25 amplified genomic off-target sites predicted exclusively by 
TALENoffer, only one was significantly modified in cells (Tables 1.16 and 1.17).  In contrast, 5 
of the 25 amplified genomic off-target sites exclusively predicted by our classifier were 
significantly modified in cells (Table 1.17).  These results indicate that our classifier 
outperformed purely computational prediction for off-target CCR5A TALEN substrates.  We 
directly compared our combined in vitro selection and machine learning method with 
TALENoffer, a recently described purely computational prediction method37 and found that our 
approach outperforms the purely computational approach for the identification of TALEN-
induced off-target substrates in cells.   
 
1.4  TALEN specificity as function of array length, interdependence of mismatches and 
estimation of total genomic TALEN cleavage  
The extensive number of quantitatively characterized off-target substrates in the selection 
data enabled us to address several key questions about TALEN specificity.  First, in order to 
assess whether mutations at one position in the target sequence affect the ability of TALEN 
repeats to productively bind other positions, we generated an expected enrichment value for 
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every possible double-mutant sequence for the L13+R13 CCR5B TALENs assuming 
independent contributions from the two corresponding single-mutation enrichments.  In general, 
the predicted enrichment values closely resembled the actual observed enrichment values for 
each double-mutant sequence (Figure 1.12), suggesting that component single mutations 
independently contributed to the overall cleavability of double-mutant sequences.   
 47 
 
 
A 
Sequence 
Observed enrichment value 
from selection 
Predicted enrichment value 
assuming independence 
TCATaACACCTGC 0.46  
TCATTACACCTGt 0.47  
TCATaACACCTGt 0.25 0.46 x 0.47 = 0.22 
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Figure 1.12.  Observed versus predicted double-mutant sequence enrichment values.  (A) 
An example calculation of a predicted double-mutant enrichment value from the L13+R13 
CCR5A TALEN selection.  All enrichment values were normalized to the on-target enrichment 
value (= 1.0 by definition).  Observed enrichment values of each single-mutant are shown and 
were multiplied together to calculate the predicted enrichment value of the corresponding 
double-mutant sequence.  This predicted enrichment value can then be compared to the observed 
enrichment value for the same double-mutant sequence.  (B) For the L13+R13 CCR5A TALEN 
selection, the observed double-mutant enrichment values of individual sequences (post-selection 
sequence abundance ÷ pre-selection sequence abundance) were normalized to the on-target 
enrichment value (= 1.0 by definition) and plotted against the corresponding predicted double-
mutant enrichment values calculated by multiplying the enrichment value of the component 
single-mutants normalized to the on-target enrichment.  The predicted double-mutant enrichment 
values assume independent contributions from each single mutation to the double-mutant’s 
enrichment value.  (C) The observed double-mutant sequence enrichment divided by the 
predicted double-mutant sequence enrichment plotted as a function of the distance (in base pairs) 
between the two mutations.  Only sequences with two mutations in the same half-site were 
considered. 
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The difference between the observed and predicted double-mutant enrichment values was 
relatively independent of the distance between the two mutations, except that two adjacent 
mismatches were slightly better tolerated than would be expected (Figure 1.12).  
To determine the potential interdependence of more than two mutations, we evaluated the 
relationship between selection enrichment values and the number of mutations in the post-
selection target for the L13+R13 CCR5B TALEN (Figure 1.13).  
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Figure 1.13.  In vitro specificity as a function of TALEN length.  The enrichment value of on-
target (zero mutation) and off-target sequences containing one to six mutations are shown for 
CCR5B TALENs of varying TALE repeat array lengths with EL/KK FokI domains.  The 
TALENs targeted DNA sites of 32 bp (L16+R16), 29 bp (L16+R13 or L13+R16), 26 bp 
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(L16+R10 or L13+R13 or L10+R16), 23 bp (L13+R10 or L10+R13) or 20 bp (L10+R10) in 
length. 
For 0 to 5 mutations, enrichment values closely followed a simple exponential function of the 
mean number of mutations (m) (Table 1.18).   
TALEN selection a b R2 
L13+R10 CCR5B 1.00 -1.88 0.999937 
L10+R10 CCR5B 1.00 -1.85 0.999901 
L10+R13 CCR5B 1.00 -1.71 0.999822 
L13+R13 CCR5B 1.00 -1.64 0.999771 
L13+R16 CCR5B 1.00 -1.15 0.998286 
L16+R10 CCR5B 1.00 -1.24 0.998252 
L10+R16 CCR5B 1.01 -1.08 0.996343 
L16+R13 CCR5B 1.01 -1.04 0.995844 
L16+R16 CCR5B 1.03 -0.70 0.977880 
L18+R18 ATM 1.08 -0.36 0.913087 
L18+R18 CCR5A 1.13 -0.21 0.798923 
Table S1.18.  Exponential fitting of enrichment values as function of mutation number.  
Enrichment values of post-selection sequences as function of mutation were normalized relative 
to on-target enrichment (= 1.0 by definition).  Normalized enrichment values of sequences with 
zero to four mutations were fit to an exponential function, a x eb, with R2 reported using the non-
linear least squares method.  
 
This relationship is consistent with a model in which each successive mutation reduces the 
binding energy by a constant amount (∆∆G), resulting in an exponential decrease in TALEN 
binding (Keq(m)) such that Keq(m) ~ e∆∆G*m.  The observed exponential relationship therefore 
suggests that the mean reduction in binding energy from a typical mismatch is independent of the 
number of mismatches already present in the TALEN:DNA interaction.  Collectively, these 
results indicate that TALE repeats bind their respective DNA base pairs independently beyond a 
slightly increased tolerance for adjacent mismatches. 
 To characterize the interdependence between the two TALE arrays that comprise a 
TALEN pair, we calculated the enrichment value for sequences with the same number of 
mutations in the left half-site and the same number of mutations in the right-half site (Figure 
1.14).   
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Figure 1.14.  In vitro specificity as a function of TALEN length by half-sites.  The 
enrichment value of on-target (zero mutation) and off-target sequences containing one to ten 
mutations are shown for CCR5B TALENs of varying TALE repeat array lengths with EL/KK 
FokI domains.  Enrichment values are for sequences with the identical number of mutations in 
the right half-site (x-axis) and identical number of mutations in the left-half site (colored lines).   
The TALENs targeted DNA sites of 32 bp (L16+R16), 29 bp (L16+R13 or L13+R16), 26 bp 
(L16+R10 or L13+R13 or L10+R16), 23 bp (L13+R10 or L10+R13) or 20 bp (L10+R10) in 
length. 
 
In general, the enrichment value drops per mutation of the left half-sites closely resembled the 
enrichment values decreases per mutation of the right half-site.  Thus a regular drop in 
enrichment is observed regardless of whether a mutation occurs in the left-half site or right-half 
site and regardless of whether there is already a mutation in the same or other half-site. This 
suggests that component mutations in either half-site independently contribute to the overall 
cleavability of a sequence. 
 Of note, a similar analysis of considering the number of mutations in each half-site (as 
opposed to the total in both half-sites combined) was used to demonstrate that the selection 
methodology cannot be used to effectively profile the specificity of TALENs containing 
homodimeric FokI domains (Figure 1.15).  Because sequences with highly on-target half-sites 
become enriched with little effect from two or mutations in the other-half site beyond, it is likely 
that two identical TALENs bind to repeats of a highly on-target site on the same molecule of 
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concatmeric half-sites.  They are then able to bridge the entire spacer, constant sequence and 
right half-site to dimerize and cleave. 
 
Figure 1.15.  In vitro specificity as a function of TALEN with homodimeric FokI domains 
by half-sites.  The enrichment value of on-target (zero mutation) and off-target sequences 
containing one to ten mutations are shown for CCR5B TALENs of varying TALE repeat array 
lengths with homodimeric FokI domains.  Enrichment values are for sequences with the identical 
number of mutations in the right half-site (x-axis) and identical number of mutations in the left-
half site (colored lines).   The TALENs targeted DNA sites of 32 bp (L16+R16), 29 bp 
(L16+R13 or L13+R16), 26 bp (L16+R10 or L13+R13 or L10+R16), 23 bp (L13+R10 or 
L10+R13) or 20 bp (L10+R10) in length. 
 
The independent binding of TALE repeats simplistically predicts that TALEN specificity 
per base pair is independent of target-site length.  To experimentally characterize the relationship 
between TALE array length and off-target cleavage, we constructed TALENs targeting 10, 13, or 
16 bps (including the 5’ T) for both the left (L10, L13, L16) and right (R10, R13, R16) half-sites.  
TALENs representing all nine possible combinations of left and right CCR5B TALENs were 
subjected to in vitro selection.  The results revealed that shorter TALENs have greater specificity 
per targeted base pair than longer TALENs (Table 1.6).  For example, sequences cleaved by the 
L10+R10 TALEN contained a mean of 0.032 mutations per recognized base pair, while those 
cleaved by the L16+R16 TALEN contained a mean of 0.067 mutations per recognized base pair.   
For selections with the longest CCR5B TALENs targeting 16+16 base pairs or CCR5A 
and ATM TALENs targeting 18+18 bp, the mean selection enrichment values do not follow a 
simple exponential decrease as function of mutation number (Figure 1.13 and Table 1.18).  It is 
possible these TALENs have greater affinity than is required to substantially bind and cleave the 
target site (referred to below as “excess DNA-binding energy”).  Thus, we hypothesize that 
excess DNA-binding energy from the larger number of TALE repeats in longer TALENs reduces 
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specificity by enabling the cleavage of sequences with more mutations, without a corresponding 
increase in the cleavage of sequences with fewer mutations, because the latter are already nearly 
completely cleaved.  Indeed, the in vitro cleavage efficiencies of discrete DNA sequences for 
these longer TALENs are independent of the presence of a small number of mutations in the 
target site (Figure 1.22), suggesting there is nearly complete binding and cleavage of sequences 
containing few mutations.  Likewise, higher TALEN concentrations also result in decreased 
enrichment values of sequences with few mutations while increasing the enrichment values of 
sequences with many mutations (Tables 1.7 and 1.8).  These results together support a model in 
which excessive TALEN binding arising from either long TALE arrays or high TALEN 
concentrations decreases the observed TALEN DNA cleavage specificity for each recognized 
base pair.  
Although longer TALENs are more tolerant of mismatched sequences (Figure 1.13 and 
Table 1.6) than shorter TALENs, in the human genome there are far fewer closely related off-
target sites for a longer target site than for a shorter target site (Figure 1.16). 
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Figure 1.16.  Predicted off-target genomic cleavage as a function of TALEN length 
considering both TALEN specificity and off-target site abundance in the human genome 
 53 
101 
100 
10-1 
10-2 
10-3 
0 2 4 6 8 10 12 14 
P
re
di
ct
ed
 g
en
om
ic
 o
ff-
ta
rg
et
 c
le
av
ag
e 
ev
en
ts
 p
er
 o
n-
ta
rg
et
 c
le
av
ag
e 
Total number of mutations in L + R half-sites 
L16+R16 
L16+R13 
L13+R16 
L16+R10 
L13+R13 
L10+R16 
L13+R10 
L10+R13 
L10+R10 
B 
 
Figure 1.16 (Continued).  Predicted off-target genomic cleavage as a function of TALEN 
length considering both TALEN specificity and off-target site abundance in the human 
genome.  (A) Number of sites in the human genome related to each of the nine CCR5B on-target 
sequences (L10, L13, or L16 combined with R10, R13, or R16), allowing for a spacer length 
from 12 to 25 bps between the two half-sites (Supplementary Algorithm). The TALENs targeted 
DNA sites of 32 bp (L16+R16), 29 bp (L16+R13 or L13+R16), 26 bp (L16+R10 or L13+R13 or 
L10+R16), 23 bp (L13+R10 or L10+R13) or 20 bp (L10+R10) in length  (B) For all nine 
CCR5B TALENs, overall genomic off-target cleavage frequency was predicted by multiplying 
the number of sites in the human genome containing a certain number of mutations by the 
enrichment value of off-target sequences containing that same number of mutations shown in 
(Figure 1.13).  Because enrichment values level off at high mutation numbers likely due to the 
limit of sensitivity of the selection, it was necessary to extrapolate high-mutation enrichment 
values by fitting low-mutation enrichment values as function of mutation number.  The overall 
predicted genomic cleavage was calculated only for mutation numbers with sites observed to 
occur more than once in the human genome.  For L16+R10 there are no genomic sequences with 
two mutations, causing the break in the corresponding line. 
 
Since off-target site abundance and cleavage efficiency both contribute to the number of off-
target cleavage events in a genomic context, we calculated overall genome cleavage specificity 
as a function of TALEN length by multiplying the extrapolated mean enrichment value of mutant 
sequences of a given length with the number of corresponding mutant sequences in the human 
genome (we note that this estimation assumes that extrapolated mean enrichments of highly 
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mutant off-target substrates correlate with cleavage rates in cells).  The decrease in potential off-
target site abundance resulting from the longer target site length is large enough to outweigh the 
decrease in specificity per recognized base pair observed for longer TALENs (Figure 1.16).  As 
a result, longer TALENs are predicted to be more specific against the set of potential cleavage 
sites in the human genome than shorter TALENs for the tested TALEN pairs targeting a total of 
20 to 32 base pairs.  Thus, despite being less specific per base pair, TALENs designed to cleave 
longer target sites are estimated to haves higher overall specificity than those that target shorter 
sites when considering the number of potential off-target sites in the human genome. 
 
1.5  Engineering and profiling TALENs with improved specificity 
 
The findings above suggest that TALEN specificity could be improved by reducing non-
specific DNA binding energy to only what is needed to support efficient on-target cleavage.  The 
most widely used 63-aa C-terminal domain between the TALE repeat array and the FokI 
nuclease domain contains ten cationic residues.4, 5, 7, 9, 10, 12  A related C-terminal domain variant 
(89% homology), containing 11 cationic residues, has also been used in other studies.6, 19, 34  We 
hypothesized that reducing the cationic charge of the canonical 63-aa TALE C-terminal domain 
would decrease non-specific DNA binding39 and improve the specificity of TALENs.   
We constructed two C-terminal domain variants in which three (“Q3”, consisting of 
K788Q, R792Q, and R801Q) or seven (“Q7”, consisting of K777Q, K778Q, K788Q, R789Q, 
R792Q, R793Q, and R801Q) cationic Arg or Lys residues in the canonical 63-aa C-terminal 
domain were mutated to Gln (Figure 1.17).   
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5’ TTCATTACACCTGCAGCT     N10-24     AGTATCAATTCTGGAAGA!
3’ AAGTAATGTGGACGTCGA     N10-24     TCATAGTTAAGACCTTCT!
TALE repeats FokI 
LTPEQVVAIASNNGGKQALETVQRLLPVLCQAHG!
RVD 
RVD code 
!
NI = A!
HD = C!
NN = G!
NG = T !
!
A 
N-terminus 
                              
!
SIVAQLSRPDPALAALTNDHLVALACLGGGRPALDAVKKGLPHAPALIKRTNRRIPERTSHRVA!
SIVAQLSRPDPALAALTNDHLVALACLGGGRPALDAVKKGLPHAPALIQRTNQRIPERTSHQVA !
SIVAQLSRPDPALAALTNDHLVALACLGGGRPALDAVQQGLPHAPALIQQTNQQIPERTSHQVA!
SIVAQLSRPDPALAALTNDHLVALACLG------------------------------------!
            !
!
C-terminal domain!
Canonical 
Q3 
Q7 
28-aa !
Figure 1.17.  TALEN architecture. The C-terminal domain variants used in this study are 
shown in green with mutations in black.   
 
We performed in vitro selections on CCR5A and ATM TALENs containing the canonical 63-aa, 
the engineered Q3, and the engineered Q7 C-terminal domains, as well as a previously reported 
28-aa truncated C-terminal domain5 with a theoretical net charge (-1) identical to that of the Q7 
C-terminal domain.  The on-target sequence enrichment values for the CCR5A and ATM 
selections increased substantially as the net charge of the C-terminal domain decreased (Figure 
1.18).  
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Figure 1.18.   In vitro specificity and discrete cleavage efficiencies of TALENs containing 
canonical or engineered C-terminal domains.  On-target enrichment values for selections of 
(A) CCR5A TALENs containing canonical, Q3, Q7, or 28-aa C-terminal domains with EL/KK 
FokI domains or (B) ATM TALENs containing canonical, Q3 or Q7 C-terminal domains with 
EL/KK FokI domains.  
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For example, the ATM selections resulted in on-target enrichment values of 510, 50, and 20 for 
the Q7, Q3, and canonical 63-aa C-terminal variants, respectively.  These results suggest that the 
TALEN variants in which cationic residues in the C-terminal domain have been partially 
replaced by neutral residues or completely removed are substantially more specific in vitro than 
the TALENs that contain the canonical, commonly used 63-aa C-terminal domain.   
The model of TALEN binding and specificity described in the main text predicts that 
reducing excess TALEN binding energy will increase TALEN DNA cleavage specificity.  To 
further test this prediction and potentially further augment TALEN specificity, we mutated one 
(“N1”, K150Q), two (“N2”, K150Q and K153Q), or three (“N3”, K150Q, K153Q, and R154Q) 
Lys or Arg residues to Gln in the N-terminal domain of TALENs targeting CCR5A and ATM.  
These N-terminal residues have been shown in previous studies to bind non-specifically to DNA, 
and mutations at these specific residues to neutralize the cationic charge decrease non-specific 
DNA binding energy.40  We hypothesized the reduction in non-specific binding energy from 
these N-terminal mutations would decrease excess TALEN binding energy resulting in increased 
specificity.  In vitro selections on these three TALEN variants revealed that the less cationic N-
terminal TALENs indeed exhibit greater enrichment values of on-target cleavage (Figures 1.8 
and 1.9 and Tables 1.8 and 1.9).  
All TALEN constructs tested specifically recognize the intended base pair across both 
half-sites, except that some of the ATM TALENs do not specifically interact with the base pair 
adjacent to the spacer (targeted by the most C-terminal TALE repeat) (Figures 1.8 -1.10).  To 
compare the broad specificity profiles of canonical TALENs with those containing engineered C-
terminal or N-terminal domains, the specificity scores of each target base pair from selections 
using CCR5A and ATM TALENs with the canonical, Q3, or Q7 C-terminal domains and N1, 
N2, or N3 N-terminal domains were subtracted by the corresponding specificity scores from 
selections on the canonical TALEN (canonical 63-aa C-terminal domain, wild-type N-terminal 
domain) (Figure 1.19).   
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Figure 1.19.  Effects of engineered TALEN domains and TALEN concentration on 
specificity.  
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Figure 1.19 (Continued).  Effects of engineered TALEN domains and TALEN 
concentration on specificity.  (A) The specificity score of the targeted base pair at each position 
of the CCR5A site was calculated for CCR5A TALENs containing the canonical, Q3, Q7, or 28-
aa C-terminal domains.  The specificity scores of the Q3, Q7, or 28-aa C-terminal domain 
TALENs subtracted by the specificity scores of the TALEN with the canonical C-terminal 
domain are shown.   (B) Same as (A) but for CCR5A TALENs containing engineered N-terminal 
domains N1, N2, or N3.  (C) Same as (A) but comparing specificity scores differences of the 
canonical CCR5A TALEN assayed at 16 nM, 8 nM or 4 nM subtracted by the specificity scores 
of canonical CCR5A TALENs assayed at 32 nM.  (D-F) Same as (A-C) but for ATM TALENs.  
 
Mutations in the C-terminal domain that increase specificity did so most strongly in the middle 
and at the C-terminal end of each half-site.  Likewise, the specificity-increasing mutations in the 
N-terminus tended to increase specificity most strongly at positions near the TALEN N-terminus 
(5’ DNA end) although mutations in the N-terminus of ATM TALEN targeting the right half-site 
did not significantly alter specificity.  These results are consistent with a local binding 
compensation model in which weaker binding at either terminus demands increased specificity in 
the TALE repeats near this terminus.  To characterize the effects of TALEN concentration on 
specificity, the specificity scores from selections of ATM and CCR5A TALENs performed at 
three different concentrations ranging from 3 nM to 16 nM were each subtracted by the 
specificity scores of corresponding selections performed at the highest TALEN concentration 
assayed, 24 nM for ATM, or 32 nM for CCR5A.  The results (Figure 1.19) indicate that 
specificity scores increase fairly uniformly across the half-sites as the concentration of TALEN 
is decreased. 
To assess the spacer-length preference of various TALEN architectures (C-terminal 
mutations, N-terminal mutations, and FokI variants) and various TALEN concentrations, the 
enrichment values of library members with 10- to 24- base pair spacer lengths in each of the 
selections with CCR5A and ATM TALEN with various combinations of the canonical, Q3, Q7, 
or 28-aa C-terminal domains; N1, N2, or N3 N-terminal mutations; and the EL/KK or ELD/KKR 
FokI variants at 4 nM to 32 nM CCR5A and ATM TALEN were calculated (Figure 1.20).   
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Figure 1.20.  Spacer-length preferences of TALENs.   
!
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Figure 1.20 (Continued).  Spacer-length preferences of TALENs.  (A) For each selection with 
CCR5A TALENs containing various combinations of the canonical, Q3, Q7, or 28-aa C-terminal 
domains; N1, N2, or N3 N-terminal mutations; and the EL/KK or ELD/KKR FokI variants and 
at 4, 8, 16, or 32 nM, the DNA spacer-length enrichment values were calculated by dividing the 
abundance of DNA spacer lengths in post-selection sequences by the abundance of DNA spacer 
lengths in the pre-selection library sequences.  (B) Same as (A) but for ATM TALENs. 
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All of the tested concentrations, N-terminal variants, C-terminal variants, and FokI variants 
demonstrated a broad DNA spacer-length preference ranging from 14- to 24- base pairs with 
three notable exceptions.  First, the CCR5A 28-aa C-terminal domain exhibited a much narrower 
DNA spacer-length preference than the broader DNA spacer-length preference of the canonical 
C-terminal domain, consistent with previous reports.5, 14, 41  Second, the CCR5A TALENs 
containing Q7 C-terminal domains showed an increased tolerance for 12-base spacers compared 
to the canonical C-terminal domain variant (Figure 1.20).  This slightly broadened spacer-length 
preference may reflect greater conformational flexibility in the Q7 C-terminal domain, perhaps 
resulting from a smaller number of non-specific protein:DNA interactions along the 
TALEN:DNA interface.  Third, the ATM TALENs with Q7 C-terminal domains and the ATM 
TALENs with N3 mutant N-terminal domains showed a narrowed spacer preference.  We 
speculate that these more specific TALENs with lower DNA-binding affinity may have faster 
off-rates that are competitive with the rate of cleavage of non-optimal DNA spacer lengths, 
altering the observed spacer-length preference.  While previous reports have focused on the 
length of the TALEN C-terminal domain as a primary determinant of DNA spacer-length 
preference, these results suggest the net charge of the C-terminal domain as well as overall 
DNA-binding affinity can also affect TALEN spacer-length preference.   For many of the 
TALENs assayed, the spacer preferences revealed in the in vitro selection results are broader 
than a previous report by Miller et al5!of a comparably narrower spacer length preference in 
cells.  However, the broader spacer preferences revealed in the in vitro selection are consistent 
with a previous report by Mussolino et al.13  This discrepancy could be explained by higher 
affinity TALENs, or by a higher concentration of TALENs used in our study and used in the 
study of Mussolino et al., leading to saturation of binding sites that allows cleavage of otherwise 
non-optimal DNA spacer lengths.   
 We also characterized the location of TALEN DNA cleavage within the spacer.  We 
created histograms reporting the number of spacer DNA bases observed preceding the right half-
site in each of the sequences from the selections with CCR5A and ATM TALEN with various 
combinations of the canonical, Q3, Q7, or 28-aa C-terminal domains; N1, N2, or N3 N-terminal 
mutations; and the EL/KK or ELD/KKR FokI variants (Figure 1.21).   
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Figure 1.21.  DNA cleavage-site preferences of TALENs.   
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Figure 1.21 (Continued).  DNA cleavage-site preferences of TALENs.  (A) For each selection 
with CCR5A TALENs with various combinations of canonical, Q3, Q7, or 28-aa C-terminal 
domains; N1, N2, or N3 N-terminal mutations; and the EL/KK or ELD/KKR FokI variants and 
at 4, 8, 16, or 32 nM, histograms of the number of spacer DNA base pairs preceding the right 
half-site for each possible DNA spacer length, normalized to the total sequence counts of the 
entire selection, are shown.  (B) Same as (A) for ATM TALENs. 
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The peaks in the histogram were interpreted to represent the most likely locations of DNA 
cleavage within the spacer.  The cleavage positions are dependent on the length of the DNA 
spacer between the TALEN binding half-sites, as might be expected from conformational 
constraints imposed by the TALEN C-terminal domain and DNA spacer lengths. 
In order to confirm the greater DNA cleavage specificity of Q7 over canonical 63-aa C-
terminal domains in vitro, a representative set of 16 off-target DNA substrates was digested in 
vitro with TALENs containing either canonical 63-aa or engineered Q7 C-terminal domains.  
ATM TALENs with the canonical 63-aa C-terminal domain demonstrated comparable in vitro 
cleavage activity on target sites with zero, one, or two mutations (Figure 1.22).   
OnA  TGAATTGGGATGCTGTTT    TTTATTTTACTGTCTTTA!
A1   TGAATTGGGtTGCTGTTT    TTTATTTTACTGTCTTTA     !
A2   TGAATTGcGATGCTGTTT    TTTATTTTACTGTCTTTA!
A3   TGAATTGGGATGCTGTTT    TTTATTTcACTGTCTTTA!
A4   TGAATTGGGATGCTGTTT    TTTATTTTACTaTCTTTA!
A5   TGAATTGcGATGCTGTTT    TTTATTTTACTaTCTTTA     !
A6   TGAgTTGGGATGCTGTTT    TTTATgTTACTGTCTTTA!
A7   TGAATTGGGtTGCTGTTT    TTTATTTgACTGTCTTTA!
A8   TGAATTGGGATGCTGaTT    TTTATTTTACTGTCcTTA!
 
OnC  TTCATTACACCTGCAGCT    AGTATCAATTCTGGAAGA!
C1   TTCATTACAtCTGCAcCT    AGTATCAATTCTGGAAGA    !
C2   TTCAaTACACCTGtAGCT    AGTATCAATTCTGGAAGA!
C3   TTCATTACACCcGCAGCa    AGTATCAATTCTGGAAGA!
C4   TTaATTgCACCTGCAGCT    AGTATCAATTCTGGAAGA!
C5   TTCATTACACCTGCAGCT    AGTATgAATTCTGtAAGA     !
C6   TTCATTACACCTGCAGCT    AGTATCAAcTCTGGAgGA!
C7   TTCATTACACCTGCAGCT    AtTATCAATTCaGGAAGA!
C8   TTCATTACACCTGCAGCT    AGTAaCAATgCTGGAAGA!
      !
!
A B 
C D 
DNA Left half-site Right half-site DNA Left half-site Right half-site 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1 
OnC C1 C2 C3 C4 C5 C6 C7 C8 
C
le
av
ag
e 
ef
fic
ie
nc
y 
 
Canonical 
Q7 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1 
OnA A1 A2 A3 A4 A5 A6 A7 A8 
C
le
av
ag
e 
ef
fic
ie
nc
y 
Canonical 
Q7 
*"
*"
*"*"*"
*"
*"
*" *" *" *" *" *"
*"
 
 
Figure 1.22.  In vitro specificity and discrete cleavage efficiencies of TALENs containing 
canonical or engineered C-terminal domains.  (A) CCR5A on-target sequence (OnC) and 
double-mutant sequences with mutations in red.  For CCR5A, sequences containing two 
mutations were assayed because one-mutation and zero-mutation sequences were similarly 
enriched (Tables 1.8 and 1.9).  (B) ATM on-target sequence (OnA), single-mutant sequences, 
and double-mutant sequences with mutations in red.  (C) Discrete in vitro cleavage efficiency of 
DNA sequences listed in (D) with CCR5A TALENs containing either canonical or engineered 
Q7 C-terminal domains with EL/KK FokI domains.  Error bars reflect s.d. from three biological 
replicates, except two replicates for C4.  * Indicates that the efficiency of cleaving a mutant 
sequence was significantly different (P value < 0.01) from cleaving the on-target sequence (with 
the same TALEN type). 
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CCR5A TALENs with the canonical 63-aa C-terminal domain TALEN demonstrate comparable 
in vitro cleavage activity on target sites with zero or two mutations.  In contrast, for 11 of the 16 
off-target substrates tested, the engineered Q7 TALEN variants showed substantially higher (~4-
fold or greater) discrimination against off-target DNA substrates with one or two mutations than 
the canonical 63-aa C-terminal domain TALENs, even though the Q7 TALENs cleaved their 
respective on-target sequences in vitro with comparable or greater efficiency than TALENs with 
the canonical 63-aa C-terminal domains (Figure 1.22).  For both the ATM and CCR5A Q7 C-
terminal TALENs, some sequences are cleaved with greater specificity than others.  Sequence-
dependent specificity is expected based on the variable specificity at each position (Figures 1.8 
and 1.9).    Overall, the discrete cleavage assays are consistent with the selection results and 
indicate that TALENs with engineered Q3 or Q7 C-terminal domains can be substantially more 
specific than TALENs with canonical 63-aa C-terminal domains in vitro. 
 To explore the greater on-target DNA cleavage activity of CCR5A TALENs with 
Q7 C-terminal domains compared to the lower activity of canonical C-terminal domains (Figure 
1.22), a time course of in vitro cleavage of discrete on-target DNA with CCR5A TALENs in 
excess over DNA was preformed (Figure 1.23).    
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Figure 1.23.  In vitro specificity and discrete cleavage efficiencies of TALENs containing 
canonical or engineered C-terminal domains.  Discrete in vitro cleavage efficiency of CCR5A 
or ATM on-target DNA sequences with CCR5A or ATM TALENs containing either canonical 
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or Q7 C-terminal domains with EL/KK FokI domains.   The TALEN protein concentration 
([TALEN]) was varied from 20 nM to 2.5 nM.  On-target DNA concentration ([DNA]) was 
varied from 1.6 nM to .2 nM.   
 
CCR5A TALENs with canonical C-terminal domains showed cleavage independent of time on 
the scale of the experiment (minutes), consistent with a model where TALENs bound almost all 
DNA but only a fraction of DNAs, ~.5, were quickly cleaved by active TALENs while an 
inactive form of TALEN bound and inhibited cleavage on the other ~.5 of DNAs over the entire 
course of the experiment. This model would require TALENs to have very tight binding 
affinities, well below the ~10 nM TALEN utilized in the digestion, consistent with previously 
reported Kds of 3 nM for TALE DNA binding domains targeting 19 bases pairs 5.  Since 
TALENs have a longer, more positively charged linker and a Fok I domain, it is entirely likely 
that TALENs have substantially lower Kds compared to these TALE constructs.  In this model, 
TALENs would also be expected to cleave quickly, much faster than 1 min-1, consistent with the 
previously reported rate of endogenous Fok I DNA cleavage of .5 s-1 6.  CCR5A TALENs with 
the Q7 C-terminal domains cleave to the same initial point in 1 minute as the canonical C-
terminal domain TALENs, ~.5, but then there was an increase in cleavage (Figure 1.23).  Again, 
it is likely TALENs bound almost all DNA but only a fraction of DNAs, ~.5, were quickly 
cleaved by active TALENs while an inactive form of TALEN initially bound and inhibited 
cleavage on the other ~.5 of DNAs but for TALENs with Q7 C-terminal domains the inactive 
TALEN falls off over the course of the experiment allowing active TALEN to bind and cleave.  
Thus, the slow increase in cleavage by the Q7 C-terminal domains could be a result of a decrease 
in affinity from the Q7 C-terminal domain increasing the off-rate of the CCR5A TALENs with 
Q7 C-terminal domains.  To preclude the possibility that TALENs are begin inactivated over the 
course of the experiment, TALENs were pre-incubated in reaction buffer without DNA for 9 min 
and then used to digest DNA normally resulting in no change in activity from TALENs not pre-
incubated (data not shown).  This model of inactive TALEN falling off allowing a catalytically 
active TALEN to bind and cleave is consistent with the observation of some single mutation sites 
having enrichments above wild type (Figure 1.16 and Tables 1.8 and 1.9) with TALENs 
binding these single mutation with excess but lower overall binding affinities and the resulting 
faster off-rates leading to some cleavage of otherwise inaccessible DNA target sites.  Taken 
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together, it seems likely, at least in vitro, there is an inactive form of TALEN binding to DNA 
with implications in cleavage efficiency for both on-target and off-target sites. 
 
 
1.6  Improved specificity of engineered TALENs in human cells 
 To determine if the increased specificity of the engineered TALENs observed in vitro 
also occurs in human cells, TALEN-induced modification rates of the on-target and top 36 
predicted off-target sites were measured for CCR5A and ATM TALENs containing all six 
possible combinations of the canonical 63-aa, Q3, or Q7 C-terminal domains and the EL/KK or 
ELD/KKR FokI domains (12 TALENs total).  We did not analyze TALENs containing a 28-aa 
C-terminal domain in these experiments because both the ATM and CCR5A on-target sites have 
DNA spacer lengths of 18 bp, which lies outside the 28-aa C-terminal domain’s preferred DNA 
spacer length range (Figure 1.20).  For both FokI variants, the TALENs with Q3 C-terminal 
domains demonstrate significant on-target activities ranging from 8% to 24% modification, 
comparable to the activity of TALENs with the canonical 63-aa C-terminal domains.  TALENs 
with canonical 63-aa or Q3 C-terminal domains and the ELD/KKR FokI domain are both more 
active in modifying the CCR5A and ATM on-target site in cells than the corresponding TALENs 
with the Q7 C-terminal domain by 5- to 9-fold (Figure 1.24).  
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Figure 1.24.  Specificity of engineered ATM and CCR5A TALENs in human cells.  (A) The 
cellular modification efficiency of canonical and engineered TALENs expressed as a percentage 
of indels consistent with TALEN-induced modification out of total sequences is shown for the 
on-target CCR5A site (OnCCR5A) and for CCR5A off-target site #5 (OffC5), the most highly 
cleaved off-target substrate tested.  All pairwise P-values comparing the number of observed 
sequences containing insertions or deletions consistent with TALEN-induced cleavage vs. the 
total number of sequences were calculated with a Fischer exact test between samples (see 
Supplementary Table S7).   P-values are < 0.005 for samples of canonical vs. Q3 vs. Q7 
TALENs in the same FokI background for both on-target and off-target sites with the exception 
of off-target site #5 modified with Q3 vs. Q7 TALENs in the EL/KK FokI background (P-value 
< 0.087).  On:off target activity, defined as the ratio of on-target to off-target modification, is 
shown above each pair of bars.   
 
Compared to the canonical 63-aa C-terminal domains, TALENs with Q3 C-terminal 
domains demonstrate a mean increase in on-target:off-target activity ratio of more than 12-fold 
and more than 9-fold for CCR5A and ATM sites, respectively, with the ELD/KKR FokI domain 
(Table 1.20).   
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 CCR5A TALEN C-terminal domain 
Site 
OnCCR5A 
Can.  
(27.6%)*  
Q3  
(24.3%)* 
Q7  
(5.57%)* 
OffC-5 12 284 >1450 
OffC-15 120 >2221 >335 
OffC-16 886 769 >835 
OffC-28 170 526 >835 
OffC-36 181 2392 >835 
A
B
ATM TALEN C-terminal domain  
Site 
OnATM 
Can. 
(16.2%)* 
Q3 
(17.1%)* 
Q7 
(1.83%)* 
OffA-2 627 >2564 >274 
OffA-11 448 >2564 >274 
OffA-13 649 >2564 >225 
OffA-23 56 >1210 >40 
     *cellular modification efficiency of on-target site 
 
Table 1.20.  Specificity of engineered ATM and CCR5A TALENs in human cells. (A) The 
on:off target activity of the canonical, Q3, and Q7 TALENs for each detected genomic off-target 
substrate of the CCR5A TALEN with the ELD/KKR FokI domain are shown.  The absolute 
genomic modification frequency for the on-target site is in parentheses with *. (B) Same as (B) 
for the ATM TALENs and off-target sites.  (D) The on:off target activities of the canonical, Q3, 
and Q7 TALENs for each detected genomic off-target substrate of the PMS2, SDHD, and 
HDAC1 TALENs with the ELD/KKR FokI domain are shown.  The absolute genome 
modification frequency for the on-target site is in parentheses. 
 
These mean improvements can only be expressed as lower limits due to the absence or near-
absence of observed cleavage events by the engineered TALENs for many off-target sequences.  
For the ATM TALENs containing Q7 C-terminal domains, the cleavage efficiency of both the 
on-target and off-target sites is so low that their specificity cannot be determined (Table 1.20).  
For the most abundantly cleaved off-target site (CCR5A off-target site #5), the Q3 C-terminal 
domain is 24-fold more specific, and the Q7 C-terminal domain is > 120-fold more specific 
(Figure 1.21 and Table 1.20), than the canonical 63-aa C-terminal domain.  Consistent with the 
improved on-target:off-target activity ratio observed in vitro, the engineered Q7 TALENs are 
more specific than the Q3 variants, which in turn are more specific than the canonical 63-aa C-
terminal domain TALENs. 
To determine if the increased specificity of the engineered TALENs observed for CCR5A 
and ATM TALENs applies more generally, three new TALENs targeting sequences in the 
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PMS2, SDHD, and HDAC1 genes12 were constructed using the canonical 63-aa, Q3, or Q7 C-
terminal domains and ELD/KKR FokI domains.  Of the 64 TALENs reported previously in 
Reyon et al, these three TALENs had target sequences with closely homologous genomic off-
target sites containing one to five mutations.  For each of these TALENs, modification rates were 
measured for genomic on-target and off-target sites.  PMS2, SDHD, and HDAC-1 TALENs with 
Q3 C-terminal domains demonstrate on-target activities ranging from 6% to 28% modification, 
comparable to the activity of TALENs with the canonical 63-aa C-terminal domains (Table 
1.21). 
HDAC1 TALEN C-terminal domain 
Site Can. Q3 Q7 
OnHDAC     (5.22%)* (6.09%)* (1.42%)* 
OffHDAC-1 100 487 > 1160 
SDHD TALEN C-terminal domain 
Site Can. Q3 Q7 
OnSDHD     (33.10%)* (28.08%)* (0.28%)* 
OffSDHD-1 135 722 > 231 
PMS2 TALEN C-terminal domain 
Site Can. Q3 Q7 
OnPMS (20.36%)*  (14.80%)* (2.87%)* 
OffPMS-1 14 83 748 
OffPMS-2 5 36 320 
 
Table 1.21.  Specificity of engineered PMS2, SDHD, and HDAC1 TALENs in human cells. 
The on:off target activities of the canonical, Q3, and Q7 TALENs for each detected genomic off-
target substrate of the PMS2, SDHD, and HDAC1 TALENs with the ELD/KKR FokI domain are 
shown.  The absolute genome modification frequency for the on-target site is in parentheses. 
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While demonstrating similar on-target activities to TALENs with canonical domains, PMS2, 
SDHD, and HDAC1 TALENs with Q3 C-terminal domains demonstrated a 5- to 7-fold increase 
in on-target:off-target activity ratio.  For the PMS2 TALENs, the Q7 C-terminal domains 
demonstrated a 53- and 64-fold increase in on-target:off-target activity ratio in cells, although as 
observed above the Q7 TALENs were less active on the target site than TALENs containing the 
canonical and Q3 C-terminal domains (Table 1.21). 
Together, these results reveal that for five families of TALENs targeting the CCR5, ATM, 
PMS2, SDHD, and HDAC1 genes, replacing the canonical 63-aa C-terminal domain with the 
engineered Q3 C-terminal domain results in comparable activity for the on-target site in cells, 
and an average 10-fold increase in specificity for all assayed off-target sites.  From the total 
results of sequencing genomic sites from cells treated with CCR5 and ATM TALENs (Table 
1.22) and with PMS2, SDHD, and HDAC1 TALENs (Table 1.23), the engineered Q7 C-terminal 
domain can offer additional gains in specificity beyond that of the Q3 TALENs, but with reduced 
on-target activity.   Collectively, these results validate a method to evaluate the specificity of 
TALEN variants that also revealed underlying principles resulting in engineered TALENs with 
improved DNA cleavage specificity in cells.   
A 
C-terminal 
domain No TALEN Q7 Q7 Q3 Q3 Canonical Canonical Canonical 
FokI domain No TALEN EL/KK  ELD/KKR  EL/KK  ELD/KKR  EL/KK  ELD/KKR Homo  
CCR5A Sites        
OnC         
Indels 1 147 705 1430 3731 841 2004 3943 
Total 42042 7192 12667 16843 15381 8546 7267 8422 
% Modified <0.006% 2.044% 5.566% 8.490% 24.257% 9.841% 27.577% 46.818% 
P-value   (5.5E-122) (<1.0E-250) (<1.0E-250) (<1.0E-250) <1.0E-250 <1.0E-250 <1.0E-250 
Specificity         
         
OffC-1         
Indels 0 0 1 1 0 0 1 1 
Total 51248 38975 79857 35490 77804 34227 87496 42497 
% Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
Table 1.22 (Continued).  Cellular modification induced by ATM and CCR5A TALENs at 
on-target and predicted off-target genomic sites. 
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OffC-2         
Indels 6 1 6 2 1 0 11 3 
Total 124356 96280 157387 93337 159817 85603 163322 114663 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 0.006% <0.006% 
P-value          
Specificity         
         
OffC-3         
Indels 6 1 6 2 1 0 11 3 
Total 124356 96280 157387 93337 159817 85603 163322 114663 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffC-4         
Indels 0 1 0 0 0 0 0 0 
Total 45377 44674 52876 35133 53909 26034 42284 40452 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffC-5         
Indels 0 0 0 3 22 134 385 395 
Total 27009 28172 26036 22432 25800 25273 17045 17077 
Modified <0.004%* <0.004%* <0.004%* 0.013% 0.085% 0.530% 2.259% 2.313% 
P-value        (1.4E-07) 4.1E-43 1.2E-160 1.2E-164 
Specificity  >576 >1450 635 284 19 12 20 
         
OffC-6         
Indels 0 0 0 0 0 0 0 0 
Total 10766 12309 10886 9240 10558 10500 5943 6560 
Modified <0.009% <0.008% <0.009% <0.011% <0.009% <0.010% <0.017% <0.015% 
P-value                 
Specificity                
         
OffC-7         
Total 0 0 0 0 0 0 0 0 
Modified 15626 28825 22138 31742 19577 11902 33200 15400 
P-value  <0.006% <0.006% <0.006% <0.006% <0.006% <0.008% <0.006% <0.006% 
Specificity                
         
OffC-9         
Indels 0 0 0 1 0 0 0 0 
Total 40603 39765 47974 51595 44002 34520 25211 30771 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffC-10         
Indels 0 0 0 0 0 0 0 0 
Total 4142 9591 5187 1413 7975 4378 2215 3779 
Modified <0.024% <0.010% <0.019% <0.071% <0.013% <0.023% <0.045% <0.026% 
P-value                 
Specificity                
Table 1.22 (Continued).  Cellular modification induced by ATM and CCR5A TALENs at 
on-target and predicted off-target genomic sites. 
 
 
 
 73 
OffC-11         
Indels 0 0 0 0 0 0 0 0 
Total 71180 55455 65015 44847 70907 50967 65257 60191 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffC-12         
Indels 0 0 0 0 0 0 0 0 
Total 3242 1784 30274 14006 4897 19830 9747 12910 
Modified <0.031% <0.056% <0.006% <0.007% <0.020% <0.006% <0.010% <0.008% 
P-value                 
Specificity                
         
OffC-13         
Indels 0 0 0 0 0 0 0 0 
Total 65518 52459 53413 38156 61600 47922 57211 78546 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffC-14         
Indels 0 0 0 0 0 0 2 0 
Total 34607 7217 26301 8339 29845 1081 9471 19026 
Modified <0.006% <0.014% <0.006% <0.012% <0.006% <0.093% 0.021% <0.006% 
P-value                 
Specificity                
 
OffC-15         
Indels 0 0 0 0 0 0 16 2 
Total 4989 4880 6026 9370 9156 7371 6967 4662 
Modified <0.020% <0.020% <0.017% <0.011% <0.011% <0.014% 0.230% 0.043% 
P-value             1.9E-04  
Specificity  >100 >335 >796 >2221 >725 120 1091 
         
OffC-16         
Indels 0 1 1 1 14 1 12 0 
Total 36228 34728 34403 34866 44362 38384 38536 32636 
Modified <0.006% <0.006% <0.006% <0.006% 0.032% <0.006% 0.031% <0.006% 
P-value         (2.5E-04)   5.2E-04   
Specificity  >307 >835 >1274 769 >1476 886 >7023 
         
OffC-17         
Indels 0 0 0 0 0 0 0 0 
Total 32112 23901 31273 33968 27437 29670 27133 31299 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
Table 1.22 (Continued).  Cellular modification induced by ATM and CCR5A TALENs at 
on-target and predicted off-target genomic sites. 
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OffC-18         
Indels 0 0 0 0 0 0 0 0 
Total 9437 9661 13505 14900 13848 12720 6624 12804 
Modified <0.011% <0.010% <0.007% <0.007% <0.007% <0.008% <0.015% <0.008% 
P-value                 
Specificity                
         
OffC-19         
Indels 1 1 1 2 2 2 1 0 
Total 22868 11479 22702 15258 20733 17449 14638 28478 
Modified <0.006% 0.009% <0.006% 0.013% 0.010% 0.011% 0.007% <0.006% 
P-value                 
Specificity                
         
OffC-20         
Indels 0 0 0 0 0 1 0 0 
Total 23335 26164 30782 15261 20231 21184 14144 18972 
Modified <0.006% <0.006% <0.006% <0.007% <0.006% <0.006% <0.007% <0.006% 
P-value                 
Specificity                
 
OffC-21         
Indels 0 0 0 0 0 0 0 0 
Total 34302 27573 31694 24451 25826 27192 18110 21161 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffC-22         
Indels 1 0 0 0 0 0 0 0 
Total 81037 86687 74274 79004 93477 92089 75359 104857 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffC-23         
Indels 0 0 0 0 0 0 0 0 
Total 18812 19337 23034 25603 25023 28615 17172 21033 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffC-24         
Indels 0 0 1 0 0 0 0 1 
Total 23538 21673 24594 27687 18343 29113 21709 26610 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffC-25         
Indels 0 0 0 0 0 0 0 0 
Total 28941 25326 25871 10641 21422 20171 18946 18711 
Modified <0.006% <0.006% <0.006% <0.009% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
Table 1.22 (Continued).  Cellular modification induced by ATM and CCR5A TALENs at 
on-target and predicted off-target genomic sites. 
 75 
 
OffC-26         
Indels 0 0 1 0 0 0 0 0 
Total 71831 48494 62650 45801 60175 65137 28795 64632 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
 
OffC-27         
Indels 0 0 0 0 0 0 0 0 
Total 12181 2423 11258 7188 5126 4003 2116 4603 
% Modified <0.008% <0.041% <0.009% <0.014% <0.020% <0.025% <0.047% <0.022% 
P-value                 
Specificity                
         
OffC-28         
Indels 0 0 0 0 6 1 12 5 
Total 10651 6410 16179 13980 13022 7232 7379 8998 
% Modified <0.009% <0.016% <0.006% <0.007% 0.046% 0.014% 0.163% 0.056% 
P-value            2.2E-05   
Specificity  >131 >835 >1187 526 712 170 843 
         
OffC-29         
Indels 0 0 0 0 0 0 0 0 
Total 4262 3766 4228 6960 3234 1516 2466 1810 
% Modified <0.023% <0.027% <0.024% <0.014% <0.031% <0.066% <0.041% <0.055% 
P-value                 
Specificity                
         
OffC-30         
Indels 0 0 0 0 0 0 0 0 
Total 11840 12257 9617 34097 20507 5029 22248 6285 
% Modified <0.008% <0.008% <0.010% <0.006% <0.006% <0.020% <0.006% <0.016% 
P-value                 
Specificity                
         
OffC-31         
Indels 0 0 0 0 0 0 0 0 
Total 64522 67791 50085 50056 56241 48287 72230 100410 
% Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffC-32         
Indels 0 0 0 0 0 0 0 0 
Total 1944 6888 9330 3207 4591 6699 13607 19115 
% Modified <0.051% <0.015% <0.011% <0.031% <0.022% <0.015% <0.007% <0.006% 
P-value                 
Specificity                
Table 1.22 (Continued).  Cellular modification induced by ATM and CCR5A TALENs at 
on-target and predicted off-target genomic sites. 
 76 
 
 
OffC-33         
Indels 0 0 0 0 0 0 0 0 
Total 34475 27039 18547 33467 15745 17075 4 18844 
% Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <25.000% <0.006% 
P-value                 
Specificity                
         
OffC-34         
Indels 0 0 0 0 0 0 0 0 
Total 9052 18858 13647 11796 6945 6114 4979 9072 
% Modified <0.011% <0.006% <0.007% <0.008% <0.014% <0.016% <0.020% <0.011% 
P-value                 
Specificity                
         
OffC-35         
Indels 0 0 0 0 0 0 0 0 
Total 23839 22290 25133 24190 10 10459 22554 11897 
% Modified <0.006% <0.006% <0.006% <0.006% <10.000% <0.010% <0.006% <0.008% 
P-value                 
Specificity                
         
OffC-36         
Indels 1 0 0 1 2 1 19 5 
Total 23412 24394 23427 24132 19723 28369 12461 18052 
Modified <0.006% <0.006% <0.006% <0.006% 0.010% <0.006% 0.152% 0.028% 
P-value             2.5E-08   
Specificity  >307 >835 >1274 2392 >1476 181 1690 
 
B 
C-term. 
Domain: No TALEN Q7 Q7 Q3 Q3 Canonical Canonical Canonical 
FokI 
Domain: No TALEN EL/KK  ELD/KKR  EL/KK  ELD/KKR  EL/KK  ELD/KKR Homo  
ATM Sites         
On-A         
Indels 1 0 46 104 309 1289 410 909 
Total 15116 1869 2520 1198 1808 19025 2533 5003 
Modified 0.007% <0.006% 1.825% 8.681% 17.091% 6.775% 16.186% 18.169% 
P-value  0  (4.4E-27) (1.4E-93) (5.6E-243) 2.6E-214 <1.0E-250 <1.0E-250 
Specificity         
 
 
 
 
 
 
        
OffA-1         
Indels 0 0 1 0 1 0 13 34 
Total 52490 45383 34195 32325 47589 39704 50349 44056 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 0.026% 0.077% 
P-value             9.3E-05 2.6E-12 
Specificity  >0 >274 >1302 >2564 >1016 627 235 
         
OffA-2         
Indels 0 0 0 0 0 0 0 0 
Total 8777 11846 11362 12273 20704 3776 5650 5025 
Modified <0.011% <0.008% <0.009% <0.008% <0.006% <0.026% <0.018% <0.020% 
P-value                 
Specificity                
Table 1.22 (Continued).  Cellular modification induced by ATM and CCR5A TALENs at 
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OffA-3         
Indels 0 0 0 0 1 0 0 0 
Total 47338 14352 21253 17777 26512 19483 43728 29469 
Modified <0.006% <0.007% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffA-4         
Indels 0 0 0 0 0 0 0 0 
Total 12292 532 1383 2597 861 2598 1356 3573 
Modified <0.008% <0.188% <0.072% <0.039% <0.116% <0.038% <0.074% <0.028% 
P-value                 
Specificity                
         
OffA-5         
Indels 0 0 0 0 0 0 0 0 
Total 60859 22846 25573 19054 25315 31754 66622 60925 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffA-6         
Indels 0 0 0 0 0 0 0 0 
Total 60859 22846 25573 19054 25315 31754 66622 60925 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
 
OffA-7         
Indels 0 0 0 0 0 0 0 0 
Total 60859 22846 25573 19054 25315 31754 66622 60925 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffA-8         
Indels 0 0 0 0 0 0 0 0 
Total 9170 1614 5934 3215 2450 12750 10120 13003 
Modified <0.011% <0.062% <0.017% <0.031% <0.041% <0.008% <0.010% <0.008% 
P-value                 
Specificity                
         
OffA-9         
Indels 0 0 0 0 0 0 0 3 
Total 8753 12766 9504 10114 11086 10676 9013 11110 
Modified <0.011% <0.008% <0.011% <0.010% <0.009% <0.009% <0.011% 0.027% 
P-value                 
Specificity                
         
OffA-10         
Indels 1 0 0 2 2 3 5 7 
Total 8151 16888 8804 7061 8891 32138 14889 40120 
Modified 0.012% <0.006% <0.011% 0.028% 0.022% 0.009% 0.034% 0.017% 
P-value                 
Specificity                
Table 1.22 (Continued).  Cellular modification induced by ATM and CCR5A TALENs at 
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OffA-11         
Indels 0 0 1 0 0 0 9 76 
Total 41343 32352 28834 28709 26188 32519 24894 19586 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 0.036% 0.388% 
P-value             1.5E-04 3.1E-38 
Specificity  >0 >274 >1302 >2564 >1016 448 47 
         
OffA-12         
Indels 0 0 0 0 0 0 0 0 
Total 13186 2326 13981 12911 21134 9220 7792 8068 
Modified <0.008% <0.043% <0.007% <0.008% <0.006% <0.011% <0.013% <0.012% 
P-value                 
Specificity                
 
OffA-13         
Indels 0 0 0 0 0 2 9 0 
Total 32704 32015 12312 23645 26315 24078 36111 22364 
Modified <0.006% <0.006% <0.008% <0.006% <0.006% 0.008% 0.025% <0.006% 
P-value             4.3E-03   
Specificity  >0 >225 >1302 >2564 816 649 >2725 
         
OffA-15         
Indels 0 0 0 0 1 0 0 0 
Total 14654 15934 12313 6581 13053 18996 10916 21519 
Modified <0.007% <0.006% <0.008% <0.015% 0.008% <0.006% <0.009% <0.006% 
P-value                 
Specificity                
         
OffA-16         
Indels 1 0 0 0 0 0 0 12 
Total 65190 35639 37252 30378 31489 22590 13594 20922 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.007% 0.057% 
P-value               4.3E-07 
Specificity  >0 >274 >1302 >2564 >1016 >2200 317 
         
OffA-17         
Indels 0 0 0 0 0 0 0 6 
Total 1972 606 1439 2113 2862 728 597 636 
Modified <0.051% <0.165% <0.069% <0.047% <0.035% <0.137% <0.168% 0.943% 
P-value               2.0E-04 
Specificity  >0 >26 >183 >489 >49 >97 19 
         
OffA-18         
Indels 0 0 0 0 0 0 0 0 
Total 5425 995 1453 1831 3132 1934 1534 5816 
Modified <0.018% <0.101% <0.069% <0.055% <0.032% <0.052% <0.065% <0.017% 
P-value                 
Specificity                
Table 1.22 (Continued).  Cellular modification induced by ATM and CCR5A TALENs at 
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OffA-19         
Indels 1 2 0 1 1 1 1 3 
Total 31094 41252 33213 29518 32337 25904 27575 38711 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 0.008% 
P-value                 
Specificity                
 
OffA-21         
Indels 0 0 0 0 0 0 0 0 
Total 15297 9710 16719 12119 15483 21692 16558 16418 
Modified <0.007% <0.010% <0.006% <0.008% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffA-22         
Indels 27 41 38 46 32 50 55 57 
Total 9406 11150 11516 10269 13814 14057 11685 14291 
Modified 0.287% 0.368% 0.330% 0.448% 0.232% 0.356% 0.471% 0.399% 
P-value                 
Specificity                
         
OffA-23         
Indels 1 0 0 0 0 0 10 20 
Total 5671 9363 2203 7011 7078 12068 3484 8619 
Modified 0.018% <0.011% <0.045% <0.014% <0.014% <0.008% 0.287% 0.232% 
P-value             4.5E-04 4.9E-04 
Specificity  >0 >40 >609 >1210 >818 56 78 
         
OffA-24         
Indels 4 0 0 1 0 1 0 2 
Total 17288 7909 14261 29936 6943 6333 14973 19953 
Modified 0.023% <0.013% <0.007% <0.006% <0.014% 0.016% <0.007% 0.010% 
P-value                 
Specificity                
         
OffA-25         
Indels 0 0 0 0 0 0 0 0 
Total 20089 45320 50758 108581 11574 20948 123827 74151 
Modified <0.006% <0.006% <0.006% <0.006% <0.009% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffA-27         
Indels 0 0 0 0 1 0 0 0 
Total 47338 14352 21253 17777 26512 19483 43728 29469 
Modified <0.006% <0.007% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
Table 1.22 (Continued).  Cellular modification induced by ATM and CCR5A TALENs at 
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OffA-29         
Indels 0 0 0 0 0 0 0 0 
Total 5174 12618 36909 18063 16486 17934 9999 35072 
Modified <0.019% <0.008% <0.006% <0.006% <0.006% <0.006% <0.010% <0.006% 
P-value                 
Specificity                
         
OffA-30         
Indels 4 4 0 7 4 4 0 3 
Total 45082 56631 36333 88651 69652 20362 29180 21350 
Modified 0.009% 0.007% <0.006% 0.008% <0.006% 0.020% <0.006% 0.014% 
P-value                 
Specificity                
         
OffA-32         
Indels 0 0 0 0 0 0 0 0 
Total 13405 6721 14013 7513 14136 22376 6407 13720 
Modified <0.007% <0.015% <0.007% <0.013% <0.007% <0.006% <0.016% <0.007% 
P-value                 
Specificity                
         
OffA-33         
Indels 0 0 0 0 1 1 0 4 
Total 108222 46866 157329 48611 92559 152094 201408 225805 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 
P-value                 
Specificity                
         
OffA-34         
Indels 0 0 0 0 0 0 0 2 
Total 3889 3158 2903 2235 2112 3022 2322 2481 
Modified <0.026% <0.032% <0.034% <0.045% <0.047% <0.033% <0.043% 0.081% 
P-value                 
Specificity                
         
OffA-35         
Indels 0 0 0 1 0 0 0 33 
Total 48482 37431 38043 31033 44803 37257 41073 47273 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% 0.070% 
P-value               7.6E-11 
Specificity  >0 >274 >1302 >2564 >1016 >2428 260 
. 
OffA-36         
Indels 0 0 2 0 0 0 0 0 
Total 27115 17075 45425 35059 22298 19610 12620 27170 
Modified <0.006% <0.006% <0.006% <0.006% <0.006% <0.006% <0.008% <0.006% 
P-value                 
Specificity                
         
Table 1.22 (Continued).  Cellular modification induced by ATM and CCR5A TALENs at 
on-target and predicted off-target genomic sites.   
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Table 1.22 (Continued).  Cellular modification induced by ATM and CCR5A TALENs at 
on-target and predicted off-target genomic sites. 
 (A) Results from sequencing CCR5A on-target and each predicted genomic off-target site that 
amplified from 50ng genomic DNA isolated from human cells treated with either no TALEN or 
TALENs containing canonical, Q3 or Q7 C-terminal domains, and either EL/KK heterodimeric, 
ELD/KKR heterodimeric, or homodimeric (Homo) FokI domains.  Indels: the number of 
observed sequences containing insertions or deletions consistent with TALEN-induced cleavage.  
Total: total number of sequence counts.  Modified: number of indels divided by total number of 
sequences as percentages.  Upper limits of potential modification were calculated for sites with 
no observed indels by assuming there is less than one indel then dividing by the total sequence 
count to arrive at an upper limit modification percentage, or taking the theoretical limit of 
detection (1/16,400), whichever value was larger.  For the OffC-5 site, the limit of detection was 
1/32,800 (see Methods).  P-values: calculated as previously reported15 using a (right) one-sided 
Fisher’s exact test between each canonical C-terminal domain TALEN-treated sample and the 
untreated control sample.  P-values of < 0.00025 were considered significant and shown.  Cut off 
at 0.00025 was based on multiple comparison correction from the Benjamini-Hochberg 
method.16, 17  For sites with a significant P-value in a canonical C-terminal domain TALEN-
treated sample, significant P-values for other TALEN-treated samples are shown in parenthesis.  
Specificity is the ratio of on-target to off-target genomic modification frequency for each site.  
(B) Same as (A) for the ATM target sites; P-values < 0.005 were considered significant and are 
shown.   
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C-term. Domain: No TALEN Q7 Q3 Canonical 
FokI Domain: No TALEN ELD/KKR  ELD/KKR  ELD/KKR 
HDAC1 Sites     
OnHDAC      
Indels 0 697 7774 4595 
Total 55902 49232 127610 88068 
Modified < 0.001% 1.416% 6.092% 5.218% 
P-value   2.98E-229 < 1.00E-250 < 1.00E-250 
Specificity     
     
OffHDAC-1     
Indels 0 2 30 169 
Total 261086 292020 239664 322463 
Modified < 0.001% < 0.001% 0.013% 0.052% 
P-value    2.51E-10 4.50E-44 
Specificity  > 1160 487 100 
     
PMS2 Sites     
OnPMS     
Indels 1 591 4364 6941 
Total 17023 20623 29496 34092 
Modified 0.006% 2.866% 14.795% 20.360% 
P-value   4.31E-151 < 1.00E-250 < 1.00E-250 
Specificity     
     
OffPMS-1     
Indels 2 10 485 3740 
Total 259211 260985 270713 259935 
Modified < 0.001% 0.004% 0.179% 1.439% 
P-value   3.86E-02 1.24E-137 < 1.00E-250 
Specificity  748 83 14 
     
OffPMS-2     
Indels 1 6 334 3000 
Total 63593 67027 81473 76343 
Modified 0.002% 0.009% 0.410% 3.930% 
P-value    8.22E-82 < 1.00E-250 
Specificity  320 36 5 
 
 
 
 
    
SDHD sites     
OnSDHD     
Indels 0 263 16217 24188 
Total 94384 93203 57748 73085 
Modified < 0.001% 0.282% 28.082% 33.096% 
P-value   1.55E-80 < 1.00E-250 < 1.00E-250 
Specificity     
     
OffSDHD-1     
Indels 0 0 31 191 
Total 65095 70344 79721 77706 
Modified < 0.001% < 0.001% 0.039% 0.246% 
P-value    9.88E-09 4.48E-51 
Specificity  > 231 722 135 
Table 1.23 (Continued).  Cellular modification induced by HDAC1, PMS2, and SDHD 
TALENs at on-target and off-target genomic sites. 
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OffSDHD-2     
Indels 0 0 0 0 
Total 146373 142097 153028 153595 
Modified < 0.001% < 0.001% < 0.001% < 0.001% 
P-value      
Specificity     
     
OffSDHD-3     
Indels 0 0 1 2 
Total 86283 85294 114095 87973 
Modified < 0.001% < 0.001% < 0.001% 0.002% 
P-value      
Specificity     
     
OffSDHD-4     
Indels 0 0 0 0 
Total 53497 57541 65379 62535 
Modified < 0.001% < 0.001% < 0.001% < 0.001% 
P-value      
Specificity     
     
Table 1.23 (Continued).  Cellular modification induced by HDAC1, PMS2, and SDHD 
TALENs at on-target and off-target genomic sites.  (A) Results from sequencing HDAC1, 
PMS2, and SDHD on-target and genomic off-target sites amplified from 250 ng of genomic 
DNA isolated from human cells treated with either no TALEN, or with corresponding TALENs 
containing canonical, Q3, or Q7 C-terminal domains with ELD/KKR heterodimeric FokI 
domains.  Indels: the number of observed sequences containing insertions or deletions consistent 
with TALEN-induced cleavage.  Total: total number of sequence counts.  Modified: number of 
indels divided by total number of sequences as percentages.  Upper limits of potential 
modification were calculated for sites with no observed indels by assuming there is less than one 
indel then dividing by the total sequence count to arrive at an upper limit modification 
percentage, or taking the theoretical limit of detection (1/82,000), whichever value was larger.  
P-values: calculated as previously reported15 using a (right) one-sided Fisher’s exact test between 
each canonical C-terminal domain TALEN-treated sample and the untreated control sample.  P-
values of < 0.025 were considered significant and shown.   Specificity is the ratio of on-target to 
off-target genomic modification frequency for each site. 
 
Discussion of TALEN specificity 
The in vitro selection results for 30 unique TALENs each challenged with 1012 closed 
related off-target sequences and subsequent analysis inform our understanding of TALEN 
specificity through four key findings: (i) TALENs are highly specific for their intended target 
base pair at 103 of the 104 positions profiled with specificity increasing near the N-terminal 
TALEN end of each TALE repeat array (corresponding to the 5’ end of the bound DNA); (ii) 
longer TALENs are more specific in a genomic context while shorter TALENs have higher 
specificity per nucleotide; (iii) TALE repeats each bind their respective base pairs relatively 
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independently; and (iv) excess DNA-binding affinity leads to increased TALEN activity against 
off-target sites and therefore decreased specificity.  
The 16 confirmed TALEN off-target sites containing eight to 12 mutations identified 
from the 76 predicted sites assayed in this study represent more bona fide genomic off-target 
sites in the human genome than have been revealed collectively to date by other methods.  These 
16 sites were modified at efficiencies ranging from 2.3% to 0.03% in human cells, demonstrating 
that TALENs can have appreciable off-target activities in human cells even at sites that are eight 
or more mutations away from the on-target sequence.  Site accessibility in cells, mediated by 
histone proteins, transcription factors, and DNA modification,22 likely account for at least some 
of the difference between our in vitro, computational, and cell-based results.   
While previous reports7,19 have investigated TALEN specificity by identifying genomic 
off-target modifications for only a single TALEN pair, our study profiles the genomic specificity 
of two independent TALEN pairs (CCR5A and ATM) and is the first to compare different 
TALEN variants (canonical 63-aa vs. Q3 vs. Q7 C-terminal domains).  It is difficult to directly 
compare our study with those that characterize different TALENs, although we note that our 
study has identified 16 bona fide heterodimeric off-target sites with eight to 12 mutations 
modified by TALENs in cells while the previous studies, using SELEX7 or IDLV19, collectively 
identified only three such sites that are distant from their corresponding on-target sequences.  
Furthermore, the same strategy used in this study has been previously shown to identify more 
off-target sites of a ZFN21, 31 than the purely cellular IDLV study18 or using SELEX data to 
predict off-target sites.32  Of the 76 total IDLV insertion sites identified in cells treated with 
TALENs,19 seven were at the target site while only three off-target sites were consistent with 
nuclease-mediated IDLV insertion.  Only one of these three genomic off-target sites was 
heterodimeric (the use of TALENs containing homodimeric Fok1 domains likely allowed for 
homodimeric off-target sites in which both right and left half-sites were targeted by the same 
TALEN).  The on-target:off-target activity ratios of 170 and 1,140 for the two bona fide TALEN 
genomic off-targets sites out of 19 identified by SELEX7 are similar to the 12 to 890 on:off-
target activity ratios observed in this study. 
The observed decrease in specificity for TALENs with more TALE repeats or more 
cationic residues in the C-terminal domain or N-terminus are consistent with a model in which 
excess TALEN binding affinity leads to increased promiscuity.  This excess binding energy 
model may explain reports that NN RVDs bind either A or G.2,!34,!30  These studies used TALE 
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arrays of more than 14 RVDs, which could have created a scenario in which excess DNA-
binding energy masked a suboptimal NN RVD interaction with A compared to G.  We observed 
NN RVDs to discriminate between A and G, consistent with reports using shorter TALE arrays 
of 13 RVDs35 and by direct biochemical interrogation.33  Excess DNA-binding energy could also 
explain the previously reported promiscuity at the 5’ terminal T of TALENs with longer C-
terminal domains29 and is consistent with a report of higher TALEN protein concentrations 
resulting in more off-target site cleavage in vivo.9  While decreasing TALEN protein expression 
in cells in theory could reduce off-target cleavage, TALE arrays are reported with on-target DNA 
binding affinities as high as Kd = 2.8 nM,33 which is sufficient to theoretically saturate target 
sites even when expressed at modest, mid-nM concentrations in the cell.  The difficulty of 
improving the specificity of such TALENs by lowering their expression levels, coupled with the 
need to maintain sufficient TALEN concentrations to effect desired levels of on-target cleavage, 
highlight the value of engineering TALENs with higher intrinsic specificity such as those 
described in this work.  
Our findings suggest that mutant C-terminal domains with reduced non-specific DNA 
binding may be used to alter the DNA-binding affinity of TALENs such that on-target sequences 
are cleaved efficiently but with minimal excess DNA-binding energy, resulting in better 
discrimination between on-target and off-target sites.!!Since TALENs targeting up to 46 total 
base pairs have been shown to be active in cells,14 it may be possible to further improve 
specificity by engineering TALENs with a combination of mutant N-terminal and C-terminal 
domains that impart reduced non-specific DNA-binding, a greater number of TALE repeats to 
contribute additional on-target DNA binding, and lower-affinity RVDs such as the NK RVD to 
recognize G.34, 35  It is tempting to speculate that the strategy of mutating residues that contribute 
to non-specific DNA binding to improve DNA specificity may also apply to other genome 
engineering proteins including Cas9 and ZFNs.  While a comparison of the specificity of various 
programmable genome-editing technologies including ZFNs, TALENs and CRISPRs would be 
of interest, in order for such a comparison to be rigorous, many new lines of experiments are 
needed so that all three technologies are evaluated on their ability to cleave the same target 
sequences in vitro and in cells under the same conditions. 
 Our model and the resulting improved TALENs would have been difficult to derive or 
validate using purely cellular off-target cleavage methods.  The ability of our profiling method to 
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reveal the broad, unobscured DNA cleavage specificity of TALENs in the absence of cellular 
complications enabled the elucidation of the inherent DNA-cleavage specificity of TALENs.  
Studies of cellular off-target cleavage are also intrinsically limited by the small number of 
sequences closely related to a target sequence of interest that are present in a genome.!!In 
contrast, each active, dimeric TALEN in this study was evaluated for its ability to cleave any of 
1012 close variants of its on-target sequence, a library size several orders of magnitude greater 
than the number of different sequences in a mammalian genome.  This dense coverage of off-
target sequence space enabled the elucidation of detailed relationships between DNA-cleavage 
specificity and target base pair position, TALE repeat length, TALEN concentration, mismatch 
location, and engineered TALEN composition.  These results collectively reveal principles for 
characterizing and improving TALENs with greater specificity that may enable a wider range of 
genome engineering applications. 
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1.7  Methods used to study TALEN specificity  
 
Oligonucleotides, PCR and DNA Purification. 
 PCR was performed with 0.4 µL of 2 U/µL Phusion Hot Start II DNA polymerase 
(Thermo-Fisher) in 50 µL with 1x HF Buffer, 0.2 mM dNTP mix (0.2 mM dATP, 0.2 mM 
dCTP, 0.2 mM dGTP, 0.2 mM dTTP) (NEB), 0.5 µM to 1 µM of each primer and a program of: 
98 ˚C, 1 min; 35 cycles of [98 ˚C, 15 s; 62 ˚C, 15 s; 72 ˚C, 1 min] unless otherwise noted. Many 
DNA reactions were purified with a QIAquick PCR Purification Kit (Qiagen) referred to below 
as Q-column purification or MinElute PCR Purification Kit (Qiagen) referred to below as M-
column purification.  All oligonucleotides were purchased from Integrated DNA Technologies 
(IDT).  Oligonucleotide sequences are listed below in Table 1.24. 
A 
oligonucleotide name oligonucleotide sequence (5’->3’) 
CCR5Aon-Circ CACCACTNTTCATTACACCTGCAGCTNNNNNNNNNNNNAGTATCAATTCTGGAAGANCGTCACGCT 
CCR5Amut-Circ CACCACTNTTCATTACACCTGCAGCTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCGTCACGCT 
TAL-Nrev 5Phos/CAGCAGCTGCCCGGT 
TAL-N1fwd 5Phos/cAGATCGCGAAGAGAGGGGGAGTAACAGCGGTAG 
TAL-N2fwd 5Phos/cAGATCGCGcAGAGAGGGGGAGTAACAGCGGTAG 
TAL-N3fwd 5Phos/cAGATCGCGcAGcagGGGGGAGTAACAGCGGTAG 
TAL-Cifwd ATC GTA GCC CAA TTG TCC A 
TAL-Cirev GTTGGTTCTTTGGATCAATGCG 
TAL-Q3 AAGTTCTCTCGGGAATCCGTTGGTTGGTTCTTTGGATCA 
TAL-Q7 
GAAGTTCTCTCGGGAATTTGTTGGTTGGTTTGTTGGATCAATGCGGGAGCATGAGGCAGACCTTGTTGGA
CTGCATC 
TAL-Ciirev CTTTTGACTAGTTGGGATCCCGCGACTTGATGGGAAGTTCTCTCGGGAAT 
CCR5A Library10 
5Phos/CACCACTNT%T%C%A%T%T%A%C%A%C%C%T%G%C%A%G%C%T%NNNNNNNNNNA%G%T%
A%T%C%A%A%T%T%C%T%G%G%A%A%G%A%NCGTCACGCT 
CCR5A Library12 
5Phos/CACCACTNT%T%C%A%T%T%A%C%A%C%C%T%G%C%A%G%C%T%NNNNNNNNNNNNA%G%
T%A%T%C%A%A%T%T%C%T%G%G%A%A%G%A%NCGTCACGCT 
CCR5A Library14 
5Phos/CACCACTNT%T%C%A%T%T%A%C%A%C%C%T%G%C%A%G%C%T%NNNNNNNNNNNNNNA%
G%T%A%T%C%A%A%T%T%C%T%G%G%A%A%G%A%NCGTCACGCT 
CCR5A Library16 
5Phos/CACCACTNT%T%C%A%T%T%A%C%A%C%C%T%G%C%A%G%C%T%NNNNNNNNNNNNNNNNA
%G%T%A%T%C%A%A%T%T%C%T%G%G%A%A%G%A%NCGTCACGCT 
CCR5A Library18 
5Phos/CACCACTNT%T%C%A%T%T%A%C%A%C%C%T%G%C%A%G%C%T%NNNNNNNNNNNNNNNN
NNA%G%T%A%T%C%A%A%T%T%C%T%G%G%A%A%G%A%NCGTCACGCT 
CCR5A Library20 
5Phos/CACCACTNT%T%C%A%T%T%A%C%A%C%C%T%G%C%A%G%C%T%NNNNNNNNNNNNNNNN
NNNNA%G%T%A%T%C%A%A%T%T%C%T%G%G%A%A%G%A%NCGTCACGCT 
CCR5A Library22 
5Phos/CACCACTNT%T%C%A%T%T%A%C%A%C%C%T%G%C%A%G%C%T%NNNNNNNNNNNNNNNN
NNNNNNA%G%T%A%T%C%A%A%T%T%C%T%G%G%A%A%G%A%NCGTCACGCT 
CCR5A Library24 
5Phos/CACCACTNT%T%C%A%T%T%A%C%A%C%C%T%G%C%A%G%C%T%NNNNNNNNNNNNNNNN
NNNNNNNNA%G%T%A%T%C%A%A%T%T%C%T%G%G%A%A%G%A%NCGTCACGCT 
CCR5B Library10 
5Phos/CCACGCTNT%C%T%T%C%A%T%T%A%C%A%C%C%T%G%C%NNNNNNNNNNC%A%T%A%C%
A%G%T%C%A%G%T%A%T%C%A%NCCTCGGGACT 
CCR5B Library12 
5Phos/CCACGCTNT%C%T%T%C%A%T%T%A%C%A%C%C%T%G%C%NNNNNNNNNNNNC%A%T%A%
C%A%G%T%C%A%G%T%A%T%C%A%NCCTCGGGACT 
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CCR5B Library14 
5Phos/CCACGCTNT%C%T%T%C%A%T%T%A%C%A%C%C%T%G%C%NNNNNNNNNNNNNNC%
A%T%A%C%A%G%T%C%A%G%T%A%T%C%A%NCCTCGGGACT 
CCR5B Library16 
5Phos/CCACGCTNT%C%T%T%C%A%T%T%A%C%A%C%C%T%G%C%NNNNNNNNNNNNNNNN
C%A%T%A%C%A%G%T%C%A%G%T%A%T%C%A%NCCTCGGGACT  
CCR5B Library18 
5Phos/CCACGCTNT%C%T%T%C%A%T%T%A%C%A%C%C%T%G%C%NNNNNNNNNNNNNNNN
NNC%A%T%A%C%A%G%T%C%A%G%T%A%T%C%A%NCCTCGGGACT 
CCR5B Library20 
5Phos/CCACGCTNT%C%T%T%C%A%T%T%A%C%A%C%C%T%G%C%NNNNNNNNNNNNNNNN
NNNNC%A%T%A%C%A%G%T%C%A%G%T%A%T%C%A%NCCTCGGGACT  
CCR5B Library22 
5Phos/CCACGCTNT%C%T%T%C%A%T%T%A%C%A%C%C%T%G%C%NNNNNNNNNNNNNNNN
NNNNNNC%A%T%A%C%A%G%T%C%A%G%T%A%T%C%A%NCCTCGGGACT  
CCR5B Library24 
5Phos/CCACGCTNT%C%T%T%C%A%T%T%A%C%A%C%C%T%G%C%NNNNNNNNNNNNNNNN
NNNNNNNNC%A%T%A%C%A%G%T%C%A%G%T%A%T%C%A%NCCTCGGGACT  
ATM Library10 
Phos/CTCCGCGTNT%G%A%A%T%T%G%G%G%A%T%G%C%T%G%T%T%T%NNNNNNNNNNT
%T%T%A%T%T%T%T%A%C%T%G%T%C%T%T%T%A%GGTACCCCA  
ATM Library12 
5Phos/CTCCGCGTNT%G%A%A%T%T%G%G%G%A%T%G%C%T%G%T%T%T%NNNNNNNNNN
NNT%T%T%A%T%T%T%T%A%C%T%G%T%C%T%T%T%A%GGTACCCCA  
ATM Library14 
5Phos/CTCCGCGTNT%G%A%A%T%T%G%G%G%A%T%G%C%T%G%T%T%T%NNNNNNNNNN
NNNNT%T%T%A%T%T%T%T%A%C%T%G%T%C%T%T%T%A%GGTACCCCA  
ATM Library16 
5Phos/CTCCGCGTNT%G%A%A%T%T%G%G%G%A%T%G%C%T%G%T%T%T%NNNNNNNNNN
NNNNNNT%T%T%A%T%T%T%T%A%C%T%G%T%C%T%T%T%A%GGTACCCCA  
ATM Library18 
5Phos/CTCCGCGTNT%G%A%A%T%T%G%G%G%A%T%G%C%T%G%T%T%T%NNNNNNNNNN
NNNNNNNNT%T%T%A%T%T%T%T%A%C%T%G%T%C%T%T%T%A%GGTACCCCA  
ATM Library20 
5Phos/CTCCGCGTNT%G%A%A%T%T%G%G%G%A%T%G%C%T%G%T%T%T%NNNNNNNNNN
NNNNNNNNNNT%T%T%A%T%T%T%T%A%C%T%G%T%C%T%T%T%A%GGTACCCCA  
ATM Library22 
5Phos/CTCCGCGTNT%G%A%A%T%T%G%G%G%A%T%G%C%T%G%T%T%T%NNNNNNNNNN
NNNNNNNNNNNNT%T%T%A%T%T%T%T%A%C%T%G%T%C%T%T%T%A%GGTACCCCA  
ATM Library24 
5Phos/CTCCGCGTNT%G%A%A%T%T%G%G%G%A%T%G%C%T%G%T%T%T%NNNNNNNNNN
NNNNNNNNNNNNNNT%T%T%A%T%T%T%T%A%C%T%G%T%C%T%T%T%A%GGTACCCCA  
#1 adapter-fwd**1 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTACTGT 
#1 adapter-rev**1 ACAGTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**2 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCTGAA 
#1 adapter-rev**2 TTCAGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**3 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTGCAA 
#1 adapter-rev**3 TTGCAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**4 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTGACT 
#1 adapter-rev**4 AGTCAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**5 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGCATT 
#1 adapter-rev**5 AATGCAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**6 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCATGA 
#1 adapter-rev**6 TCATGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**7 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTATGCT 
#1 adapter-rev**7 AGCATAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**8 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCTAGT 
#1 adapter-rev**8 ACTAGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**9 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTAA 
#1 adapter-rev**10 TTAGCAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**10 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGTA 
#1 adapter-rev**11 TACTGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**11 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGTACT 
#1 adapter-rev**12 AGTACAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**12 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTACTGT 
#1 adapter-rev**13 ACAGTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**13 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTAA 
#1 adapter-rev**14 TTAGCAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**14 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGTA 
#1 adapter-rev**14 TACTGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**15 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGTACT 
#1 adapter-rev**15 AGTACAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
#1 adapter-fwd**16 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTACTGT 
#1 adapter-rev**16 ACAGTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGG 
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#2A primer-fwd AATGATACGGCGACCAC 
#2A primer-
rev*CCR5A GTTCAGACGTGTGCTCTTCCGATCTNNNNAGTGGTGAGCGTGACG 
#2A primer-rev*ATM GTTCAGACGTGTGCTCTTCCGATCTNNNNACGCGGAGTGGGGTACC 
#2A primer-
rev*CCR5B CAGACGTGTGCTCTTCCGATCNNNNAGCGTGGAGTCCCGAGG 
#2B primer-fwd AATGATACGGCGACCAC 
#2B primer-rev**1 CAAGCAGAAGACGGCATACGAGATTGTTGACTGTGACTGGAGTTCAGACGTGTGCTCTTC 
#2B primer-rev**2 CAAGCAGAAGACGGCATACGAGATACGGAACTGTGACTGGAGTTCAGACGTGTGCTCTTC 
#2B primer-rev**3 CAAGCAGAAGACGGCATACGAGATTCTAACATGTGACTGGAGTTCAGACGTGTGCTCTTC 
#2B primer-rev**4 CAAGCAGAAGACGGCATACGAGATCGGGACGGGTGACTGGAGTTCAGACGTGTGCTCTTC 
 CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTCAGACGTGTGCTCTTCCG 
#1 Lib. adapter-
fwd*CCR5A 
GTACCCAGATCGGAAGAGCACACGTCTGAACTCCAGTCACACAGTGATCTCGTATGCCGTCTTCT
GCTTG 
#1 Lib. adapter-
rev*CCR5A GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTG 
#1 Lib. adapter-
fwd*ATM 
GTACGATGCGATCGGAAGAGCACACGTCTGAACTCCAGTCACTTAGGCATCTCGTATGCCGTCTT
CTGCTTG 
#1 Lib. adapter-
rev*ATM GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCGCATC 
#1 Lib. adapter-
fwd*CCR5B 
TCGGGAACGTGATCGGAAGAGCACACGTCTGAACTCCAGTCACCGTCTAATCTCGTATGCCGTCT
TCTGCTTG 
#1 Lib. adapter-
rev*CCR5B GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCACGTT 
#2A Lib. primer-rev CAAGCAGAAGACGGCATACGA 
#2A Lib. primer-
fwd*CCR5A 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCGT
CACGCTCACCACT 
#2A Lib. primer-
fwd*ATM 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGT
ACCCCACTCCGCGT 
#2A Lib. primer-
fwd*CCR5B 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCT
CGGGACTCCACGCT 
#2B Lib. primer-rev CAAGCAGAAGACGGCATACGA 
#2B Lib. primer-fwd AATGATACGGCGACCAC 
G adapter-fwd ACACTCTTTCCCTACACGACGCTCTTCCGATCT 
G adapter-rev /5Phos/GATCGGAAGAGCACACGTCTGAACTCCA 
G-B primer-fwd AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC  
G-B primer-rev**1 CAAGCAGAAGACGGCATACGAGATGTGCGGACGTGACTGGAGTTCAGACGTGTGCT 
G-B primer-rev**2 CAAGCAGAAGACGGCATACGAGATCGTTTCACGTGACTGGAGTTCAGACGTGTGCT 
G-B primer-rev**3 CAAGCAGAAGACGGCATACGAGATAAGGCCACGTGACTGGAGTTCAGACGTGTGCT 
G-B primer-rev**4 CAAGCAGAAGACGGCATACGAGATTCCGAAACGTGACTGGAGTTCAGACGTGTGCT 
G-B primer-rev**5 CAAGCAGAAGACGGCATACGAGATTACGTACGGTGACTGGAGTTCAGACGTGTGCT 
G-B primer-rev**6 CAAGCAGAAGACGGCATACGAGATATCCACTCGTGACTGGAGTTCAGACGTGTGCT 
G-B primer-rev**7 CAAGCAGAAGACGGCATACGAGATAAAGGAATGTGACTGGAGTTCAGACGTGTGCT 
G-B primer-rev**8 CAAGCAGAAGACGGCATACGAGATATATCAGTGTGACTGGAGTTCAGACGTGTGCT 
CCR5AonCfwd CGACGGTCTAGAGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGT 
CCR5Amut1fwd CGACGGTCTAGAGTCTTCATTACAtCTGCAcCTCTCATTTTCCATACAGT 
CCR5Amut2fwd CGACGGTCTAGAGTCTTCAaTACACCTGtAGCTCTCATTTTCCATACAGT 
CCR5Amut3fwd CGACGGTCTAGAGTCTTCgTTACACCTGCAtCTCTCATTTTCCATACAGT 
CCR5Amut4fwd CGACGGTCTAGAGTCTTaATTgCACCTGCAGCTCTCATTTTCCATACAGT 
CCR5AonCrev CCGACGAAGCTTTTCTTCCAGAATTGATACTGACTGTATGGAAAATGA 
CCR5Amut1rev CCGACGAAGCTTTTCTTaCAGAATTcATACTGACTGTATGGAAAATGA 
CCR5Amut2rev CCGACGAAGCTTTTCcTCCAGAgTTGATACTGACTGTATGGAAAATGA 
CCR5Amut3rev CCGACGAAGCTTTTCTTCCtGAATTGATAaTGACTGTATGGAAAATGA 
CCR5Amut4rev CCGACGAAGCTTTTCTTCCAGcATTGtTACTGACTGTATGGAAAATGA 
ATMonAfwd CGACGGTCTAGATTTGAATTGGGATGCTGTTTTTAGGTATTCTATTCAAATT 
ATMmut1fwd CGACGGTCTAGATTTGAATTGGGtTGCTGTTTTTAGGTATTCTATTCAAATT 
ATMmut2fwd CGACGGTCTAGATTTGAATTGcGATGCTGTTTTTAGGTATTCTATTCAAATT 
ATMmut3wd CGACGGTCTAGATTTGAgTTGGGATGCTGTTTTTAGGTATTCTATTCAAATT 
ATMmut4fwd CGACGGTCTAGATTTGAATTGGGATGCTGaTTTTAGGTATTCTATTCAAATT 
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ATMonArev CCGACGAAGCTTAATAAAGACAGTAAAATAAATTTGAATAGAATACCTAAAA 
ATMmut1rev CCGACGAAGCTTAATAAAGACAGTgAAATAAATTTGAATAGAATACCTAAAA 
ATMmut2rev CCGACGAAGCTTAATAAAGAtAGTAAAATAAATTTGAATAGAATACCTAAAA 
ATMmut3rev CCGACGAAGCTTAATAAAGACAGTAAgATAAATTTGAATAGAATACCTAAAA 
ATMmut4rev CCGACGAAGCTTAATAAcGACAGTAAAATAAATTTGAATAGAATACCTAAAA 
CCR5BonBfwd CGACGGTCTAGAAAGGTCTTCATTACACCTGCAGCTCTCATTTTCCATACAGTCA 
CCR5Bmut1fwd CGACGGTCTAGAGTCTTCATTACACCTGtAGCTCTCATTTTC 
CCR5Bmut2fwd CGACGGTCTAGAGTCTTCATaACACCTGCAGCTCTCATTTTC 
CCR5Bmut3fwd CGACGGTCTAGAGTCTTCATTACACCcGCAGCTCTCATTTTC 
CCR5Bmut4fwd CGACGGTCTAGAGTCTTCATaACACCTGtAGCTCTCATTTTC 
CCR5Bmut5fwd CGACGGTCTAGAGTCTTCATTAtACCTaCAGCTCTCATTTTC 
CCR5Bmut6fwd CGACGGTCTAGAGTCTTCATTgCACCcGCAGCTCTCATTTTC 
CCR5BonBrev CCGACGAAGCTTTCTTCCAGAATTGATACTGACTGTATGGAAAATGAGAGCT 
CCR5Bmut1rev CCGACGAAGCTTTCTTCCAGAATTGATACTaACTGTATGGAAAATGAGAGCT 
CCR5Bmut2rev CCGACGAAGCTTTCTTCCAGAATTGATACTGACTGTATcGAAAATGAGAGCT 
CCR5Bmut3rev CCGACGAAGCTTTCTTCCAGAATTGATACTGACTGaATGGAAAATGAGAGCT 
CCR5Bmut4rev CCGACGAAGCTTTCTTCCAGAATTGATACcGACTGTATGGAAAATGAGAGCT 
CCR5Bmut5rev CCGACGAAGCTTTCTTCCAGAATTGATACTaACTGTATcGAAAATGAGAGCT 
CCR5Bmut6rev CCGACGAAGCTTTCTTCCAGAATTGATACTGAaTGTgTGGAAAATGAGAGCT 
CCR5Bmut7rev CCGACGAAGCTTTCTTCCAGAATTGATACTGAtaGTATGGAAAATGAGAGCT 
pUC19Ofwd GCGACACGGAAATGTTGAATACTCAT 
pUC19Orev CAGCGAGTCAGTGAGCGA 
 
B 
Site Fwd primer Rev primer PCR 
OnCCR5A TCACTTGGGTGGTGGCTGTG GACCATGACAAGCAGCGGCA  
OffC-1 AGTCCAAGACCAGCCTGGGG AAGAACCTGTTGTCTAATCCAGCA   
OffC-2 GAACCTGTTGTCTAATCCAGCGTC CTGCAAAGAAGGCCAGGCA   
OffC-3 GAACCTGTTGTCTAATCCAGCGTC CTGCAAAGAAGGCCAGGCA   
OffC-4 TGACCTGTTTGTTCAGGTCTTCC CCATATGGTCCCTGTCGCAA   
OffC-5 TCCAGTTGCTGTCCCTTCAGA ACAGGGAGAGCCACCAATGC   
OffC-6 GCCCGGCCTGTCCTGTATTT CACCCACACATGCACTTCCC   
OffC-7 TGGCTATTCTAGTTCTTTTGCAT CCATGCCCTAGGGATTTGTGGA   
OffC-8 CGCTGAAGGCTGTCACCCTAA TGGACCTAAGAGTCCTGCCCAT  ND 
OffC-9 CCACCACCACACAACTTCACA CAGCTGGCGAGAACTGCAAA  
OffC-10 TTCCAGGTCCTTTGCACAAATA GCAAGGTCGTTGGATAGAAGTTGA   
OffC-11 CACCGAAAGCAACCCATTCC TGATCTGCCCACCCCAGACT    
OffC-12 TTCATTCTCACCATCTGGAATTGG TCTGGCTGGACTGCTCTGGTT   
OffC-13 TGGCATGTGGATCAGTACCCA TAGAACATGCCCGCGAACAG   
OffC-14 CTGACGTCCATGTCAACGGG TTTGAATTCCCCCTCCCCAT   
OffC-15 GCTCCTTTCTGAGAAGCACCCAT GGCAGATGGTGGCAGGTCTT    
OffC-16 ATGAGGGCTTGGATTGGCTG CCACCTCCCCCACTGCAATA   
OffC-17 GGAGGCCTTCATTGTGTCACG AACTCCACCTGGGTGCCCTA   
OffC-18 CGTGGTCCCCCAGAAATCAC GGAGCAGGAGTTGGTGGCAT   
OffC-19 GATTGCATAGGTTAGCATTGCC GCCCCTGTTGGTTGACTCCC   
OffC-20 TTCCAGCGAATGGAAAGTGCT AAGCCCAGGAATAAGGGCCA   
OffC-21 AAGCATGCTCACACTGTGGTGTA TTGCTTGAGGCGGAAGTTGC   
OffC-22 TGACCCTCCAGCAAAGGTGA CCCCAGGGACTGAGCATGAG   
OffC-23 GCTTTGCTTGCACTGTGCCTT GGGGACAGACTGTGAGGGCT    
OffC-24 TCAAAAGGATGTGATCTGCCACA GGCCTCTTTGAGGGCCAGTT   
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OffC-25 CCAGGGCTCAATTCTTAGACCG AAAAGAGCAGGGCTGCCATC   
OffC-26 TGTTCATGCCTGCACAGTGG TGGATGTGCCCTCTACCACA   
OffC-27 TTTGGCAAGGAATTCACAGTTC TCATGCCTGCACAGTGGTTG   
OffC-28 GGAGGATGTCTTTGTGGTAGGGG CGCTGCCAAGCAAACTCAAA   
OffC-29 TCCCCCAACTTCACTGTTTTT GCAATGAGCATGTGGACACCA   
OffC-30 TTCTCTGTTTCCAGTGATTTCAGA GTCGCAAAACAGCCAGTTGC +DMSO 
OffC-31 TGGCTTGGTTAATGGACAATGG CCTGCAAGGAGCAAGGCTTC +DMSO 
OffC-32 TGGGCTTCGTTGACTTAAAGAG GGACAAGAGGGCCAGGGTTT   
OffC-33 TCTTAAACATGTGGAACCCAGTCAT TGAAAACCCACAGAGTGGGAGA   
OffC-34 GCAGATTCATTAGCGTTTGTGGC TGCATGGGTGTAAATGTAGCAGAAA   
OffC-35 CCAAGGATCAATACCTTTGGAGGA GCCCTCCCTTGAATCAGGCT   
OffC-36 TTCCCCTAACCAGGGGCAGT GTGGTGAGTGGGTGTGGCAG +DMSO 
OffC-38 CGCCCATGAGAAAGAGTCCA CTACACCCCCTCCCCAAAGG  
OffC-39 GCTGTCATTTCCAAAGCCGC GGCCTCTAGAGTGAGGGGGTTG  
OffC-40 GCTGTCATTTCCAAAGCGGC GGCCAACAAGATGCCAAGGT  
OffC-42 AGTTCTCAGCAACTAAAGTATTGA CTGGGATTACAGGCGTGAGC ND 
OffC-45 CCATCATTGGCATCATGGGA TGGAATGGAGTGGCCAACCT ND 
OffC-49 GTCAGGACCACACAAGAAAATAAAA GGGAATGCCAGTCTTTGCCA  
OffC-56 CCCAGCCGATGACCAGAAAT GCCAGCTGAGCTCTTTGCTGTA  
OffC-65 ACCCATTGATAAGGCACATTCT AGTCAAACTCATCTAACACTCCAG  
OffC-69 TCTCCCACACCCCACATTCA TGCGATAAGGTTGCAATGACA  
OffC-76 TAGGGCGCCTCAGATCCACT GAGCTGCAGGCCTTGAATGG  
OffC-137 AGCCACAAGGGCCTGCTGTA ACTGCGCCCAGCCTATCACT  
OffC-150 GCTTTTCTTTTCAGCCAAATGAAAGTT ACGTGCGTCCCTGTCACTCA  
OnATM AGCGCCTGATTCGAGATCCT ATGCCAAATTCATATGCAAGGC  
OffA-1 CCTGCCATTGAATTCCAGCCT TGTCTGCCTTTCCTGTCCCC   
OffA-2 GACTGCCACTGCACTCCCAC GGATACCCTTGCCTCCCCAC   
OffA-3 CCTCCCATTTTCCTTCCTCCA CTGGGAGACACAGGTGGCAG   
OffA-4 TCCTCCAATTTTCCTTCCTCCA CTGGGAGACACAGGTGGCAG   
OffA-5 CTGGGAGACACAGGTGGCAG AGGACCAATGGGGCCAATCT   
OffA-6 CTGGGAGACACAGGTGGCAG AGGACCAATGGGGCCAATCT   
OffA-7 CTGGGAGACACAGGTGGCAG AGGACCAATGGGGCCAATCT   
OffA-8 GCATGCCAAAGAAATTGTAGGC TTCCCCCTGTCATGGTCTTCA   
OffA-9 GCATCTCTGCATTCCTCAGAAGTGG AGAAACTGAGCAAGCCTCAGTCAA   
OffA-10 GGGATACCAAAGAGCTTTTGTTTTGTT CAGAGGCTGCATGATGCCTAATA   
OffA-11 TGCAGCTACGGATGAAAACCAT TCAGAATACCTCCCCGCCAG   
OffA-12 GCATAAAGCACAGGATGGGAGA TCCCTCTTTAACGGTTATGTTGGC   
OffA-13 TGGGTTAAGTAATTTCGAAAGGAGAA ATGTGCCCCACACATTGCC +DMSO 
OffA-14 GAGTGAGCCACTGCACCCAG CGTGTGGTGGTGGCACAAG ND 
OffA-15 CCTCCCTCTGGCTCCCTCCC ACCAGGGCCTGTTGGGGGTT   
OffA-16 TGCTCCCTGACCTTCCTGAGA CCATTGGAATGAGAACCTTCTGG   
OffA-17 GGTGGAACAATCCACCTGTATTAGC GAATGTGACACCACCACCGC   
OffA-18 GGCTTTGCAAACATAAACACTCA CCTTCTGAGCAGCTGGGACAA   
OffA-19 CACTGGAACCCAGGAGGTGG CCTCCCATTGGAGCCTTGGT  ND 
OffA-20 CAGCCTGCCTGGGTGACAG CATCTGAGCTCAAAACTGCTGC +DMSO 
OffA-21 GCCACTGCATTGCATTTTCC TGAGGGCAGGTCTGTTTCCTG  
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OffA-22 GGGAGGATCTCTCGAGTCCAGG CCTTGCCTGACTTGCCCTGT   
OffA-23 TGTTTAGTAATTAAGACCCTGGCTTTC GCGACAGGTACAAAGCAGTCCAT   
OffA-24 GCCCTTTGATTTCATCTGTTTCCC CATTGCTGCCATTGCACTCC   
OffA-25 AAACTGGCACATGTACTCCT ACATGATTTGATTTTTCATGTGTTT   
OffA-26 GGGTGGAAGGTGAGAGGAGATT CGCAGATGGGCATGTTATTG ND 
OffA-27 CCTCCCATTTTCCTTCCTCCA GACTGCCACTGCACTCCCAC   
OffA-28 AGCCAAGATTGCACCATTGC GTCCCTGACGGAGGCTGAGA ND 
OffA-29 TGGTTGGATTTTGGCTCTGTCAC TGTCAATATCAATACCCTGCTTTCCTC   
OffA-30 TGGTTACTTTTAAAGGGTCATGATGGA AAAAATGGATGCAAAGCCAAA +DMSO 
OffA-31 GGGACACAGAGCCAAACCGT TGTGCACATGTACCCTAAAACT ND 
OffA-32 CAGTCATTGTTTCTAGGTAGGGGA TTGGCAATTTGGGTGCAACA   
OffA-33 TGGATAACCTGCAGATTTGTTTCTG TGAGCCCAGGAGTTTCAGGC   
OffA-34 TCGTGTGTGTGTGTTTGCTTCA CAGTGGTTCGGGAAACAGCA   
OffA-35 TGGGAATGTAAATCTGACTGGCTG CTGGAACTCTGGGCATGGCT   
OffA-36 GCTGCAATTGCTTTTTGGCA TGGACCCCTCCCTTACACC   
CP_CCRoff-1 TTGTTCCAACCAGCTTCATGATAA CCTCCTTAAAGCTTCTTGCCA  
CP_CCRoff-2 TGTGACACAAACCATTGCATTC CTATGAAGAGCTATTGATGCAGAA  
CP_CCRoff-3 TCCAGAATAATCACTGTGGCTGC ACCAGGGGAAACTAGTGGGAGG  
CP_CCRoff-4 AACTTACTATCTGCTGGACACATTG CTAGAGCCCCTGTTGGTTGACT  
CP_CCRoff-5 GCTGGGCTAGACCACAATTTTT CAAGGTTCAGTTTCCCTGCTCT  
CP_CCRoff-6 TGTAATAGCAAGGCTTCAGGAC AGAAAAGTTTCAGTGAAGAAAAACG  
CP_CCRoff-7 AGTTCTCAGCAACTAAAGTATTGA CTGGGATTACAGGCGTGAGC ND 
CP_CCRoff-8 GGAGGCTGAGGTGAGAGGTT ATCACCCGTCTTCTGCATCG  
CP_CCRoff-9 ACCTGTTGTCTAATCCAGCGTC GAGACCAGGAGTCCGAGACC  
CP_CCRoff-10 ACCTGTTGTCTAATCCAGCGTC GAGACCAGGAGTCCGAGACC  
CP_CCRoff-11 CAGGAGTCCAAGACCAGCCT AACCTGTTGTCTAATCCAGCA  
CP_CCRoff-12 ACCCATTGATAAGGCACATTCT AGTCAAACTCATCTAACACTCCAG  
CP_CCRoff-13 TAGGGTCTCACCCACTTGCTC GCCTTGGGTCAGTCCTGGAG  
CP_CCRoff-14 TTGGAGGGAATGAGTTGGCTG AGTATTTGGCACAGTGATGGG  
CP_CCRoff-15 AGAAGCAGGTACCTTCCCACC GCATGTTAAGCCATAGAAAGGGC  
CP_CCRoff-16 AAAAAGCTCCAGCCCAGTCTC TTTGGAATTGATCCATTGAATTTGA  
CP_CCRoff-17 TCTGTCCCTCCTACTGAGGC TGGAAGGCTCATTTTGTTGTTTCC  
CP_CCRoff-18 GGATGTCTTTGTGGTAGGGGT TGCTGTCACTTGGGAAAAGAA  
CP_CCRoff-19 TGTCTCTAGAAGCTAATCACTTTTT AGAATAGTCTGCAGCTCTTTCAA  
CP_CCRoff-20 CCATGTGCATCTGTGCCGC AACCCTTGAGAGATGAGAAGAGA  
CP_CCRoff-21 GCATTTCAGGTGGTGCTGGA AAGAGAAGAGATTCCTTGGGGG  
CP_CCRoff-22 AAAGCACCGACAAGCTCCG AAAGACACCCCCAGTCTGCT  
CP_CCRoff-23 TGATTTTGAGAGCATTGATTTTCAT AGCACAGCGTCAGTGATCT  
CP_CCRoff-24 AGGAAAAACAAAGTTGAGTGAGA TAGCTAGAATCAGTTAAGTTCCTGT  
CP_CCRoff-25 GATTGTGCCACTGCACTCCA CCCATCCCTCCTCCACCCTA  
CP_CCRoff-26 CCTGTGAAGTGTGCCGAAGA TTTCTTCAGGAGGGGTGCCT  
CP_CCRoff-27 TGTGATCCCCACAGAAGCCA ACCAAGGGTCTCCTCTGTAACC  
CP_CCRoff-28 AGGGTCATCTGGGAATATAGCTC TCTGGCTGGAAATTCAAAATGA  
CP_CCRoff-29 CACTAATCATCAGGGAAATGCAA TGAAACTGTTTTCCATAGACGTAGT  
CP_CCRoff-30 ACCATCTGTGGTAGGCAGAAT GCTCACCTGATAACCCAGGC  
CP_CCRoff-31 CTGTCCATGGTTGATGGATGCT CCCCCTTCTCTTTTCACTCCCT  
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Table 1.24 (Continuted).  Oligonucleotides used in this study. (A) All oligonucleotides were 
purchased from Integrated DNA Technologies. ‘/5Phos/’ indicates 5’ phosphorylated 
oligonucleotides. A % symbol indicates that the preceding nucleotide was incorporated as a 
mixture of phosphoramidites consisting of 79 mol% of the phosphoramidite corresponding to the 
preceding nucleotide and 7 mol% of each of the other three canonical phosphoramidites.  An (*) 
indicates that the oligonucleotide primer was specific to a selection sequence (either CCR5A, 
ATM or CCR5B).  An (**) indicates that the oligonucleotide adapter or primer had a unique 
sequence identifier to distinguish between different samples (selection conditions or cellular 
TALEN treatment).   (B) Combinations of oligonucleotides used to construct discrete DNA 
substrates used in TALEN digestion assays.  (C) Primer pairs for PCR amplifying on-target and 
off-target genomic sites.  +DMSO: DMSO was used in the PCR; ND: no correct DNA product 
was detected from the PCR reaction. 
 
TALEN Construction 
 The canonical TALEN plasmids were constructed by the FLASH method12 with each 
TALEN targeting 10-18 base pairs.  N-terminal mutations were cloned by PCR with Q5 Hot 
Start Master Mix (NEB) [98 ˚C, 22 s; 62 ˚C, 15 s; 72 °C, 7 min]) using phosphorylated TAL-
N1fwd (for N1), phosphorylated TAL-N2fwd (for N2), or phosphorylated TAL-N3fwd (for N3) 
and phosphorylated TAL-Nrev as primers.  1 µL DpnI (NEB) was added and the reaction was 
incubated at 37 °C for 30 min then M-column purified.  ~25 ng of eluted DNA was blunt-end 
ligated intramolecularly in 10 µL 2x Quick Ligase Buffer, 1 µL of Quick Ligase (NEB) in a total 
volume of 20 µL at room temperature (~21 °C) for 15 min. 1 µL of this ligation reaction was 
transformed into Top10 chemically competent cells (Invitrogen).  C-terminal domain mutations 
were cloned by PCR using TAL-Cifwd and TAL-Cirev primers, then Q-column purified.  ~1 ng 
of this eluted DNA was used as the template for PCR with TAL-Cifwd and either TAL-Q3 (for 
Q3) or TAL-Q7 (for Q7) for primers, then Q-column purified. ~1 ng of this eluted DNA was 
used as the template for PCR with TAL-Cifwd and TAL-Ciirev for primers, then Q-column 
purified. ~1 µg of this DNA fragment was digested with HpaI and BamHI in 1x NEBuffer 4 and 
cloned21 into ~2 µg of desired TALEN plasmid pre-digested with HpaI and BamHI.   TALENs 
containing the N-terminal mutant domains, the Q3 C-terminal domains and the Q7 C-terminal 
will be available from Addgene. 
 
 
In Vitro TALEN Expression 
 94 
 TALEN proteins, all containing a 3xFLAG tag, were expressed by in vitro 
transcription/translation.  800 ng of TALEN-encoding plasmid or no plasmid (“empty lysate” 
control) was added to an in vitro transcription/translation reaction using the TNT® Quick 
Coupled Transcription/Translation System, T7 Variant (Promega) in a final volume of 20 µL at 
30 °C for 1.5 h.  Western blots were used to visualize protein using the anti-FLAG M2 
monoclonal antibody (Sigma-Aldrich).  TALEN concentrations were calculated by comparison 
to standard curve of 1 ng to 16 ng N-terminally FLAG-tagged bacterial alkaline phosphatase 
(Sigma-Aldrich).  
 
In Vitro Selection for DNA Cleavage 
 Pre-selection libraries were prepared with 10 pmol of oligo libraries containing partially 
randomized target half-site sequences (CCR5A, ATM, or CCR5B) and fully randomized 10- to 
24-bp spacer sequences (Table 1.24).  Oligonucleotide libraries were separately circularized by 
incubation with 100 units of CircLigase II ssDNA Ligase (Epicentre) in 1x CircLigase II 
Reaction Buffer (33 mM Tris-acetate, 66 mM potassium acetate, 0.5 mM dithiothreitol, pH 7.5) 
supplemented with 2.5 mM MnCl2  in 20 µL total for 16 h at 60 °C then incubated at 80 °C for 
10 min.  2.5 µL of each circularization reaction was used as a substrate for rolling-circle 
amplification at 30 °C for 16 h in a 50-µL reaction using the Illustra TempliPhi 100 
Amplification Kit (GE Healthcare).  The resulting concatemerized libraries were quantified with 
Quant-iT™ PicoGreen ® dsDNA Kit (Invitrogen) and libraries with different spacer lengths 
were combined in an equimolar ratio. 
 For selections on the CCR5B sequence libraries, 500 ng of pre-selection library was 
digested for 2 h at 37 °C in 1x NEBuffer 3 with in vitro transcribed/translated TALEN plus 
empty lysate (30 µL total). For all CCR5B TALENs, in vitro transcribed/translated TALEN 
concentrations were quantified by Western blot (during the blot, TALENs were stored for 16 h at 
4 °C) and then TALEN was added to 40 nM final concentration per monomer.  For selections on 
CCR5A and ATM sequence libraries, the combined pre-selection library was further purified in a 
300,000 MWCO spin column (Sartorius) with three 500-µL washes in 1x NEBuffer 3.  125 ng 
pre-selection library was digested for 30 min at 37 °C in 1x NEBuffer 3 with a total 24 µL of 
fresh in vitro transcribed/translated TALENs and empty lysate.  For all CCR5A and ATM 
TALENs, 6 µL of in vitro transcription/translation left TALEN and 6 µL of right TALEN were 
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used, corresponding to a final concentration in a cleavage reaction of 16 nM ± 2 nM or 12 nM ± 
1.5 nM for CC5A or ATM TALENs, respectively.  These TALEN concentrations were 
quantified by Western blot performed in parallel with digestion.  
 For all selections, the TALEN-digested library was incubated with 1 µL of 100 µg/µL 
RNase A (Qiagen) for 2 min and then Q-column purified.  50 µL of purified DNA was incubated 
with 3 µL of 10 mM dNTP mix (10 mM dATP, 10 mM dCTP, 10 mM dGTP, 10 mM dTTP) 
(NEB), 6 µL of 10x NEBuffer 2, and 1 µL of 5 U/µL Klenow Fragment DNA Polymerase 
(NEB) for 30 min at room temperature and Q-column purified.  50 µL of the eluted DNA was 
ligated with 2 pmol of heated and cooled #1 adapters containing barcodes corresponding to each 
sample (selections with different TALEN concentrations or constructs) (Table 1.24). Ligation 
was performed in 1x T4 DNA Ligase Buffer (50 mM Tris-HCl, 10 mM MgCl2 , 1 mM ATP, 10 
mM DTT, pH 7.5) with 1 µL of 400 U/µL T4 DNA ligase (NEB) in 60 µL total volume for 16 h 
at room temperature, then Q-column purified.   
 6 µL of the eluted DNA was amplified by PCR in 150 µL total reaction volume (divided 
into 3x 50 µL reactions) for 14 to 22 cycles using the #2A adapter primers in Table 1.24.  The 
PCR products were purified by Q-column.  Each DNA sample was quantified with Quant-iT™ 
PicoGreen® dsDNA Kit (Invitrogen) and then pooled into an equimolar mixture.  500 ng of 
pooled DNA was run a 5% TBE 18-well Criterion PAGE gel (BioRad) for 30 min at 200 V and 
DNAs of length ~230 bp (corresponding to 1.5 target site repeats plus adapter sequences) were 
isolated and purified by Q-column.  ~2 ng of eluted DNA was amplified by PCR for 5 to 8 cycles 
with #2B adapter primers (Table 1.24) and purified by M-column.   
 10 µL of eluted DNA was purified using 12 µL of AMPure XP beads (Agencourt) and 
quantified with an Illumina/Universal Library Quantification Kit (Kapa Biosystems).  DNA was 
prepared for high-throughput DNA sequencing according to Illumina instructions and sequenced 
using a MiSeq DNA Sequencer (Illumina) using a 12 pM final solution and 156-bp paired-end 
reads.  To prepare the pre-selection library for sequencing, the pre-selection library was digested 
with 1 µL to 4 µL of appropriate restriction enzyme (CCR5A = Tsp45I, ATM = Acc65I, CCR5B 
= AvaI (NEB)) for 1 h at 37 °C then ligated as described above with 2 pmol of heated and cooled 
#1 library adapters (Table 1.24).  Pre-selection library DNA was prepared as described above 
using #2A library adapter primers and #2B library adapter primers in place of #2A adapter 
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primers and #2B adapter primers, respectively (Table 1.24).  The resulting pre-selection library 
DNA was sequenced together with the TALEN-digested samples. 
 
Discrete In Vitro TALEN Cleavage Assays 
 Discrete DNA substrates for TALEN digestion were constructed by combining pairs of 
oligonucleotides as specified in Table 1.24 with restriction cloning21 into pUC19 (NEB).  
Corresponding cloned plasmids were amplified by PCR (59 °C annealing for 15 s) for 24 cycles 
with pUC19Ofwd and pUC19Orev primers (Table 1.24) and Q-column purified.  50 ng of 
amplified DNAs were digested in 1x NEBuffer 3 with 3 µL each of in vitro 
transcribed/translated TALEN left and right monomers (corresponding to a ~16 nM to ~12 nM 
final TALEN concentration), and 6 µL of empty lysate in a total reaction volume of 120 µL.  The 
digestion reaction was incubated for 30 min at 37 °C, then incubated with 1 µL of 100 µg/µL 
RNase A (Qiagen) for 2 min and purified by M-column.  The entire 10 µL of eluted DNA with 
glycerol added to 15% was analyzed on a 5% TBE 18-well Criterion PAGE gel (Bio-Rad) for 45 
min at 200 V, then stained with 1x SYBR Gold (Invitrogen) for 10 min.  Bands were visualized 
and quantified on an AlphaImager HP (Alpha Innotech).   
 
Cellular TALEN Cleavage Assays 
 TALENs were cloned into mammalian expression vectors12 and the resulting TALEN 
vectors transfected into U2OS-EGFP cells as previously described.12  Genomic DNA was 
isolated after 2 days as previously described.12  For each assay, 50 ng of isolated genomic DNA 
was amplified by PCR [98 °C, 15 s 67.5 °C, 15 s; 72 °C, 22s] for 35 cycles with pairs of primers 
with or without 4% DMSO as specified in Table 1.24.  Two PCR reactions were performed for 
OffC-5 to improve the limit of detection.  The relative dsDNA content of the PCR reaction for 
each genomic site was quantified with Quant-iT™ PicoGreen ® dsDNA Kit (Invitrogen) and 
then pooled into an equimolar mixture, keeping no-TALEN and all TALEN-treated samples 
separate.  DNA corresponding to 150 to 350 bp was purified by PAGE as described above.   
 44 µL of eluted DNA was incubated with 5 µL of 1x T4 DNA Ligase Buffer and 1 µL of 
10 U/µL Polynucleotide kinase (NEB) for 30 min at 37 °C and Q-column purified.  43 µL of 
eluted DNA was incubated with 1 µL of 10 mM dATP (NEB), 5 µL of 10x NEBuffer 2, and 1 
µL of 5 U/µL DNA Klenow Fragment (3’→ 5’ exo–) (NEB) for 30 min at 37 °C and purified by 
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M-column.  10µL of eluted DNA was ligated as above with 10 pmol of heated and cooled G 
(genomic) adapters (Table 1.24) and purified by Q-column.  8 µL of eluted DNA was amplified 
by PCR for 6 to 8 cycles with G-B primers containing barcodes corresponding to each sample.  
Each sample DNA was quantified with Quant-iT™ PicoGreen ® dsDNA Kit (Invitrogen) and 
then pooled into an equimolar mixture.  The combined DNA was subjected to high-throughput 
sequencing using a MiSeq as described above. 
 
Data Analysis  
 .DNA sequences can be found at the NCBI’s Sequence Read Archive with Accession 
Cdoe SRP035232.  Specificity scores were calculated as previously described.21  Sample sizes 
for sequencing experiments were maximized (within practical experimental considerations) to 
ensure greatest power to detect effects. Statistical analysis on the distribution of number of 
mutations in various TALEN selections was performed as previously described21.  Statistical 
analysis of TALEN modified genomic sites was performed as previously described31 with 
multiple comparison correction using the Benjamini-Hochberg method.42, 43   
To determine extrapolated mean enrichment curves mutation enrichment value as 
function of mutation number were fit to an exponential function, a*eb, with R2 reported utilizing 
the non-linear least squares method.  These exponential decrease, b, were used to extrapolate all 
mean enrichment values beyond five mutations to determine the extrapolated mean enrichment. 
 
Computational Filtering of Pre-selection Sequences and Selected Sequences 
For Pre-selection Sequences 
 1) Search for 16 bp constant sequence (CCR5A = CGTCACGCTCACCACT, CCR5B = 
CCTCGGGACTCCACGCT, ATM = GGTACCCCACTCCGCGT ) immediately after first 4 
bases read (random bases), accepting only sequences with the 16bp constant sequence allowing 
for one mutation.  
2) Search for 9 bp final sequence at a position at least the minimum possible full site 
length away and up to the max full site length away from constant sequence to confirm the 
presence of a full site, accept only sequences with this 9 bp final sequence. (Final sequence: 
CCR5A = CGTCACGCT, CCR5B = CCTCGGGAC, ATM = GGTACGTGC ) 
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3) Search for instances of each half-site with the least amount of mutations from the 
target half-site in the full site, accept any sequences with proper left and right half-site order of 
left then right. 
4) Determine DNA spacer sequence between the two half sites, the single flanking 
nucleotide to left of the left half-site and single flanking nucleotide to right of the right half-site 
(sequence between half sites and constant sequences). 
5) Filter by sequencing read quality scores, accepting sequences with quality scores of 
‘A’ or better across three fourths of the half site positions. 
 
For Selected Sequences 
 1) Output to separate files all sequence reads and position quality scores of all sequences 
starting with correct 5 bp barcodes corresponding to different selection conditions. 
  2) Search for the initial 16 bp sequence immediately after the 5 bp barcode repeated at a 
psotion at least the minimum possible full site length away and up to the max full site length 
away from initial sequence to confirm the presence of a full site with repeated sequence, accept 
only sequences with a 16bp repeat allowing for 1 mutation. 
 3) Search for 16 bp constant sequence within the full site, accept only sequences with a 
constant sequence allowing for one mutation.  Parse sequence to start with constant sequence 
plus 5’ sequence to second instance of repeated sequence then initial sequence after barcode to 
constant sequence resulting in constant sequences sandwiching the equivalent of one full site: 
CONSTANT – LFLANK – LHS – SPACER – RHS – RFLANK – CONSTANT 
LFLANK = Left Flank Sequence (designed as a single random base) 
LHS = Left Half Site Sequence 
RHS = Right Half Site Sequence 
RFLANK = Right Flank Sequence (designed as a single random base) 
CONSTANT = Constant Sequence (CCR5A = CGTCACGCTCACCACT, CCR5B = 
CCTCGGGACTCCACGCT, ATM = GGTACCCCACTCCGCGT ) 
4) Search for instances of each half-site with the fewest number of mutations from the 
target half-site in the full site, accept any sequences with proper left and right half-site order of 
left then right. 
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5) With half site positions determine corresponding spacer (sequence between the two 
half sites), left flank and right flank sequences (sequence between half sites and constant 
sequences).   
6) Determine sequence end by taking sequence from the start of read after the 5 bp 
barcode sequence to the beginning of the constant sequence. 
SEQUENCESTART – RHS – RFLANK – CONSTANT 
7) Filter by sequencing read quality scores, accepting sequences with quality scores of A 
or better across three fourths of the half site positions.   
8) Selected sequences were filtered by sequence end, by accepting only sequences with 
sequence ends in the spacer that were 2.5-fold more abundant than the amount of sequence end 
background calculated as the mean of the number of sequences with ends zero to five base pairs 
into each half-site from the spacer side (sequence end background number was calculated for 
both half sites with the closest half site to the sequence end utilized as sequence end background 
for comparison). 
 
Computational Search for Genomic Off-Target Sites Related to the CCR5B Target Site 
 1) The Patmatch program18 was used to search the human genome (GRCh37/hg19 build) 
for pattern sequences as follows: CCR5B left half-site sequence (L16, L13 or L10) 
NNNNNNNNN… CCR5B right half-site sequence (R16, R13 or R10)[M,0,0] where number of 
Ns varied from 12 to 25 and M (indicating mutations allowed) varied from 0 to 14. 
 2) The number of output off-target sites were deconvoluted since the program outputs all 
sequences with X or fewer mutations, resulting in the number of off-target sites in the human 
genome that are a specific number of mutations away from the target site.  
 
Identification of Indels in Sequences of Genomic Sites 
1) For each sequence the primer sequence was used to identify the genomic site.   
2) Sequences containing the reference genomic sequence corresponding to 8 bp to the left 
of the target site and reference genomic sequence 6 to 10 bp (or 6 bp for genomic sites at the 
very end of sequencing reads and 10bp for genomic sites with low complexity or highly 
repetitive regions) to the right of the full target site were considered target site sequences.   
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3) Any target site sequences corresponding to the same size as the reference genomic site 
were considered unmodified and any sequences not the reference size were aligned with 
ClustalW19 to the reference genomic site.   
4) Aligned sequences with more than two insertions or two deletions in the DNA spacer 
sequence between the two half-site sequences were considered indels.  Since high-throughput 
sequencing can result in insertions or deletions of one or two base pairs (mis-phasing) at a low 
but relevant rate - we only considering indels of three bp that are more likely to arise from 
TALEN induced modifications. 
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preformed and analyze initial in vitro off-target cleavage assays.  Steven Lin and Enbo Ma 
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results.  Together Vikram Pattanayak and I preformed and analyzed the in vitro off-target 
cleavage assays and cellular off-target modification assays. 
 
Text in this chapter appeared in Nature Biotechnology, 2013, 31, 839-843. 
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2.1  Introduction to RNA-guided Cas9 nuclease specificity 
 Sequence-specific endonucleases including zinc-finger nucleases (ZFNs) and 
transcription activator-like effector nucleases (TALENs) have become important tools to modify 
genes in induced pluripotent stem cells (iPSCs),1-3 in multi-cellular organisms,4-8 and in ex vivo 
gene therapy clinical trials.9, 10  Although ZFNs and TALENs have proved effective for such 
genetic manipulation, a new ZFN or TALEN protein must be generated for each DNA target site.  
In contrast, the RNA-guided Cas9 endonuclease uses RNA:DNA hybridization to determine 
target DNA cleavage sites, enabling a single monomeric protein to cleave, in principle, any 
sequence specified by the guide RNA (Figure 2.1).11  
a Cas9 
gRNA 
PAM 
 
Figure 2.1.  Architecture of Cas9.  (a) Cas9 protein (yellow) binds to target DNA in 
complex with a guide RNA (gRNA, green).  The S. pyogenes Cas9 protein recognizes the 
PAM sequence NGG (blue), initiating unwinding of dsDNA and gRNA:DNA base pairing.  
Black triangles indicate the cleavage points three bases from the PAM on both top and 
bottom strands. 
 
Previous studies12-17 demonstrated that Cas9 mediates genome editing at sites 
complementary to a 20-nucleotide sequence in a bound guide RNA.  In addition, target sites 
must include a protospacer adjacent motif (PAM) at the 3’ end adjacent to the 20-nucleotide 
target site; for Streptococcus pyogenes Cas9, the PAM sequence is NGG.  Cas9-mediated DNA 
cleavage specificity both in vitro and in cells has been inferred previously based on assays 
against small collections of potential single-mutation off-target sites.  These studies suggested 
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that perfect complementarity between guide RNA and target DNA is required in the 7-12 base 
pairs adjacent to the PAM end of the target site (3’ end of the guide RNA) and mismatches are 
tolerated at the non-PAM end (5’ end of the guide RNA).11, 12, 17-19 
Although such a limited number of nucleotides specifying Cas9:guide RNA target 
recognition would predict multiple sites of DNA cleavage in genomes of moderate to large size 
(> ~107 bp), Cas9:guide RNA complexes have been successfully used to modify both cells12, 13, 15 
and organisms.14  A study using Cas9:guide RNA complexes to modify zebrafish embryos 
observed toxicity at a rate similar to that of ZFNs and TALENs.14  A recent, broad study of the 
specificity of DNA binding (transcriptional repression) in E. coli of a catalytically inactive Cas9 
mutant using high-throughput sequencing found no detectable off-target transcriptional 
repression in the relatively small E. coli transcriptome.20   While these studies have substantially 
advanced our basic understanding of Cas9, a systematic and comprehensive profile of 
Cas9:guide RNA-mediated DNA cleavage specificity generated from measurements of Cas9 
cleavage on a large number of related mutant target sites has not been described.  Such a 
specificity profile is needed to understand and improve the potential of Cas9:guide RNA 
complexes as research tools and future therapeutic agents. 
2.2  Profiling the specificity of RNA-guided Cas9 nucleases  
 We modified our previously published in vitro selection,21 adapted to process the blunt-
ended cleavage products produced by Cas9 instead of the overhang-containing products of ZFN 
cleavage, to determine the off-target DNA cleavage profiles of Cas9:single guide RNA 
(sgRNA)11 complexes.  Each selection experiment used DNA substrate libraries containing ~1012 
sequences, a size sufficiently large to include ten-fold coverage of all sequences with eight or 
fewer mutations relative to each 22-base pair target sequence (including the two-base pair PAM) 
(Figure 2.1).  We used partially randomized nucleotide mixtures at all 22 target-site base pairs to 
create a binomially distributed library of mutant target sites with an expected mean of 4.62 
mutations per target site.  In addition, target site library members were flanked by four fully 
randomized base pairs on each side to test for specificity patterns beyond those imposed by the 
canonical 20-base pair target site and PAM. 
Pre-selection libraries of 1012 individual potential off-target sites were generated for each 
of four different target sequences in the human clathrin light chain A (CLTA) gene (Figure 2.2).  
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Figure 2.2.  Target sites profiled in human CLTA gene.  (a) The 5’ end of the sgRNA has 20 
nucleotides that are complementary to the target site.  The target site contains an NGG motif 
(PAM) adjacent to the region of RNA:DNA complementarity.  (b) Four human clathrin gene 
(CLTA) target sites are shown.  (c, d) Four human clathrin gene (CLTA) target sites are shown 
with sgRNAs.  sgRNA v1.0 is shorter than sgRNA v2.1.  The PAM is shown in red for each site.  
The non-PAM end of the target site corresponds to the 5’ end of the sgRNA.  
 
 Synthetic 5’-phosphorylated 53-base oligonucleotides were self-ligated into circular single-
stranded DNA in vitro, then converted into concatemeric 53-base pair repeats through rolling-
circle amplification.  The resulting pre-selection libraries were incubated with their 
corresponding Cas9:sgRNA complexes.  Cleaved library members containing free 5’ phosphates 
were separated from intact library members through the 5’ phosphate-dependent ligation of non-
phosphorylated double-stranded sequencing adapters.  The ligation-tagged post-selection 
libraries were amplified by PCR.  The PCR step generated a mixture of post-selection DNA 
fragments containing 0.5, 1.5, or 2.5, etc. repeats of library members cleaved by Cas9, resulting 
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from amplification of an adapter-ligated cut half-site with or without one or more adjacent 
corresponding full sites (Figure 2.3). 
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Figure 2.3.  In vitro selection overview.  A modified version of our previously described in 
vitro selection was used to comprehensively profile Cas9 specificity.  A concatemeric pre-
selection DNA library in which each molecule contains one of 1012 distinct variants of a target 
DNA sequence (white rectangles) was generated from synthetic DNA oligonucleotides by 
ligation and rolling-circle amplification.  This library was incubated with a Cas9:sgRNA 
complex of interest.  Cleaved library members contain 5’ phosphate groups (green circles) and 
therefore are substrates for adapter ligation and PCR.  The resulting amplicons were subjected to 
high-throughput DNA sequencing and computational analysis.  
 
Post-selection library members with 1.5 target-sequence repeats were isolated by gel purification 
and analyzed by high-throughput sequencing.  In a final computational selection step to 
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minimize the impact of errors during DNA amplification or sequencing, only sequences with two 
identical copies of the repeated cut half-site were analyzed.  
Pre-selection libraries were incubated under enzyme-limiting conditions (200 nM target 
site library, 100 nM Cas9:sgRNA v2.1) or enzyme-excess conditions (200 nM target site library, 
1000 nM Cas9:sgRNA v2.1) for each of the four guide RNAs targets tested (CLTA1, CLTA2, 
CLTA3, and CLTA4) (Figure 2.2).  A second guide RNA construct, sgRNA v1.0, which is less 
active than sgRNA v2.1, was assayed under enzyme-excess conditions alone for each of the four 
guide RNA targets tested (200 nM target site library, 1000 nM Cas9:sgRNA v1.0).  The two 
guide RNA constructs differ in their length (Figure 2.2) and in their DNA cleavage activity level 
under the selection conditions, consistent with previous reports15 (Figure 2.4).  
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Figure 2.4.  Cas9:guide RNA cleavage of on-target DNA sequences in vitro.  Discrete DNA 
cleavage assays on an approximately 1-kb linear substrate were performed with 200 nM on-
target site and 100 nM Cas9:v1.0 sgRNA, 100 nM Cas9:v2.1 sgRNA, 1000 nM Cas9:v1.0 
sgRNA, and 1000 nM Cas9:v2.1 sgRNA for each of four CLTA target sites.  For CLTA1, 
CLTA2, and CLTA4, Cas9:v2.1 sgRNA shows higher activity than Cas9:v1.0 sgRNA.  For 
CLTA3, the activities of the Cas9:v1.0 sgRNA and Cas9:v2.1 sgRNA were comparable. 
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Both pre-selection and post-selection libraries were characterized by high-throughput DNA 
sequencing and computational analysis.  As expected, library members with fewer mutations 
were significantly enriched in post-selection libraries relative to pre-selection libraries. 
We calculated specificity scores to quantify the enrichment level of each base pair at each 
position in the post-selection library relative to the pre-selection library, normalized to the 
maximum possible enrichment of that base pair.  Positive specificity scores indicate base pairs 
that were enriched in the post-selection library and negative specificity scores indicate base pairs 
that were de-enriched in the post-selection library.  For example, a score of +0.5 indicates that a 
base pair is enriched to 50% of the maximum enrichment value, while a score of –0.5 indicates 
that a base pair is de-enriched to 50% of the maximum de-enrichment value.  
 
Figure 2.5.  In vitro selection results for Cas9:CLTA1 sgRNA.  Heat maps21 show the 
specificity profiles of Cas9:CLTA1 sgRNA v2.1 under enzyme-limiting conditions (a, b), 
Cas9:CLTA1 sgRNA v1.0 under enzyme-excess conditions (c, d), and Cas9:CLTA1 sgRNA 
v2.1 under enzyme-excess conditions (e, f).  Heat maps show all post-selection sequences (a, c, 
e) or only those sequences containing a single mutation in the 20-base pair sgRNA-specified 
target site and two-base pair PAM (b, d, f).  Specificity scores of 1.0 (dark blue) and -1.0 (dark 
red) corresponds to 100% enrichment for and against, respectively, a particular base pair at a 
particular position.  Black boxes denote the intended target nucleotides.   
 111 
+1.0 to +0.9 
+0.9 to +0.7 
-0.7 to +0.5 
+0.5 to +0.3 
+0.3 to +0.1 
+0.1 to -0.1 
-0.1 to -0.3 
-0.3 to -0.5 
-0.5 to -0.7 
-0.7 to -0.9 
-0.9 to -1.0 
specificity 
score 
 
Figure 2.6.  In vitro selection results for Cas9:CLTA4 sgRNA.  Heat maps2 show the 
specificity profiles of Cas9:CLTA4 sgRNA v2.1 under enzyme-limiting conditions (a, b), 
Cas9:CLTA4 sgRNA v1.0 under enzyme-excess conditions (c, d), and Cas9:CLTA4 sgRNA 
v2.1 under enzyme- saturating conditions (e, f).  Heat maps show all post-selection sequences (a, 
c, e) or only those sequences containing a single mutation in the 20-base pair sgRNA-specified 
target site and two-base pair PAM (b, d, f).  Specificity scores of 1.0 (dark blue) and -1.0 (dark 
red) corresponds to 100% enrichment for and against, respectively, a particular base pair at a 
particular position.  Black boxes denote the intended target nucleotides. 
 
In addition to the two base pairs specified by the PAM, all 20 base pairs targeted by the 
guide RNA were enriched in the sequences from the CLTA1 selections (Figure 2.5).  For the 
CLTA4 selections (Figure 2.6), guide RNA-specified base pairs were enriched at all positions 
except for the two most distal base pairs from the PAM (5’ end of the guide RNA), respectively.  
At these non-specified positions farthest from the PAM, at least two of the three alternate base 
pairs were nearly as enriched as the specified base pair.  Our finding that the entire 20 base-pair 
target site and two base pair PAM can contribute to Cas9:sgRNA DNA cleavage specificity 
contrasts with the results from previous single-substrate assays suggesting that only 7-12 base 
pairs and two base pair PAM are specified.11, 12, 15 
All single-mutant pre-selection (n ≥ 14,569) and post-selection library members (n ≥ 
103,660) were computationally analyzed to provide a selection enrichment value for every 
possible single-mutant sequence.  The results of this analysis (Figure 2.5 and Figure 2.6) show 
that when only single-mutant sequences are considered, the six to eight base pairs closest to the 
PAM are generally highly specified and the non-PAM end is poorly specified under enzyme-
limiting conditions, consistent with previous findings.11, 12, 17-19   Under enzyme-excess 
conditions, however, single mutations even in the six to eight base pairs most proximal to the 
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PAM are tolerated, suggesting that the high specificity at the PAM end of the DNA target site 
can be compromised when enzyme concentrations are high relative to substrate (Figure 2.5 and 
Figure 2.6).  The observation of high specificity against single mutations close to the PAM only 
applies to sequences with a single mutation and the selection results do not support a model in 
which any combination of mutations is tolerated in the region of the target site farthest from the 
PAM.  
Importantly, the selection results also reveal that the choice of guide RNA hairpin affects 
cleavage of off-target sites.  The shorter, less-active sgRNA v1.0 constructs are less tolerant of 
mutations than the longer, more-active sgRNA v2.1 constructs when assayed under identical, 
enzyme-excess conditions that reflect an excess of enzyme relative to substrate in a cellular 
context (Figure 2.5 and Figure 2.6).  Thus, these results indicate that different guide RNA 
architectures result in different off-target DNA cleavage activities, and that guide RNA-
dependent changes in specificity do not affect all positions in the target site equally.  Given the 
inverse relationship between Cas9:sgRNA concentration and specificity described above, we 
speculate that the differences in off-target activities between guide RNA architectures arises 
from differences in their overall level of DNA-cleavage activities.  
To confirm that the in vitro selection results accurately reflect the cleavage behavior of 
Cas9 in vitro, we performed discrete cleavage assays of six CLTA4 off-target substrates 
containing one to three mutations in the target site.  We calculated enrichment values for all 
sequences in the post-selection libraries for the Cas9:CLTA4 v2.1 sgRNA under enzyme-excess 
conditions by dividing the abundance of each sequence in the post-selection library by the 
calculated abundance in the pre-selection library.  Under enzyme-excess conditions, the single 
one, two, and three mutation sequences with the highest enrichment values (27.5, 43.9, and 95.9) 
were cleaved to ≥ 71% completion (Figure 2.7).   
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CLTA4-0 GCAGATGTAGTGTTTCCACAGGG! 7.9 85% 
CLTA4-1 GaAGATGTAGTGTTTCCACAGGG! 27.5 84% 
CLTA4-2a GaAGATGTAGTGTTTCCACtGGG! 43.9 79% 
CLTA4-2b GCAGATGgAGgGTTTCCACAGGG! 1.0 35% 
CLTA4-2c GCAGATGTAGTGTTaCCAgAGGG! 0.064  none detected 
CLTA4-3 GggGATGTAGTGTTTCCACtGGG! 95.9 72%  
 
Figure 2.7.  Cas9:guide RNA cleavage of off-target DNA sequences in vitro.  Discrete DNA 
cleavage assays on a 96-bp linear substrate were performed with 200 nM DNA and 1000 nM 
Cas9:CLTA4 v2.1 sgRNA for the on-target CLTA4 site (CLTA4-0) and five CLTA4 off-target 
sites identified by in vitro selection.  Enrichment values shown are from the in vitro selection 
with 1000 nM Cas9:CLTA4 v2.1 sgRNA.  CLTA4-1 and CLTA4-3 were the most highly 
enriched sequences under these conditions.  CLTA4-2a, CLTA4-2b, and CLTA4-2c are two-
mutation sequences that represent a range of enrichment values from high enrichment to no 
enrichment to high de-enrichment.  Red lowercase letters indicate mutations relative to the on-
target CLTA4 site.  The enrichment values are qualitatively consistent with the observed amount 
of cleavage in vitro. 
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A two-mutation sequence with an enrichment value of 1.0 was cleaved to 35%, and a two-
mutation sequence with an enrichment value near zero (0.064) was not cleaved.  The three-
mutation sequence, which was cleaved to 77% by CLTA4 v2.1 sgRNA, was cleaved to a lower 
efficiency of 53% by CLTA4 v1.0 sgRNA (Figure 2.8).   
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Figure 2.8.  Effect of guide RNA architecture and Cas9:sgRNA concentration on in vitro 
cleavage of an off-target site.  Discrete DNA cleavage assays on a 96-bp linear substrate were 
performed with 200 nM DNA and 100 nM Cas9:v1.0 sgRNA, 100 nM Cas9:v2.1 sgRNA, 1000 
nM Cas9:v1.0 sgRNA, or 1000 nM Cas9:v2.1 sgRNA for the CLTA4-3 off-target site (5’ 
GggGATGTAGTGTTTCCACtGGG - mutations are shown in lowercase letters).  DNA cleavage 
is observed under all four conditions tested, and cleavage rates are higher under enzyme-excess 
conditions, or with v2.1 sgRNA compared with v1.0 sgRNA.  
 
These results indicate that the selection enrichment values of individual sequences are predictive 
of in vitro cleavage efficiencies. 
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 To determine if results of the in vitro selection and in vitro cleavage assays pertain to 
Cas9:guide RNA activity in human cells, we identified 51 off-target sites (19 for CLTA1 and 32 
for CLTA4) containing up to eight mutations that were both enriched in the in vitro selection and 
present in the human genome.  We expressed Cas9:CLTA1 sgRNA v1.0, Cas9:CLTA1 sgRNA 
v2.1, Cas9:CLTA4 sgRNA v1.0, Cas9:CLTA4 sgRNA v2.1, or Cas9 without sgRNA in 
HEK293T cells by transient transfection and used genomic PCR and high-throughput DNA 
sequencing to look for evidence of Cas9:sgRNA modification at 46 of the 51 off-target sites as 
well as at the on-target loci; no specific amplified DNA was obtained for five of the 51 predicted 
off-target sites (three for CLTA1 and two for CLTA4). 
 Deep sequencing of genomic DNA isolated from HEK293T cells treated with 
Cas9:CLTA1 sgRNA or Cas9:CLTA4 sgRNA identified sequences evident of non-homologous 
end-joining (NHEJ) at the on-target sites and at five of the 49 tested off-target sites (CLTA1-1-1, 
CLTA1-2-2, CLTA4-3-1, CLTA4-3-3, and CLTA4-4-8).  The CLTA4 target site was modified 
by Cas9:CLTA4 v2.1 sgRNA at a frequency of 76%, while off-target sites, CLTA4-3-1 CLTA4-
3-3, and CLTA4-4-8, were modified at frequencies of 24%, 0.47% and 0.73%, respectively. The 
CLTA1 target site was modified by Cas9:CLTA1 v2.1 sgRNA at a frequency of 0.34%, while 
off-target sites, CLTA1-1-1 and CLTA1-2-2, were modified at frequencies of 0.09% and 0.16%, 
respectively (Table 2.1). 
a 
    
in vitro 
enrichment 
modification frequency 
in HEK293T cells P-value 
 
number of 
mutations sequence gene v1.0 v2.1 
no 
sgRNA v1.0 v2.1 v1.0 v2.1 
CLTA1-0-1 0 
AGTCCTCATCTCCCTCAAGCAGG 
CLTA 41.4 23.3 0.003% 0.042% 0.337% 
1.1E-
05 6.9E-55 
CLTA1-1-1 1 
AGTCCTCAaCTCCCTCAAGCAGG 
TUSC3 25.9 14 0.003% 0.031% 0.091% 
2.6E-
03 2.0E-10 
CLTA1-2-1 2 AGcCCTCATtTCCCTCAAGCAGG CACNA2D3 15.4 26.2 0% 0% 0%   
CLTA1-2-2 2 AcTCCTCATCcCCCTCAAGCCGG ACAN 29.2 18.8 0.014% 0.005% 0.146%  4.6E-08 
CLTA1-2-3 2 AGTCaTCATCTCCCTCAAGCAGa  0.06 1.27 n.t. n.t. n.t.   
CLTA1-3-1 3 cGTCCTCcTCTCCCcCAAGCAGG  0 2.07 0.004% 0% 0%   
CLTA1-3-2 3 tGTCCTCtTCTCCCTCAAGCAGa BC029598 0 1.47 0% 0% 0%   
CLTA1-4-1 4 AagCtTCATCTCtCTCAAGCTGG    0% 0.006% 0%   
CLTA1-4-2 4 AGTaCTCtTtTCCCTCAgGCTGG ENTPD1   0.007% 0.004% 0.015%   
CLTA1-4-3 4 AGTCtTaAatTCCCTCAAGCAGG    0.003% 0% 0.001%   
CLTA1-4-4 4 AGTgCTCATCTaCCagAAGCTGG    0.008% 0% 0%   
CLTA1-4-5 4 ccTCCTCATCTCCCTgcAGCAGG    0.013% 0.004% 0%   
CLTA1-4-6 4 ctaCaTCATCTCCCTCAAGCTGG    0% 0.008% 0.016%   
CLTA1-4-7 4 gGTCCTCATCTCCCTaAAaCAGa 
POLQ 
(coding)   0.011% 0.037% 0%   
CLTA1-4-8 4 tGTCCTCATCggCCTCAgGCAGG    0% 0% 0.016%   
CLTA1-5-1 5 AGaCacCATCTCCCTtgAGCTGG PSAT1   0% 0.003% 0.006%   
CLTA1-5-2 5 AGgCaTCATCTaCaTCAAGtTGG    0% 0% 0%   
CLTA1-5-3 5 AGTaaTCActTCCaTCAAGCCGG 
ZDHHC3, 
EXOSC7   n.t. n.t. n.t.   
CLTA1-5-4 5 tccCCTCAcCTCCCTaAAGCAGG    0.008% 0.029% 0.004%   
CLTA1-5-5 5 tGTCtTtATtTCCCTCtAGCTGG    0% 0% 0.009%   
CLTA1-6-1 6 AGTCCTCATCTCCCTCAAGCAGG    0% 0% 0%   
Table 2.1 (Continued).  Cellular modification induced by Cas9:CLTA1 sgRNA and 
Cas9:CLTA4 sgRNA. 
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b 
    
in vitro 
enrichment 
modification frequency in 
HEK293T cells P-value 
 
# of 
mutation
s sequence gene v1.0 v2.1 
no 
sgRNA v1.0 v2.1 v1.0 v2.1 
CLTA4-0-1 0 GCAGATGTAGTGTTTCCACAGGG CLTA 20 7.95 0.021% 11% 76% <1E-55 <1E-55 
CLTA4-3-1 3 aCAtATGTAGTaTTTCCACAGGG  16.5 12.5 0.006% 0.055% 24% 6.0E-04 <1E-55 
CLTA4-3-2 3 GCAtATGTAGTGTTTCCAaATGt  2.99 6.97 0.017% 0% 0.014%   
CLTA4-3-3 3 cCAGATGTAGTaTTcCCACAGGG CELF1 1.00 4.95 0% 0% 0.469%  2.5E-21 
CLTA4-3-4 3 GCAGtTtTAGTGTTTtCACAGGG BC073807 0.79 3.12 0% 0% 0%   
CLTA4-3-5 3 GCAGAgtTAGTGTTTCCACACaG MPPED2 0 1.22 0.005% 0.015% 0.018%   
CLTA4-3-6 3 GCAGATGgAGgGTTTtCACAGGG DCHS2 1.57 1.17 0.015% 0.023% 0.021%   
CLTA4-3-7 3 GgAaATtTAGTGTTTCCACAGGG  0.43 0.42 0.005% 0.012% 0.003%   
CLTA4-4-1 4 aaAGAaGTAGTaTTTCCACATGG    n.t. n.t. n.t.   
CLTA4-4-2 4 aaAGATGTAGTcaTTCCACAAGG    0.004% 0% 0.005%   
CLTA4-4-3 4 aaAtATGTAGTcTTTCCACAGGG    0.004% 0.009% 0%   
CLTA4-4-4 4 atAGATGTAGTGTTTCCAaAGGa NR1H4   0.032% 0.006% 0.052%   
CLTA4-4-5 4 cCAGAgGTAGTGcTcCCACAGGG    0.005% 0.006% 0.007%   
CLTA4-4-6 4 cCAGATGTgagGTTTCCACAAGG XKR6   0.018% 0% 0.007%   
CLTA4-4-7 4 ctAcATGTAGTGTTTCCAtATGG HKR1   0.006% 0% 0.008%   
CLTA4-4-8 4 ctAGATGaAGTGcTTCCACATGG CDK8   0.009% 0.013% 0.730%  9.70E-21 
CLTA4-4-9 4 GaAaATGgAGTGTTTaCACATGG    0% 0% 0.004%   
CLTA4-4-10 4 GCAaATGaAGTGTcaCCACAAGG    0.004% 0% 0%   
CLTA4-4-11 4 GCAaATGTAtTaTTTCCACtAGG NOV   0% 0.00% 0%   
CLTA4-4-12 4 GCAGATGTAGctTTTgtACATGG    0% 0.00% 0%   
CLTA4-4-13 4 GCAGcTtaAGTGTTTtCACATGG GRHL2   0.020% 0.02% 0.030%   
CLTA4-4-14 4 ttAcATGTAGTGTTTaCACACGG LINC00535   n.t. n.t. n.t.   
CLTA4-5-1 5 GaAGAgGaAGTGTTTgCcCAGGG RNH1   0.004% 0.01% 0.006%   
CLTA4-5-2 5 GaAGATGTgGaGTTgaCACATGG FZD3   0.004% 0.00% 0%   
CLTA4-5-3 5 GCAGAaGTAcTGTTgttACAAGG    0.002% 0.00% 0.003%   
CLTA4-5-4 5 GCAGATGTgGaaTTaCaACAGGG SLC9A2   0% 0.00% 0%   
CLTA4-5-5 5 GCAGtcaTAGTGTaTaCACATGG    0.004% 0.00% 0.005%   
CLTA4-5-6 5 taAGATGTAGTaTTTCCAaAAGt    0.007% 0.01% 0%   
CLTA4-6-1 6 GCAGcTGgcaTtTcTCCACACGG    n.t. n.t. n.t.   
CLTA4-6-2 6 GgAGATcTgaTGgTTCtACAAGG    0.007% 0.00% 0.009%   
CLTA4-6-3 6 taAaATGcAGTGTaTCCAtATGG SMA4   0.015% 0.00% 0%   
CLTA4-7-1 7 GCcagaaTAGTtTTTCaACAAGG SEPHS2   0% 0.00% 0.007%   
CLTA4-7-2 8 ttgtATtTAGaGaTTgCACAAGG RORB   0% 0.00% 0%   
Table 2.1 (Continued).  Cellular modification induced by Cas9:CLTA1 sgRNA and 
Cas9:CLTA4 sgRNA.  (a) 20 human genomic DNA sequences were identified that were 
enriched in the Cas9:CLTA1 v2.1 sgRNA in vitro selections under enzyme-limiting or enzyme-
excess conditions.  Sites shown in red contain insertions or deletions (indels) that are consistent 
with significant Cas9:sgRNA-mediated modification in HEK293T cells.  In vitro enrichment 
values for selections with Cas9:CLTA1 v1.0 sgRNA or Cas9:CLTA1 v2.1 sgRNA are shown for 
sequences with three or fewer mutations.  Enrichment values were not calculated for sequences 
with four or more mutations due to low numbers of in vitro selection sequence counts.  
Modification frequencies (number of sequences with indels divided by total number of 
sequences) in HEK293T cells treated with Cas9 without sgRNA (“no sgRNA”), Cas9 with 
CLTA1 v1.0 sgRNA, or Cas9 with CLTA1 v2.1 sgRNA.  P-values are listed for those sites that 
show significant modification in v1.0 sgRNA- or v2.1 sgRNA-treated cells compared to cells 
treated with Cas9 without sgRNA.  P-values were calculated using a one-sided Fisher exact text.  
“Not tested (n.t.)” indicates that PCR of the genomic sequence failed to provide specific 
amplification products. (b) Same as (a) for CLTA4 sgRNA with 33 human genomic DNA 
sequences were identified that were enriched in the Cas9:CLTA4 v2.1 sgRNA in vitro selections 
under enzyme-limiting or enzyme-excess conditions 
 
Under enzyme-excess conditions with the v2.1 sgRNA, the two verified CLTA1 off-
target sites, CLTA1-1-1 and CLTA1-2-2, were two of the three most highly enriched sequences 
identified in the in vitro selection.  CLTA4-3-1 and CLTA4-3-3 were the highest and third-
highest enriched sequences of the seven CLTA4 three-mutation sequences enriched in the in 
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vitro selection that are also present in the genome. The in vitro selection enrichment values of the 
four-mutation sequences were not calculated, since 12 out of the 14 CLTA4 sequences in the 
genome containing four mutations, including CLTA4-4-8, were observed at a level of only one 
sequence count in the post-selection library.  Taken together, these results confirm that several of 
the off-target substrates identified in the in vitro selection that are present in the human genome 
are indeed cleaved by Cas9:sgRNA complexes in human cells, and also suggest that the most 
highly enriched genomic off-target sequences in the selection are modified in cells to the greatest 
extent.   
 The off-target sites we identified in cells were among the most-highly enriched in our in 
vitro selection and contain up to four mutations relative to the intended target sites.  While it is 
possible that heterochromatin or covalent DNA modifications could diminish the ability of a 
Cas9:guide RNA complex to access genomic off-target sites in cells, the identification of five out 
of 49 tested cellular off-target sites in this study, rather than zero or many, strongly suggests that 
Cas9-mediated DNA cleavage is not limited to specific targeting of only a 7-12-base pair target 
sequence, as suggested in recent studies.11, 12, 19  
The cellular genome modification data are also consistent with the tradeoff between 
activity and specificity of sgRNA v1.0 compared to sgRNA v2.1 sgRNAs observed in the in 
vitro selection data and discrete assays.  The on-target CLTA4-0-1 site had a modification 
frequency that was seven-fold lower (11% vs. 76%) in cells expressing Cas9:sgRNA v1.0 
compared to cells expressing Cas9:sgRNA v2.1.  Although the CLTA4-3-3, and CLTA4-4-8 
sites were modified by the Cas9-sgRNA v2.1 complexes, no evidence of modification at any of 
these three sites was detected in Cas9:sgRNA v1.0-treated cells.  The CLTA4-3-1 site, which 
was modified at 32% of the frequency of on-target CLTA4 site modification in Cas9:v2.1 
sgRNA-treated cells, was modified at only 0.5% of the on-target modification frequency in v1.0 
sgRNA-treated cells, representing a 62-fold change in selectivity.  Taken together, these results 
demonstrate that guide RNA architecture can have a significant influence on both Cas9 activity 
and specificity in cells.  Our specificity profiling findings present an important caveat to recent 
and ongoing efforts to improve the overall DNA modification activity of Cas9:guide RNA 
complexes through guide RNA engineering.11, 15 
 Overall, the off-target DNA cleavage profiling of Cas9 and subsequent analyses show 
that (i) Cas9:guide RNA recognition extends to 18-20 specified target site base pairs and a two-
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base pair PAM for the four target sites tested; (ii) increasing Cas9:guide RNA concentrations can 
decrease DNA-cleaving specificity in vitro; (iii) using more active sgRNA architectures can 
increase DNA-cleavage activity both in vitro and in cells but also increase cleavage of off-target 
sites both in vitro and in cells; and (iv) as predicted by our in vitro results, Cas9:guide RNA can 
modify off-target sites in cells with up to four mutations relative to the on-target site.  Our 
findings provide key insights to our understanding of RNA-programmed Cas9 specificity, and 
reveal a previously unknown role for sgRNA architecture in DNA-cleavage specificity.  The 
principles revealed in this study may also apply to Cas9-based effectors engineered to mediate 
functions beyond DNA cleavage. 
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2.3  Methods used to study RNA-guided Cas9 nuclease specificity 
Oligonucleotides 
All oligonucleotides used in this study were purchased from Integrated DNA 
Technologies.  Oligonucleotide sequences are listed in Table 2.2. 
oligonucleotide name oligonucleotide sequence (5’->3’) 
CLTA1 v2.1 template fwd TAA TAC GAC TCA CTA TAG GAG TCC TCA TCT CCC TCA AGC GTT TTA GAG CTA TGC TG 
CLTA2 v2.1 template fwd TAA TAC GAC TCA CTA TAG GCT CCC TCA AGC AGG CCC CGC GTT TTA GAG CTA TGC TG 
CLTA3 v2.1 template fwd TAA TAC GAC TCA CTA TAG GTG TGA AGA GCT TCA CTG AGT GTT TTA GAG CTA TGC TG 
CLTA4 v2.1 template fwd TAA TAC GAC TCA CTA TAG GGC AGA TGT AGT GTT TCC ACA GTT TTA GAG CTA TGC TG 
v2.1 template rev GAT AAC GGA CTA GCC TTA TTT TAA CTT GCT ATG CTT TTC AGC ATA GCT CTA AAA C 
CLTA1 v1.0 template CGG ACT AGC CTT ATT TTA ACT TGC TAT TTC TAG CTC TAA AAC GCT TGA GGG AGA TGA GGA 
CTC CTA TAG TGA GTC GTA TTA 
CLTA2 v1.0 template CGG ACT AGC CTT ATT TTA ACT TGC TAT TTC TAG CTC TAA AAC GCG GGG CCT GCT TGA GGG 
AGC CTA TAG TGA GTC GTA TTA 
CLTA3 v1.0 template CGG ACT AGC CTT ATT TTA ACT TGC TAT TTC TAG CTC TAA AAC ACT CAG TGA AGC TCT TCA 
CAC CTA TAG TGA GTC GTA TTA 
CLTA4 v1.0 template CGG ACT AGC CTT ATT TTA ACT TGC TAT TTC TAG CTC TAA AAC TGT GGA AAC ACT ACA TCT 
GCC CTA TAG TGA GTC GTA TTA 
T7 promoter oligo TAA TAC GAC TCA CTA TAG G 
CLTA1 lib /5Phos/AAC ACA NNN NC*C* NG*C* T*T*G* A*G*G* G*A*G* A*T*G* A*G*G* A*C*T* NNN NAC CTG 
CCG AGA ACA CA 
CLTA2 lib /5Phos/TCT TCT NNN NC*C* NG*C* G*G*G* G*C*C* T*G*C* T*T*G* A*G*G* G*A*G* NNN NAC CTG 
CCG AGT CTT CT 
CLTA3 lib /5Phos/AGA GAA NNN NC*C* NA*C* T*C*A* G*T*G* A*A*G* C*T*C* T*T*C* A*C*A* NNN NAC CTG CCG 
AGA GAG AA 
CLTA4 lib /5Phos/TTG TGT NNN NC*C* NT*G* T*G*G* A*A*A* C*A*C* T*A*C* A*T*C* T*G*C* NNN NAC CTG CCG 
AGT TGT GT 
CLTA1 site fwd CTA GCA GTC CTC ATC TCC CTC AAG CAG GC 
CLTA1 site rev AGC TGC CTG CTT GAG GGA GAT GAG GAC TG 
CLTA2 site fwd CTA GTC TCC CTC AAG CAG GCC CCG CTG GT 
CLTA2 site rev AGC TAC CAG CGG GGC CTG CTT GAG GGA GA 
CLTA3 site fwd CTA GCT GTG AAG AGC TTC ACT GAG TAG GA 
CLTA3 site rev AGC TTC CTA CTC AGT GAA GCT CTT CAC AG 
CLTA4 site fwd CTA GTG CAG ATG TAG TGT TTC CAC AGG GT 
CLTA4 site rev AGC TAC CCT GTG GAA ACA CTA CAT CTG CA 
test fwd  GCG ACA CGG AAA TGT TGA ATA CTC AT 
test rev GGA GTC AGG CAA CTA TGG ATG AAC G 
off-target CLTA4-0 fwd ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GCA GAT GTA GTG TTT CCA CAG GGT 
off-target CLTA4-1 fwd ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GAA GAT GTA GTG TTT CCA CAG GGT 
off-target CLTA4-2a fwd ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GAA GAT GTA GTG TTT CCA CTG GGT 
off-target CLTA4-2b fwd ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GCA GAT GGA GGG TTT CCA CAG GGT 
off-target CLTA4-2c fwd ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GCA GAT GTA GTG TTA CCA GAG GGT 
off-target CLTA4-3 fwd ACT GTG AAG AGC TTC ACT GAG TAG GAT TAA GAT ATT GGG GAT GTA GTG TTT CCA CTG GGT 
off-target CLTA4-0 rev TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CTG TGG AAA CAC TAC ATC TGC 
off-target CLTA4-1 rev TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CTG TGG AAA CAC TAC ATC TTC 
off-target CLTA4-2a rev TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CAG TGG AAA CAC TAC ATC TTC 
off-target CLTA4-2b rev TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CTG TGG AAA CCC TCC ATC TGC 
off-target CLTA4-2c rev TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CTC TGG TAA CAC TAC ATC TGC 
off-target CLTA4-3 rev TCC CTC AAG CAG GCC CCG CTG GTG CAC TGA AGA GCC ACC CAG TGG AAA CAC TAC ATC CCC 
adapter1(AACA) AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TAA 
CA 
adapter2(AACA) TGT TAG ATC GGA AGA GCG TCG TGT AGG GAA AGA GTG TAG ATC TCG GTG G 
adapter1(TTCA) AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TTT 
CA 
adapter2(TTCA) TGA AAG ATC GGA AGA GCG TCG TGT AGG GAA AGA GTG TAG ATC TCG GTG G 
adapter1 AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC T 
adapter2 AGA TCG GAA GAG CGT CGT GTA GGG AAA GAG TGT AGA TCT CGG TGG 
Table 2.2 (Continued).  Oligonucleotides used in this study.   
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lib adapter1 GAC GGC ATA CGA GAT 
CLTA1 lib adapter2 AAC AAT CTC GTA TGC CGT CTT CTG CTT G 
CLTA2 lib adapter2 TCT TAT CTC GTA TGC CGT CTT CTG CTT G 
CLTA3 lib adapter2 AGA GAT CTC GTA TGC CGT CTT CTG CTT G 
CLTA4 lib adapter2 TTG TAT CTC GTA TGC CGT CTT CTG CTT G 
CLTA1 sel PCR CAA GCA GAA GAC GGC ATA CGA GAT TGT GTT CTC GGC AGG T 
CLTA2 sel PCR CAA GCA GAA GAC GGC ATA CGA GAT AGA AGA CTC GGC AGG T 
CLTA3 sel PCR CAA GCA GAA GAC GGC ATA CGA GAT TTC TCT CTC GGC AGG T 
CLTA4 sel PCR CAA GCA GAA GAC GGC ATA CGA GAT ACA CAA CTC GGC AGG T 
PE2 short AAT GAT ACG GCG ACC ACC GA 
CLTA1 lib seq PCR 
AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TNN 
NNA CCT ACC TGC CGA GAA CAC A 
CLTA2 lib seq PCR 
AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TNN 
NNA CCT ACC TGC CGA GTC TTC T 
CLTA3 lib seq PCR 
AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TNN 
NNA CCT ACC TGC CGA GAG AGA A 
CLTA4 lib seq PCR 
AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TNN 
NNA CCT ACC TGC CGA GTT GTG T 
lib fwd PCR CAA GCA GAA GAC GGC ATA CGA GAT 
CLTA1-0-1 (Chr. 9) fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CAA GTC TAG CAA GCA GGC CA 
CLTA1-0-1 (Chr. 12) fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CAG GCA CTG AGT GGG AAA GT 
CLTA1-1-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TAA CCC CAA GTC AGC AAG CA 
CLTA1-2-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTG CTG GTC AAT ACC CTG GC 
CLTA1-2-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGA GTA CCC CTG AAA TGG GC 
CLTA1-3-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCG CTA CCA ATC AGG GCT TT 
CLTA1-3-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCA TTG CCA CTT GTT TGC AT 
CLTA1-4-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCT ACC CCC ACA ACT TTG CT 
CLTA1-4-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GTG TAC ATC CAG TGC ACC CA 
CLTA1-4-3 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCG GAA AGG ACT TTG AAT ACT TGT 
CLTA1-4-4 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CGG CCC AAG ACC TCA TTC AC 
CLTA1-4-5 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GTC CTC TCT GGG GCA GAA GT 
CLTA1-4-6 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AGC TGA GTC ATG AGT TGT CTC C 
CLTA1-4-7 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CTG CCA GCT TCT CAC ACC AT 
CLTA1-4-8 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CTG AAG GAC AAA GGC GGG AA 
CLTA1-5-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AAG GTG CTA AAG GCT CCA CG 
CLTA1-5-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GAC CAT TGG TGA GCC CAG AG 
CLTA1-5-3 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTT TTC GGG CAA CTG CTC AC 
CLTA1-5-4 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GCA AGC CTT CTC TCC TCA GA 
CLTA1-5-5 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT ACA CAA ACT TCC CTG AGA CCC 
CLTA1-6-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGA GTT AGC CCT GCT GTT CA 
CLTA4-0-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGA AGA GCT TCA CTG AGT AGG A 
CLTA4-3-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCC CCT TAC AGC CAA TTT CGT 
CLTA4-3-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGC TGA TGA AAT GCA ATT AAG AGG T 
CLTA4-3-3 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GGT CCC TGC AAG CCA GTA TG 
CLTA4-3-4 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT ATC AAA GCC TTG TAT CAC AGT T 
CLTA4-3-5 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCC AAA TAA TGC AGG AGC CAA 
CLTA4-3-6 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CTG CCT TTA GTG GGA CAG ACT T 
CLTA4-3-7 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AGT AAC CCT AGT AGC CCT CCA 
CLTA4-4-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CAT TGC AGT GAG CCG AGA TTG 
CLTA4-4-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGG CAA AGT TCA CTT CCA TGT 
CLTA4-4-3 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGC TCT GTG ATG TCT GCC AC 
CLTA4-4-4 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGT GTA GGA TTG TGA ACC AGC A 
CLTA4-4-5 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCC CAG CCC AGC ATT TTT CT 
CLTA4-4-6 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AGG TTG CTT TGT GCA CAG TC 
CLTA4-4-7 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCT GGC TTG GGA TGT TGG AA 
CLTA4-4-8 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTG CCC AAG GTC ATA CTG CT 
CLTA4-4-9 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT ACC CAC TAG GTA GCC ATA ATC CA 
Table 2.2 (Continued).  Oligonucleotides used in this study.   
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CLTA4-4-10 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CGG TCA TGT CGC TTG GAA GA 
CLTA4-4-11 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTG GCC CAT ATT GCT TTA TGC TG 
CLTA4-4-12 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT ATT AGG GGT TGG CTG CAT GA 
CLTA4-4-13 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCA AGA CGT GTT GCA TGC TG 
CLTA4-4-14 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TGG GAG GTG ATA AAT TCC CTA AAT 
CLTA4-5-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CCA GAG ACA AAG GTG GGG AG 
CLTA4-5-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCA TAC AGA AGA GCA AAG TAC CA 
CLTA4-5-3 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CAA AGA GGG GTA TCG GGA GC 
CLTA4-5-4 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT AAA TGG AAG AAC CAA GTA GAT GAA 
CLTA4-5-5 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TTT TGG TTG ACA GAT GGC CAC A 
CLTA4-5-6 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT TCT TAC TTG TGT GAT TTT AGA ACA A 
CLTA4-6-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GAT GGT TCA TGC AGA GGG CT 
CLTA4-6-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GCT GGT CTT TCC TGA GCT GT 
CLTA4-6-3 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT CTC CAT CAG ATA CCT GTA CCC A 
CLTA4-7-1 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GGG AAA ACA CTC TCT CTC TGC T 
CLTA4-7-2 fwd ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT GGA GGC CAC GAC ACA CAA TA 
CLTA1-0-1 (Chr. 9) rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAC AGG GTG GCT CTT CAG TG 
CLTA1-0-1 (Chr. 12) rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGC ACA TGT TTC CAC AGG GT 
CLTA1-1-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGT GTT TCC AGG AGC GGT TT 
CLTA1-2-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AAG CCT CAG GCA CAA CTC TG 
CLTA1-2-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TAG GGG AGG GGC AAA GAC A 
CLTA1-3-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGG AAC AGT GGT ATG CTG GT 
CLTA1-3-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGT GTG GAC ACT GAC AAG GAA 
CLTA1-4-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TCA CTG CCT GGG TGC TTT AG 
CLTA1-4-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TAC CCC AGC CTC CAG CTT TA 
CLTA1-4-3 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGA CTA CTG GGG AGC GAT GA 
CLTA1-4-4 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGG CTG TTA TGC AGG AAA GGA A 
CLTA1-4-5 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GCG GTT GAG GTG GAT GGA AG 
CLTA1-4-6 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGC AGC ATC CCT TAC ATC CT 
CLTA1-4-7 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGA AAA AGC TTC CCC AGA AAG GA 
CLTA1-4-8 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CTG CAC CAA CCT CTA CGT CC 
CLTA1-5-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CTG GAG AGG GCA TAG TTG GC 
CLTA1-5-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGG AAG GCT CTT TGT GGG TT 
CLTA1-5-3 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTC CTA GCG GGA ACT GGA AA 
CLTA1-5-4 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGG CTA ATG GGG TAG GGG AT 
CLTA1-5-5 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGT CCA TGT TGG CTG AGG TG 
CLTA1-6-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAG GCC AAC CTT GAC AAC TT 
CLTA4-0-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGC AGG CCA AAG ATG TCT CC 
CLTA4-3-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TCT GCT CTT GAG GTT ATT TGT CC 
CLTA4-3-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGG ACC AAT TTG CTA CTC ATG G 
CLTA4-3-3 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGG AGG CTG TAA ACG TCC TG 
CLTA4-3-4 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGC TAT GAT TTG CTG AAT TAC TCC T 
CLTA4-3-5 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GCA ATT TTG CAG ACC ACC ATC 
CLTA4-3-6 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGC AGC TTG CAA CCT TCT TG 
CLTA4-3-7 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TCA TGA GAG TTT CCC CAA CA 
CLTA4-4-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT ACT TGA GGG GGA AAA AGT TTC TTA 
CLTA4-4-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGG TCC CTG TCT GTC ATT GG 
CLTA4-4-3 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AAG CGA GTG ACT GTC TGG GA 
CLTA4-4-4 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAT GGG TGG GAC ACG TAG TT 
CLTA4-4-5 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGC TTT CCT GGA CAC CCT ATC 
CLTA4-4-6 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT AGA GCG AGG GAG CGA TGT A 
CLTA4-4-7 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTG TGG ACC ACT GCT TAG TGC 
CLTA4-4-8 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAA CTA CCC TGA GGC CAC C 
CLTA4-4-9 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGT CAG CAC TCC TCA GCT TT 
CLTA4-4-10 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TGG AGG ATG CAT GCC ACA TT 
Table 2.2 (Continued).  Oligonucleotides used in this study.   
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CLTA4-4-11 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CCC AGC CTC TTT GAC CCT TC 
CLTA4-4-12 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CCC ACA CCA GGC TGT AAG G 
CLTA4-4-13 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TAG ATA TAT GGG TGT GTC TGT ACG 
CLTA4-4-14 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTC CAA AGT GGC TGA ACC AT 
CLTA4-5-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CCC ACA GGG CTG ATG TTT CA 
CLTA4-5-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTG TAA TGC AAC CTC TGT CAT GC 
CLTA4-5-3 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CCA GCT CCA GCA ATC CAT GA 
CLTA4-5-4 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT TTT GGG AAA GAT AGC CCT GGA 
CLTA4-5-5 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAA TGA AAC AGC GGG GAG GT 
CLTA4-5-6 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT ACA ATC ACG TGT CCT TCA CT 
CLTA4-6-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT CAG ATC CCT CCT GGG CAA TG 
CLTA4-6-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GTC AGG AGG CAA GGA GGA AC 
CLTA4-6-3 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT ACT TCC TTC CTT TTG AGA CCA AGT 
CLTA4-7-1 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GCG GCA GAT TCC TGG TGA TT 
CLTA4-7-2 rev GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATCT GGT CAC CAT CAG CAC AGT CA 
PE1-barcode1 CAA GCA GAA GAC GGC ATA CGA GAT ATA TCA GTG TGA CTG GAG TTC AGA CGT GTG CT 
PE1-barcode2 CAA GCA GAA GAC GGC ATA CGA GAT TTT CAC CGG TGA CTG GAG TTC AGA CGT GTG CT 
PE1-barcode3 CAA GCA GAA GAC GGC ATA CGA GAT CCA CTC ATG TGA CTG GAG TTC AGA CGT GTG CT 
PE1-barcode4 CAA GCA GAA GAC GGC ATA CGA GAT TAC GTA CGG TGA CTG GAG TTC AGA CGT GTG CT 
PE1-barcode5 CAA GCA GAA GAC GGC ATA CGA GAT CGA AAC TCG TGA CTG GAG TTC AGA CGT GTG CT 
PE1-barcode6 CAA GCA GAA GAC GGC ATA CGA GAT ATC AGT ATG TGA CTG GAG TTC AGA CGT GTG CT 
PE2-barcode1 AAT GAT ACG GCG ACC ACC GAG ATC TAC ACA TTA CTC GAC ACT CTT TCC CTA CAC GAC  
PE2-barcode2 AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CCG GAG AAC ACT CTT TCC CTA CAC GAC  
PE2-barcode3 AAT GAT ACG GCG ACC ACC GAG ATC TAC ACC GCT CAT TAC ACT CTT TCC CTA CAC GAC  
Table 2.2 (Continued).  Oligonucleotides used in this study.  All oligonucleotides were 
purchased from Integrated DNA Technologies.  An asterisk (*) indicates that the preceding 
nucleotide was incorporated as a hand mix of phosphoramidites consisting of 79 mol% of the 
phosphoramidite corresponding to the preceding nucleotide and 4 mol% of each of the other 
three canonical phosphoramidites. “/5Phos/” denotes a 5’ phosphate group installed during 
synthesis. 
 
 
Expression and Purification of S. pyogenes Cas9 
E. coli Rosetta (DE3) cells were transformed with plasmid pMJ80611, encoding the S. 
pyogenes cas9 gene fused to an N-terminal 6xHis-tag/maltose binding protein.  The resulting 
expression strain was inoculated in Luria-Bertani (LB) broth containing 100 µg/mL of ampicillin 
and 30 µg/mL of chloramphenicol at 37 °C overnight.  The cells were diluted 1:100 into the 
same growth medium and grown at 37 °C to OD600 ~0.6.  The culture was incubated at 18 °C for 
30 min, and isopropyl β-D-1-thiogalactopyranoside (IPTG) was added at 0.2 mM to induce Cas9 
expression.  After ~17 h, the cells were collected by centrifugation at 8,000 g and resuspended in 
lysis buffer (20 mM tris(hydroxymethyl)-aminomethane (Tris)-HCl, pH 8.0, 1 M KCl, 20 % 
glycerol, 1 mM tris (2-carboxyethyl)phosphine (TCEP)).  The cells were lysed by sonication (10 
sec pulse-on and 30 sec pulse-off for 10 min total at 6 W output) and the soluble lysate was 
obtained by centrifugation at 20,000 g for 30 min.  The cell lysate was incubated with nickel-
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nitriloacetic acid (nickel-NTA) resin (Qiagen) at 4 °C for 20 min to capture His-tagged Cas9.  
The resin was transferred to a 20-mL column and washed with 20 column volumes of lysis 
buffer.  Cas9 was eluted in 20 mM Tris-HCl (pH 8), 0.1 M KCl, 20 % glycerol, 1 mM TCEP, 
and 250 mM imidazole, and concentrated by Amicon ultra centrifugal filter (Millipore, 30-kDa 
molecular weight cut-off) to ~50 mg/mL.  The 6xHis tag and maltose-binding protein were 
removed by TEV protease treatment at 4 °C for 20 h and captured by a second Ni-affinity 
purification step.  The eluent, containing Cas9, was injected into a HiTrap SP FF column (GE 
Healthcare) in purification buffer containing 20 mM Tris-HCl (pH 8), 0.1 M KCl, 20 % glycerol, 
and 1 mM TCEP.  Cas9 was eluted with purification buffer containing a linear KCl gradient 
from 0.1 M to 1 M over five column volumes.  The eluted Cas9 was further purified by a HiLoad 
Superdex 200 column in purifiation buffer, snap-frozen in liquid nitrogen, and stored in aliquots 
at -80 °C. 
 
In Vitro RNA Transcription 
100 pmol CLTA(#) v2.1 fwd and v2.1 template rev were incubated at 95 °C and cooled 
at 0.1 °C/s to 37 °C in NEBuffer2 (50 mM sodium chloride, 10 mM Tris-HCl, 10 mM 
magnesium chloride, 1 mM dithiothreitol, pH 7.9) supplemented with 10 µM dNTP mix (Bio-
Rad).  10 U of Klenow Fragment (3'→5' exo–) (NEB) were added to the reaction mixture and a 
double-stranded CLTA(#) v2.1 template was obtained by overlap extension for 1 h at 37 °C.  200 
nM CLTA(#) v2.1 template alone or 100 nM CLTA(#) template with 100 nM T7 promoter oligo 
was incubated overnight at 37 °C with 0.16 U/µL of T7 RNA Polymerase (NEB) in NEB 
RNAPol Buffer (40 mM Tris-HCl, pH 7.9, 6 mM magnesium chloride, 10 mM dithiothreitol, 2 
mM spermidine) supplemented with 1 mM rNTP mix (1 mM rATP, 1 mM rCTP, 1 mM rGTP, 1 
mM rUTP).  In vitro transcribed RNA was precipitated with ethanol and purified by gel 
electrophoresis on a Criterion 10% polyacrylamide TBE-Urea gel (Bio-Rad).  Gel-purified 
sgRNA was precipitated with ethanol and redissolved in water. 
 
In Vitro Library Construction 
 10 pmol of CLTA(#) lib oligonucleotides were separately circularized by incubation with 
100 units of CircLigase II ssDNA Ligase (Epicentre) in 1x CircLigase II Reaction Buffer (33 
mM Tris-acetate, 66 mM potassium acetate, 0.5 mM dithiothreitol, pH 7.5) supplemented with 
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2.5 mM manganese chloride in a total reaction volume of 20 µL for 16 hours at 60 °C.  The 
reaction mixture was incubated for 10 minutes at 85 °C to inactivate the enzyme.  5 µL (5 pmol) 
of the crude circular single-stranded DNA were converted into the concatemeric pre-selection 
libraries with the illustra TempliPhi Amplification Kit (GE Healthcare) according to the 
manufacturer’s protocol.  Concatemeric pre-selection libraries were quantified with the Quant-it 
PicoGreen dsDNA Assay Kit (Invitrogen). 
 
In Vitro Cleavage of On-Target and Off-Target Substrates 
Plasmid templates for PCR were constructed by ligation of annealed oligonucleotides 
CLTA(#) site fwd/rev into HindIII/XbaI double-digested pUC19 (NEB).  On-target substrate 
DNAs were generated by PCR with the plasmid templates and test fwd and test rev primers, then 
purified with the QIAquick PCR Purification Kit (Qiagen).  Off-target substrate DNAs were 
generated by primer extension. 100 pmol off-target (#) fwd and off-target (#) rev primers were 
incubated at 95 °C and cooled at 0.1 °C/s to 37 °C in NEBuffer2 (50 mM sodium chloride, 10 
mM Tris-HCl, 10 mM magnesium chloride, 1 mM dithiothreitol, pH 7.9) supplemented with 10 
µM dNTP mix (Bio-Rad).  10 U of Klenow Fragment (3'→5' exo-) (NEB) were added to the 
reaction mixture and double-stranded off-target templates were obtained by overlap extension for 
1 h at 37 °C  followed by enzyme inactivation for 20 min at 75 °C, then purified with the 
QIAquick PCR Purification Kit (Qiagen).  200 nM substrate DNAs were incubated with 100 nM 
Cas9 and 100 nM (v1.0 or v2.1) sgRNA or 1000 nM Cas9 and 1000 nM (v1.0 or v2.1) sgRNA in 
Cas9 cleavage buffer (200 mM HEPES, pH 7.5, 1.5 M potassium chloride, 100 mM magnesium 
chloride, 1 mM EDTA, 5 mM dithiothreitol) for 10 min at 37 °C.  On-target cleavage reactions 
were purified with the QIAquick PCR Purification Kit (Qiagen), and off-target cleavage 
reactions were purified with the QIAquick Nucleotide Removal Kit (Qiagen) before 
electrophoresis in a Criterion 5% polyacrylamide TBE gel (Bio-Rad). 
 
In Vitro Selection 
200 nM concatemeric pre-selection libraries were incubated with 100 nM Cas9 and 100 
nM sgRNA or 1000 nM Cas9 and 1000 nM sgRNA in Cas9 cleavage buffer (200 mM HEPES, 
pH 7.5, 1.5 M potassium chloride, 100 mM magnesium chloride, 1 mM EDTA, 5 mM 
dithiothreitol) for 10 min at 37 °C.  Pre-selection libraries were also separately incubated with 2 
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U of BspMI restriction endonuclease (NEB) in NEBuffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 
mM MgCl2, 1 mM dithiothreitol, pH 7.9) for 1 h at 37 °C.  Blunt-ended post-selection library 
members or sticky-ended pre-selection library members were purified with the QIAQuick PCR 
Purification Kit (Qiagen) and ligated to 10 pmol adapter1/2(AACA) (Cas9:v2.1 sgRNA, 100 
nM), adapter1/2(TTCA) (Cas9:v2.1 sgRNA, 1000 nM), adapter1/2 (Cas9:v2.1 sgRNA, 1000 
nM), or lib adapter1/CLTA(#) lib adapter 2 (pre-selection) with 1,000 U of T4 DNA Ligase 
(NEB) in NEB T4 DNA Ligase Reaction Buffer (50 mM Tris-HCl, pH 7.5, 10 mM magnesium 
chloride, 1 mM ATP, 10 mM dithiothreitol) overnight (> 10 h) at room temperature.  Adapter-
ligated DNA was purified with the QIAquick PCR Purification Kit and PCR-amplified for 10-13 
cycles with Phusion Hot Start Flex DNA Polymerase (NEB) in Buffer HF (NEB) and primers 
CLTA(#) sel PCR/PE2 short (post-selection) or CLTA(#) lib seq PCR/lib fwd PCR (pre-
selection).  Amplified DNAs were gel purified, quantified with the KAPA Library Quantification 
Kit-Illumina (KAPA Biosystems), and subjected to single-read sequencing on an Illumina MiSeq 
or Rapid Run single-read sequencing on an Illumina HiSeq 2500 (Harvard University FAS 
Center for Systems Biology Core facility, Cambridge, MA). 
 
Selection Analysis 
Pre-selection and post-selection sequencing data were analyzed as previously described21, 
with modification  using scripts written in C++.  Specificity scores were calculated with the 
formulae: positive specificity score = (frequency of base pair at position[post-selection] - 
frequency of base pair at position[pre-selection]) / (1 - frequency of base pair at position[pre-
selection]) and negative specificity score = (frequency of base pair at position[post-selection] - 
frequency of base pair at position[pre-selection]) / (frequency of base pair at position[pre-
selection]).  Normalization for sequence logos was performed as previously described22. 
 
Cellular Cleavage Assays 
HEK293T cells were split at a density of 0.8x105 per well (6-well plate) before 
transcription and maintained in Dulbecco’s modified eagle medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) in a 37°C humidified incubator with 5% CO2.  After 1 day, cells 
were transiently transfected using Lipofectamine 2000 (Invitrogen) following the manufacturer’s 
protocols. HEK293T cells were transfected at 70% confluency in each well of 6-well plate with 
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1.0 µg of the Cas9 expression plasmid (Cas9-HA-2xNLS-GFP-NLS) and 2.5 µg of the single-
strand RNA expression plasmid pSiliencer-CLTA (version 1.0 or 2.1). The transfection 
efficiencies were estimated to be ~70%, based on the fraction of GFP-positive cells observed by 
fluorescence microscopy.  48 h after transfection, cells were washed with phosphate buffered 
saline (PBS), pelleted and frozen at -80 °C.  Genomic DNA was isolated from 200 µL cell lysate 
using the DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer’s protocol. 
 
Off-Target Site Sequence Determination 
100 ng genomic DNA isolated from cells treated with Cas9 expression plasmid and 
single-strand RNA expression plasmid (treated cells) or Cas9 expression plasmid alone (control 
cells) were amplified by PCR with 10 s 72°C extension for 35 cycles with primers CLTA(#)-(#)-
(#) fwd and CLTA(#)-(#)-(#) rev and Phusion Hot Start Flex DNA Polymerase (NEB) in Buffer 
GC (NEB), supplemented with 3% DMSO.  Relative amounts of crude PCR products were 
quantified by gel, and Cas9-treated (control) and Cas9:sgRNA-treated PCRs were separately 
pooled in equimolar concentrations before purification with the QIAquick PCR Purification Kit 
(Qiagen). Purified DNA was amplified by PCR with primers PE1-barcode# and PE2-barcode# 
for 7 cycles with Phusion Hot Start Flex DNA Polymerase (NEB) in Buffer HF (NEB).  
Amplified control and treated DNA pools were purified with the QIAquick PCR Purification Kit 
(Qiagen), followed by purification with Agencourt AMPure XP (Beckman Coulter).  Purified 
control and treated DNAs were quantified with the KAPA Library Quantification Kit-Illumina 
(KAPA Biosystems), pooled in a 1:1 ratio, and subjected to paired-end sequencing on an 
Illumina MiSeq. 
 
Statistical Analysis 
Statistical analysis was performed as previously described21.  P-values from cellular off-
target modification assays were calculated for a one-sided Fisher exact test.   
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3.1  Introduction to specificity of RNA-guided Cas9 nucleases and nickases 
The recent development of robust, predictable, and user-friendly methods for the 
generation of sequence-specific DNA-binding proteins has led to a rapid expansion of the field 
of genome editing.  Today, user-defined site-specific genome modification has become a 
powerful tool in biological research,1,2 and holds significant potential to serve as the basis of a 
new generation of human therapeutics.3  One such programmable endonuclease system uses the 
CRISPR-derived Cas9 nuclease complexed with a guide RNA (gRNA) to target dsDNA 
sequences for cleavage.4 The gRNA programs Cas9 DNA cleavage specificity through ~17 to 20 
bp of complementarity between the gRNA and the target DNA sequence when complexed with 
Cas9.5  Provided that the target sequence is adjacent to a short 3’ motif, the protospacer adjacent 
motif (PAM) required for initial binding and Cas9 activation4 (Figure 3.1), any locus can in 
principle be targeted.   
 
Figure'3.1.''Architecture'of'Cas9.'!(a)!Cas9!protein!(yellow)!binds!to!target!DNA!in!complex!with!a!guide!RNA!(gRNA,!green).!!The!S.#pyogenes!Cas9!protein!recognizes!the!PAM!sequence!NGG!(blue),!initiating!unwinding!of!dsDNA!and!gRNA:DNA!base!pairing.!!Black!triangles!indicate!the!cleavage!points!three!bases!from!the!PAM!on!both!top!and!bottom!strands.!
 
In cells, Cas9:gRNA-induced double strand breaks can result in functional gene knockout 
through non-homologous end joining (NHEJ) or alteration of a target locus to virtually any 
sequence through homology-directed repair (HDR) with an exogenous DNA template.6–8  Cas9 is 
an especially convenient genome editing platform,9 as a genome editing agent for each new 
a Cas9 
gRNA 
PAM 
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target site of interest can be accessed by simply generating the corresponding gRNA. This 
approach has been widely used to create targeted knockouts and gene insertions in cells and 
model organisms, and has also been recognized for its potential therapeutic relevance. 
 
 While Cas9:gRNA systems provide an unprecedented level of programmability and ease 
of use, our group10 and others11–14 have reported the ability of Cas9 to cleave off-target genomic 
sites, resulting in modification of unintended loci that can limit the usefulness and safety of Cas9 
as a research tool and as a potential therapeutic.  We hypothesized that engineering Cas9 variants 
to cleave DNA only when two simultaneous, adjacent Cas9:DNA binding events take place 
could substantially improve genome editing specificity since the likelihood of two adjacent off-
target binding events is much smaller than the likelihood of a single off-target binding event 
(approximately 1/n2 vs. 1/n).  Such an approach is distinct from the recent development of 
mutant Cas9 proteins that cleave only a single strand of dsDNA (“nickases”).  Nickases can be 
used to nick opposite strands of two nearby target sites, generating what is effectively a double 
strand break, and paired Cas9 nickases can effect substantial on-target DNA modification with 
reduced off-target modification.5,14,15  Because each of the component Cas9 nickases remains 
catalytically active4,8,16 and single-stranded DNA cleavage events are weakly mutagenic,17,18 
nickases can induce genomic modification even when acting as monomers.7,14,19  Indeed, Cas9 
nickases have been previously reported to induce off-target modifications in cells.5,15  Moreover, 
since paired Cas9 nickases can efficiently induce dsDNA cleavage-derived modification events 
when bound up to ~100 bp apart,15 the statistical number of potential off-target sites for paired 
nickases is larger than that of a more spatially constrained dimeric Cas9 cleavage system. 
 
3.2  Screening and optimizing FokI-dCas9 architectures for genome modification 
To further improve the specificity of the Cas9:gRNA system, we sought to engineer an 
obligate dimeric Cas9 system analogous to previously developed dimeric zinc-finger nucleases 
(ZFNs) and TALENs.  These nucleases have been widely used as research tools in cell culture 
and in vivo20, and ZFNs are currently in clinical trials as potential human therapeutics.3  Based on 
ZFN and TALEN examples, we speculated that fusing the FokI restriction endonuclease 
cleavage domain to a catalytically dead Cas9 (dCas9) could create an obligate dimeric Cas9 that 
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would cleave DNA only when two distinct FokI-dCas9:gRNA complexes bind to adjacent sites 
(“half-sites”) with particular spacing constraints (Figure 3.2).   
 
Figure 3.2.  Architectures of FokI-dCas9 fusion.  Monomers of FokI nuclease (red) fused to 
dCas9 bind to separate sites within the target locus.  Only adjacently bound FokI-dCas9 
monomers can assemble a catalytically active FokI nuclease dimer, triggering dsDNA cleavage 
 
In contrast with Cas9 nickases, in which single-stranded DNA cleavage by monomers takes 
place independently, the DNA cleavage of FokI-dCas9 requires simultaneous binding of two 
distinct FokI-dCas9 monomers because monomeric FokI nuclease domains are not catalytically 
competent.21  In principle this approach should increase the specificity of DNA cleavage relative 
to wild-type Cas9 by doubling the number of specified target bases contributed by both 
monomers of the FokI-dCas9 dimer, and should also offer improved specificity compared to 
nickases due to inactivity of monomeric FokI-dCas9:gRNA complexes, and the more stringent 
spatial requirements for assembly of a FokI-dCas9 dimer. 
 While fusions of dCas9 to short functional peptide tags have been described to enable 
gRNA-programmed transcriptional regulation,22 no fusions of Cas9 with active enzyme domains 
have been previously reported to our knowledge.  Therefore we began by constructing and 
characterizing a wide variety of FokI-dCas9 fusion proteins with distinct configurations of a 
FokI nuclease domain, dCas9 containing inactivating mutations D10A and H840A, and a nuclear 
localization sequence (NLS).  We fused FokI to either the N- or C-terminus of dCas9, and varied 
the location of the NLS to be at either terminus or between the two domains (Figure 3.3).  
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Figure 3.3.  Architectures of FokI-dCas9 fusion variants.  FokI-dCas9 fusion architectures 
tested.  Four distinct configurations of NLS, FokI nuclease, and dCas9 were assembled.  17 
protein linker variants were also tested (see main text).   
We further varied the length of the linker sequence as either one or three repeats of Gly-Gly-Ser 
(GGS) between the FokI and dCas9 domains.  Since previously developed dimeric nuclease 
systems are sensitive to the length of the spacer sequence between half-sites,23,24 we also tested a 
wide range of spacer sequence lengths between two gRNA binding sites within a test target gene, 
Emerald GFP (referred to hereafter as GFP).  Two sets of gRNA binding-site pairs with different 
orientations were chosen within GFP (Figure 3.4). 
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Figure 3.4.  gRNA pairs targeting DNA sequences in a genomic GFP gene.  gRNA target 
sites tested within GFP.  Seven gRNA target sites were chosen to test FokI-dCas9 activity in an 
orientation in which the PAM is distal from the cleaved spacer sequence (orientation A).  
Together, these seven gRNAs enabled testing of FokI-dCas9 fusion variants across seven spacer 
lengths ranging from 5 to 43 bp. (b)  Seven gRNA target sites were chosen to test FokI-dCas9 
candidate activity in an orientation in which the PAM is adjacent from the cleaved spacer 
sequence (orientation B).  Together, these seven gRNAs enabled testing of FokI-dCas9 fusion 
variants across six spacer lengths ranging from 4 to 42 bp. 
One set placed the pair of NGG PAM sequences distal from the spacer sequence, with the 5’ end 
of the gRNA adjacent to the spacer (orientation A) (Figure 3.4), while the other placed the PAM 
sequences immediately adjacent to the spacer (orientation B) (Figure 3.4).   By pairwise 
combination of the gRNA targets, we tested seven and six spacer lengths in both dimer 
orientations, ranging from 5 to 43 bp in orientation A, and 4 to 42 bp in orientation B.  In total, 
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DNA constructs corresponding to 104 pairs of FokI-dCas9:gRNA complexes were generated and 
tested, exploring four fusion architectures, 17 protein linker variants (described below), both 
gRNA orientations and 13 spacer lengths between half-sites. 
 To assay the activities of these candidate FokI-dCas9:gRNA pairs, we used a previously 
described flow cytometry-based fluorescence assay5,12 in which DNA cleavage and NHEJ of a 
stably integrated constitutively expressed GFP gene in HEK293 cells leads to loss of cellular 
fluorescence (Figure 3.5).   
 
Figure 3.5.  GFP disruption assay for measuring genomic DNA-modification activity.  (a) A 
HEK293-derived cell line constitutively expressing a genomically integrated EmGFP gene was 
used to test the activity of candidate FokI-dCas9 fusion constructs.  Co-transfection of these cells 
with appropriate nuclease and gRNA expression plasmids leads to dsDNA cleavage within the 
EmGFP coding sequence, stimulating error-prone NHEJ and generating indels that can disrupt 
the expression of GFP, leading to loss of cellular fluorescence.  The fraction of cells displaying a 
loss of GFP fluorescence is then quantitated by flow cytometry.  (b) Typical epifluorescence 
microscopy images at 200x magnification of EmGFP-HEK293 cells before and after co-
transfection with wild-type Cas9 and gRNA expression plasmids. 
For comparison, we assayed the initial set of FokI-dCas9 variants side-by-side with the 
corresponding Cas9 nickases and wild-type Cas9 in the same expression plasmid across both 
gRNA spacer orientation sets A and B.  Cas9 protein variants and gRNA were generated in cells 
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by transient co-transfection of the corresponding Cas9 protein expression plasmids together with 
the appropriate pair of gRNA expression plasmids.  The FokI-dCas9 variants, nickases, and wild-
type Cas9 all targeted identical DNA sites using identical gRNAs.  
 Most of the initial FokI-dCas9 fusion variants were inactive or very weakly active.  The 
NLS-FokI-dCas9 architecture (listed from N to C terminus), however, resulted in a 10% increase 
of GFP-negative cells above corresponding the no-gRNA control when used in orientation A, 
with PAMs distal from the spacer (Figure 3.6).   
 
Figure 3.6.  Activities of FokI-dCas9 fusion candidates combined with gRNA pairs of 
different orientations and varying spacer lengths.  Activity of FokI-dCas9 fusion orientations 
in GFP disruption assay.  The fusion architectures described in Figure 3.3 were tested for 
functionality by flow cytometry using the GFP loss-of-function reporter across all (a) orientation 
A gRNA spacers and (b) orientation B gRNA spacers.  All FokI-dCas9 fusion data shown are the 
results of single trials.  Wild-type Cas9 and Cas9 nickase data are the average of two replicates, 
while the ‘no treatment’ negative control data is the average of 6 replicates, with error bars 
representing one standard deviation.  The gray dotted line across the Y-axis corresponds to the 
average of the ‘no treatment’ controls performed on the same day 
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In contrast, NLS-FokI-dCas9 activity was undetectable when used on gRNA pairs with PAMs 
adjacent to the spacer (Figure 3.6).  Examination of the recently reported Cas9 structures25,26 
reveals that the Cas9 N-terminus protrudes from the RuvCI domain, which contacts the 5’ end of 
the gRNA:DNA duplex.  We speculate that this arrangement places an N-terminally fused FokI 
distal from the PAM, resulting in a preference for gRNA pairs with PAMs distal from the 
cleaved spacer.  While other FokI-dCas9 fusion pairings and the other gRNA orientation in some 
cases showed modest activity (Figure 3.6), we chose NLS-FokI-dCas9 with gRNAs in 
orientation A for further development.  
 Next we optimized the protein linkers between the NLS and FokI domain, and between 
the FokI domain and dCas9 in the NLS-FokI-dCas9 architecture.  We tested 17 linkers with a 
wide range of amino acid compositions, predicted flexibilities, and lengths varying from 9 to 21 
residues (Figure 3.7).   
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Figure 3.7.  Optimization of protein linkers in NLS-FokI-dCas9.  (a)  All linker variants tested.  
Wild-type Cas9 and Cas9 nickase were included for comparison.  The initial active construct NLS-
FokI-dCas9 with a (GGS)3 linker between FokI and dCas9 was tested across a range of alternate 
linkers.  The final choice of linkers for fCas9 is highlighted in blue.  (b) The activity of FokI-
dCas9 fusions with linker variants.  Each variant was tested across a range of spacer lengths from 5 
to 43 bp using gRNA pair orientation A.  A control lacking gRNA (grey) was included for each 
separate fusion construct.  NLS-FokI-dCas9 variant L8 showed the best activity, approaching the 
activity of Cas9 nickase.  Variants L4 through L9 show peak activity with 14- and 25-bp spacer 
lengths, suggesting two optimal spacer lengths roughly one helical turn of dsDNA apart.   
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Between the FokI domain and dCas9 we identified a flexible 18-residue linker, (GGS)6, and a 
16-residue “XTEN” linker (FokI-L8 in Figure 3.7) based on a previously reported engineered 
protein with an open, extended conformation,27 as supporting the highest levels of genomic GFP 
modification (Figure 3.7).   
 The XTEN protein was originally designed to extend the serum half-life of translationally 
fused biologic drugs by increasing their hydrodynamic radius, acting as protein-based functional 
analog to chemical PEGylation. Possessing a chemically stable, non-cationic, and non-
hydrophobic primary sequence, and an extended conformation, we hypothesized that a portion of 
XTEN could functional as a stable, inert linker sequence for fusion proteins.  The sequence of 
the XTEN protein tag from E-XTEN was analyzed, and repeating motifs within the amino acid 
sequence were aligned.  The sequence used in the FokI-dCas9 fusion construct FokI-L8 (Figure 
3.7) was derived from the consensus sequence of a common E-XTEN motif, and a 16 amino acid 
sequence was chosen from within this motif to test as a FokI-dCas9 linker. 
Many of the FokI-dCas9 linkers tested including the optimal XTEN linker resulted in 
nucleases with a marked preference for spacer lengths of ~15 and ~25 bp between half-sites, 
with all other spacer lengths, including 20 bp, showing substantially lower activity (Figure 3.7).  
This pattern of linker preference is consistent with a model in which the FokI-dCas9 fusions 
must bind to opposite faces of the DNA double helix to cleave DNA, with optimal binding 
taking place ~1.5 or 2.5 helical turns apart.  The variation of NLS-FokI linkers did not strongly 
affect nuclease performance, especially when combined with the XTEN FokI-dCas9 linker 
(Figure 3.7).  In addition to assaying linkers between the FokI domain and dCas9 in the NLS-
FokI-dCas9 architecture, we also tested four linker variants between the N-terminal NLS and the 
FokI domain (Figure 3.7).  Although a NLS-GSAGSAAGSGEF-FokI-dCas9 linker exhibited 
nearly 2-fold better GFP gene modification than the other NLS-FokI linkers tested when a simple 
GGS linker was used between the FokI and dCas9 domains (Figure 3.7), the GSAGSAAGSGEF 
linker did not perform substantially better when combined with the XTEN linker between the 
FokI and dCas9 domains.   
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3.3  Characterizing the activity and specificity of FokI-dCas9 (fCas9)  
The NLS-GGS-FokI-XTEN-dCas9 construct consistently exhibited the highest activity 
among the tested candidates, inducing loss of GFP in ~15% of cells, compared to ~20% and 
~30% for Cas9 nickases and wild-type Cas9 nuclease, respectively (Figure 3.8). 
  
Figure 3.8.  Genomic DNA modification by fCas9, Cas9 nickase, and wild-type Cas9 at 
GFP target site.  (a) GFP disruption activity of fCas9, Cas9 nickase, or wild-type Cas9 with 
either no gRNA, or gRNA pairs of variable spacer length targeting the GFP gene in orientation 
A.  (b) Indel modification efficiency from PAGE analysis of a Surveyor cleavage assay of 
renatured target-site DNA amplified from cells treated with fCas9, Cas9 nickase, or wild-type 
Cas9 and two gRNAs spaced 14 bp apart targeting the GFP site (gRNAs G3 and G7), each 
gRNA individually, or no gRNAs.  The indel modification percentage is shown below each lane 
for samples with modification above the detection limit (~2%).  (c) Indel modification efficiency 
for (c) two pairs of gRNAs spaced 14 or 25bp apart targeting the GFP site. 
All subsequent experiments were performed using this construct, hereafter referred to as fCas9.  
To confirm the ability of fCas9 to efficiently modify genomic target sites, we used the T7 
endonuclease I Surveyor assay28 to measure the amount of mutation at each of seven target sites 
within the integrated GFP gene in HEK293 cells treated with fCas9, Cas9 nickase, or wild-type 
Cas9 and either two distinct gRNAs in orientation A or no gRNAs as a negative control.  
Consistent with our flow cytometry-based studies, fCas9 was able to modify the GFP target sites 
with optimal spacer lengths of ~15 or ~25 bp at a rate of ~20%, comparable to the efficiency of 
nickase-induced modification and approximately two-thirds that of wild-type Cas9 (Figure 3.8).  
 Next we evaluated the ability of the optimized fCas9 to modify four distinct endogenous 
genomic loci by Surveyor assay.  CLTA (two sites), EMX (two sites), HBB (six sites) VEGF 
(three sites), and were targeted with two gRNAs per site in orientation A spaced at various 
lengths (Figure 3.9).   
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Figure 3.9.  Target DNA sequences in endogenous human EMX, VEGF, CLTA, and HBB 
genes.  gRNA target sites tested within endogenous human EMX, VEGF, CLTA, and HBB genes.  
Thirteen gRNA target sites were chosen to test the activity of the optimized fCas9 fusion in an 
orientation in which the PAM is distal from the cleaved spacer sequence (orientation A).  
Together, these 13 gRNAs enabled testing of fCas9 fusion variants across eight spacer lengths 
ranging from 5 to 47 bp. 
Consistent with the results of the experiments targeting GFP, at appropriately spaced target half-
sites fCas9 induced efficient modification of all four genes, ranging from 8% to 22% target 
chromosomal site modification (Figure 3.10).   
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Spacer!(bp)!!
CLTA/1!
CCCCAAGTCTAGCAAGCAGGCCAAAGATGTCTCCCGCATGCGCTCAGTCCTCATCTCCCTCAAGCAGG!
CCCCAAGTCTAGCAAGCAGGCCA!(C1)!!!!!!!!!!!!!!!!!AGTCCTCATCTCCCTCAAGCAGG!(C2)!!!!!!!!!!!!!!!!!!!!!!!!!!22!
!
CLTA/2!
CCCTGTGGAAACACTACATCTGCAATATCTTAATCCTACTCAGTGAAGCTCTTCACAGTCATTGG!
CCCTGTGGAAACACTACATCTGC!(C3)!!!!!!!!!!!!!!GTGAAGCTCTTCACAGTCATTGG!(C4)!!!!!!!!!!!!!!!!!!!!!!!!!!!!!19!
!
HBC!
CCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATGAAGTTGGTGGTGAGGCCCTGGGCAGGTTGGTATCAAGGTTACAAGACAGGTTTAAGG!
CCGTTACTGCCCTGTGGGGCAAG(H1)!CGTGGATGAAGTTGGTGGTGGG!(H2)!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!5!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!TGAAGTTGGTGGTGAGGCCCTGG!(H3)!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!11!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!TTGGTGGTGAGGCCCTGGGCAGG!(H4)!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!16!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!TGGTGAGGCCCTGGGCAGGTTGG!(H5)!!!!!!!!!!!!!!!!!!!!!!!!!!!!20!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!CCCTGGGCAGGTTGGTATCAAGG!(H6)!!!!!!!!!!!!!!!!!!!!28!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!AAGGTTACAAGACAGGTTTAAGG!(H7)!47!
!
EMX!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
CCCTTCTTCTTCTGCTCGGACTCAGGCCCTTCCTCCTCCAGCTTCTGCCGTTTGTACTTTGTCCTCCGGTTCTGG!!!!!!!!!
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Figure 3.10.  Genomic DNA modification by fCas9, Cas9 nickase, and wild-type Cas9 at 
endogenous human genes.   Indel modification efficiency for (a) six pairs of gRNAs targeting 
the GFP site, (b) two pairs of gRNAs targeting the CLTA site, (c) two pairs of gRNAs targeting 
the EMX site (d) six pairs of gRNAs targeting the HBB site, and (e) three pairs of gRNAs 
targeting the VEGF site.  Error bars reflect standard error of the mean from three biological 
replicates performed on different days. 
 
Among the gRNA spacer lengths resulting in the highest modification at each of the five genes 
targeted (including GFP), fCas9 induced on average 15.6% (± 6.3% s.d.) modification, while 
Cas9 nickase and wild-type Cas9 induced on average 22.1% (± 4.9% s.d.) and 30.4% (± 3.1% 
s.d.) modification, respectively, from their optimal gRNA pairs for each gene.  Because 
decreasing the amount of Cas9 expression plasmid and gRNA expression plasmid during 
transfection generally did not proportionally decrease genomic modification activity for Cas9 
nickase and fCas9 (Figure 3.11), expression was likely not limiting under the conditions tested. 
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Figure 3.11.  Efficiency of genomic DNA modification by fCas9, Cas9 nickase, and wild-
type Cas9 with varying amounts of Cas9 and gRNA expression plasmids.  Indel modification 
efficiency from a Surveyor assay of renatured target-site DNA amplified from a population of 
cells treated with fCas9, Cas9 nickase, or wild-type Cas9 and two target site gRNAs.  Titrating 
the total amount of expression plasmids (Cas9 expression + gRNA expression plasmid), 
700/250, 350/125, 175/62.5, 88/31 ng of Cas9 expression plasmid/ng of gRNA expression 
plasmid were combined with inert carrier plasmid to ensure uniform transfection of 950 ng of 
plasmid across all treatments.  Indel modification efficiency for (a) gRNAs spaced 19-bp apart 
targeting the CLTA site, (b) gRNAs spaced 23 bp apart targeting the EMX site, and (c) gRNAs 
spaced 14 bp apart targeting the VEGF site.  Error bars represent the standard error of the mean 
from three biological replicates performed on separate days. 
 As the gRNA requirements of fCas9 potentially restricts the number of potential off-
target substrates of fCas9, we compared the effect of guide RNA orientation on the ability of 
fCas9, Cas9 nickase, and wild-type Cas9 to cleave target GFP sequences.  Consistent with 
previous reports,9,14,15 Cas9 nickase efficiently cleaved targets when guide RNAs were bound 
either in orientation A or orientation B, similar to wild-type Cas9 (Figure 3.12).  In contrast, 
fCas9 only cleaved the GFP target when guide RNAs were aligned in orientation A (Figure 
3.12).  This orientation requirement further limits opportunities for undesired off-target DNA 
cleavage. 
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Figure 3.12.  DNA modification of fCas9, Cas9 nickase, and wild-type Cas9 as function of 
gRNA spacer length and orientation.  (a) GFP gene disruption by wild-type Cas9, Cas9 
nickase, fCas9 using gRNA pairs in orientation A.  High activity of fCas9 requires spacer lengths 
of ~15 and 25 bp, roughly one DNA helical turn apart.  (b) GFP gene disruption using gRNA 
pairs in orientation B.  Cas9 nickase, but not fCas9, accepts either orientation of gRNA pairs.    
 
 Importantly, no modification was observed by GFP disruption or Surveyor assay when 
any of four single gRNAs were expressed individually with fCas9, as expected since two 
simultaneous binding events are required for FokI activity (Figure 3.8 and Figure 3.13).   In 
contrast, GFP disruption resulted from expression of any single gRNA with wild-type Cas9 (as 
expected) and, for two single gRNAs, with Cas9 nickase (Figure 3.13).   
Figure 3.13.  Ability of fCas9, Cas9 nickase, and wild-type Cas9 to disrupt GFP in the 
presence of a single gRNA.  GFP gene disruption by fCas9, but not Cas9 nickase or wild-type 
Cas9, depends on the presence of two gRNAs.  Four single gRNAs were tested along with three 
gRNA pairs of varying spacer length.  In the presence of gRNA pairs in orientation A with 
spacer lengths of 14 or 25 bp (gRNAs 1+5, and gRNAs 3+7, respectively), fCas9 is active, but 
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not when a gRNA pair with a 10-bp spacer (gRNAs 1+4) is used.  “no treatment” refers to cells 
receiving no plasmid DNA.  
 
Surprisingly, Surveyor assay revealed that although GFP was heavily modified by wild-type 
Cas9 with single gRNAs, neither fCas9 nor Cas9 nickase showed detectable modification 
(< ~2%) in cells treated with single gRNAs (Figure 3.14).   
 
Figure 3.14.  Ability of fCas9, Cas9 nickase, and wild-type Cas9 to modify genomic DNA in 
the presence of a single gRNA.  (a) Surveyor assay of a genomic GFP target from DNA of cells 
treated with the indicated combination of Cas9 protein and gRNA(s).  Single gRNAs do not 
induce genome modification at a detectable level (< 2% modification) for both fCas9 and Cas9 
nickase.  Wild-type Cas9 effectively modifies the GFP target for all tested single and paired 
gRNAs.  For both fCas9 and Cas9 nickase, appropriately paired gRNAs induce genome 
modification at levels comparable to those of wild-type Cas9.  (b) Results from sequencing GFP 
on-target sites amplified from 150 ng genomic DNA isolated from human cells treated with a 
plasmid expressing either wild-type Cas9, Cas9 nickase, or fCas9 and either a single plasmid 
expressing a single gRNAs (G1, G3, G5 or G7), or two plasmids each expressing a different 
gRNA (G1+G5, or G3+G7).  As a negative control, transfection and sequencing were performed 
in triplicate as above without any gRNA expression plasmids.  Error bars represent s.d.  
Sequences with more than one insertion or deletion at the GFP target site (the start of the G1 
binding site to the end of the G7 binding site) were considered indels.  Indel percentages were 
calculated by dividing the number of indels by total number of sequences.  While wild-type Cas9 
produced indels across all gRNA treatments, fCas9 and Cas9 nickase produced indels efficiently 
(> 1%) only when paired gRNAs were present.  Indels induced by fCas9 and single gRNAs were 
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not detected above the no-gRNA control, while Cas9 nickase and single gRNAs modified the 
target GFP sequence at an average rate of 0.12%.  
 
High-throughput sequencing to detect indels at the GFP target site in cells treated with a single 
gRNA and fCas9, Cas9 nickase, or wild-type Cas9 revealed the expected substantial level of 
modification by wild-type Cas9 (3-7% of sequence reads).  Modification by fCas9 in the 
presence of any of the four single gRNAs was not detected above background (< ~0.03% 
modification), consistent with the requirement of fCas9 to engage two gRNAs in order to cleave 
DNA.  In contrast, Cas9 nickases in the presence of single gRNAs resulted in modification levels 
ranging from 0.05% to 0.16% at the target site (Figure 3.14).  The detection of bona fide indels 
at target sites following Cas9 nickase treatment with single gRNAs confirms the mutagenic 
potential of genomic DNA nicking, consistent with previous reports.14,17–19   
 The observed rate of nickase-induced DNA modification, however, did not account for 
the much higher GFP disruption signal in the flow cytometry assay (Figure 3.13 and Figure 
3.14).  Since the gRNAs that induced GFP signal loss with Cas9 nickase (gRNAs G1 and G3) 
both target the non-template strand of the GFP gene, and since targeting the non-template strand 
with dCas9 in the coding region of a gene is known to mediate efficient transcriptional 
repression,29 we speculate that Cas9 nickase combined with the G1 or G3 single guide RNAs 
induced substantial transcriptional repression, in addition to a low level of genome modification.  
The same effect was not seen for fCas9, suggesting that fCas9 may be more easily displaced 
from DNA by transcriptional machinery.  Taken together, these results indicate that fCas9 can 
modify genomic DNA efficiently and in a manner that requires simultaneous engagement of two 
guide RNAs targeting adjacent sites, unlike the ability of wild-type Cas9 and Cas9 nickase to 
cleave DNA when bound to a single guide RNA. 
 The above results collectively reveal much more stringent spacer, gRNA orientation, and 
guide RNA pairing requirements for fCas9 (Figure 3.15) compared with Cas9 nickase (Figure 
3.10 and Figure 3.12).  In contrast with fCas9, Cas9 nickase cleaved sites across all spacers 
assayed (5- to 47- bp in orientation A and 4 to 42 bp in orientation B in this work).   
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Figure 13.15.  fCas9 indel frequency of genomic targets reflects gRNA pair spacer length 
preference.  The graph shows the relationship between spacer length (number of bp between 
two gRNAs) and the indel modification efficiency of fCas9 normalized to the indel modification 
efficiency of the same gRNAs co-expressed with wild-type Cas9 nuclease.  Colored triangles 
below the X-axis denote spacer lengths that were tested but which yielded no detectable indels 
for the indicated target gene.  These results suggest that fCas9 requires ~15 bp or ~25 bp 
between half-sites to efficiency cleave DNA.   
These observations are consistent with previous reports of Cas9 nickases modifying sites 
targeted by gRNAs with spacer lengths up to 100 bp apart.15  The more stringent spacer and 
gRNA orientation requirements of fCas9 compared with Cas9 nickase reduces the number of 
potential genomic off-target sites of the former by approximately 10-fold (Table 3.1).   
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Spacer length (b) 
 
Number of paired gRNA sites 
in orientation A 
Number of paired gRNA sites 
in orientation B 
-8 6874293 NC 
-7 6785996 NC 
-6 6984064 NC 
-5 7023260 NC 
-4 6487302 NC 
-3 6401348 NC 
-2 6981383 NC 
-1 7230098 NC 
0 7055143 NC 
1 6598582 NC 
2 6877046 NC 
3 6971447 NC 
4 6505614 5542549 
5 6098107 5663458 
6 6254974 6819289 
7 6680118 6061225 
8 7687598 5702252 
9 6755736 7306646 
10 6544849 6387485 
11 6918186 6172852 
12 6241723 5799496 
13 6233385 7092283 
14 6298717 7882433 
15 6181422 7472725 
16 6266909 6294684 
17 6647352 6825904 
18 6103603 6973590 
19 5896092 6349456 
20 6000683 5835825 
21 5858015 6056352 
22 6116108 6531913 
23 5991254 6941816 
24 6114969 6572849 
25 6135119 5671641 
b 
Cas9 variant Preferred spacer lengths (bp) Total sites 
fCas9  13 to 19, or 22 to 29, in orientation A 92354891 
Cas9 nickase 
-8 to 100 in orientation A 
4 to 42 in orientation B 953048977 
Table 3.1 (Continued).  Paired gRNA target site abundances for fCas9 and Cas9 nickase in 
the human genome.   
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Table 3.1 (Continued).  Paired gRNA target site abundances for fCas9 and Cas9 nickase in 
the human genome. (a) Column 2 shows the number of sites in the human genome with paired 
gRNA binding sites in orientation A allowing for a spacer length from -8 bp to 25 bp (column 1) 
between the two gRNA binding sites. gRNA binding sites in orientation A have the NGG PAM 
sequences distal from the spacer sequence (CCNN20-spacer-N20NGG).   Column 3 shows the 
number of sites in the human genome with paired gRNA binding sites in orientation B allowing 
for a spacer length from 4 to 25 bp (column 1) between the two gRNA binding sites.  gRNA 
binding sites in orientation B have the NGG PAM sequences adjacent to the spacer sequence 
(N20NGG spacer CCNN20) .  NC indicates the number of sites in the human genome was not 
calculated.  Negative spacer lengths refer to target gRNA binding sites that overlap by the 
indicated number of base pairs. (b) Sum of the number of paired gRNA binding sites in 
orientation A with spacer lengths of 13 to 19 bp, or 22 to 29 bp, the spacer preference of fCas9 
(Figure 3.15).  Sum of the number of paired gRNA binding sites with spacer lengths of -8 bp to 
100 bp in orientation A, or 4 to 42 bp in orientation B, the spacer preference of Cas9 nickases (4 
to 42 bp in orientation B is based on Figure 3.12, and -8 bp to 100 bp in orientation A is based 
on previous reports2,3).   
 !
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Although the more stringent spacer requirements of fCas9 also reduce the number of potential 
targetable sites, sequences that conform to the fCas9 spacer and dual PAM requirements exist in 
the human genome on average once every 34 bp (9.2 x 107 sites in 3.1 x 109 bp).  We also 
anticipate that the growing number of Cas9 homologs with different PAM specificities30 will 
further increase the number of targetable sites using the fCas9 approach. 
 To evaluate the DNA cleavage specificity of fCas9, we measured the modification of 
known Cas9 off-target sites of CLTA, EMX, and VEGF genomic target sites.5,10,12,15  The target 
site and its corresponding known off-target sites (Table 3.1) were amplified from genomic DNA 
isolated from HEK293 cells treated with fCas9, Cas9 nickase, or wild-type Cas9 and two gRNAs 
spaced 19 bp apart targeting the CLTA site, two gRNAs spaced 23 bp apart targeting the EMX 
site, two gRNAs spaced 14 bp apart targeting the VEGF site, or two gRNAs targeting an 
unrelated site (GFP) as a negative control.   
 
Genomic target site 
EMX_On GAGTCCGAGCAGAAGAAGAAGGG 
EMX_Off1 GAGgCCGAGCAGAAGAAagACGG 
EMX_Off2 GAGTCCtAGCAGgAGAAGAAGaG 
EMX_Off3 GAGTCtaAGCAGAAGAAGAAGaG 
EMX_Off4 GAGTtaGAGCAGAAGAAGAAAGG 
  
VEG_On GGGTGGGGGGAGTTTGCTCCTGG 
VEG_Off1 GGaTGGaGGGAGTTTGCTCCTGG 
VEG_Off2 GGGaGGGtGGAGTTTGCTCCTGG 
VEG_Off3 cGGgGGaGGGAGTTTGCTCCTGG 
VEG_Off4 GGGgaGGGGaAGTTTGCTCCTGG 
  
CLT2_On GCAGATGTAGTGTTTCCACAGGG 
CLT2_Off1 aCAaATGTAGTaTTTCCACAGGG 
CLT2_Off2 cCAGATGTAGTaTTcCCACAGGG 
CLT2_Off3 ctAGATGaAGTGcTTCCACATGG 
Table 3.2.  Known off-target substrates of Cas9 target sites in EMX, VEGF, and CLTA.  
List of genomic on-target and off-targets sites of the EMX, VEGF, and CLTA are shown with 
mutations from on-target in lower case and red.  PAMs are shown in blue. 
 
In total 11 off-target sites were analyzed by high-throughput sequencing. Sequences containing 
insertions or deletions of two or more base pairs in potential genomic off-target sites and present 
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in significantly greater numbers (P value < 0.005, Fisher’s exact test) in the target gRNA-treated 
samples versus the control gRNA-treated samples were considered Cas9 nuclease-induced 
genome modifications.  The sensitivity of the high-throughput sequencing method for detecting 
genomic off-target cleavage is limited by the amount genomic DNA (gDNA) input into the PCR 
amplification of each genomic target site.  A 1 ng sample of human gDNA represents only ~330 
unique genomes, and thus only ~330 unique copies of each genomic site are present.  PCR 
amplification for each genomic target was performed on a total of 150 ng of input gDNA, which 
provides amplicons derived from at most 50,000 unique gDNA copies.  Therefore, the high-
throughput sequencing assay cannot detect rare genome modification events that occur at a 
frequency of less than 1 in 50,000, or 0.002%. 
For 10 of the 11 off-target sites assayed, fCas9 did not result in any detectable genomic 
off-target modification within the sensitivity limit of our assay (< 0.002%), while demonstrating 
substantial on-target modification efficiencies of 5% to 10% (Figure 13.16 and Table 3.3). 
Figure 3.16.  DNA modification specificity of fCas9, Cas9 nickase, and wild-type Cas9. The 
indel mutation frequency from high-throughput DNA sequencing of amplified genomic on-target 
sites and off-target sites from human cells treated with fCas9, Cas9 nickase, or wild-type Cas9 
and (a) two gRNAs spaced 19 bp apart targeting the CLTA site (gRNAs C1 and C2), (b) two 
gRNAs spaced 23 bp apart targeting the EMX site (gRNAs E1 and E2), or (c, d) two gRNAs 
spaced 14 bp apart targeting the VEGF site (gRNAs V1 and V2). (d) Two in-depth trials to 
measure genome modification at VEGF off-target site 1.  Trial 1 used 150 ng of genomic input 
DNA and > 8 x 105 sequence reads for each sample; trial 2 used 600 ng of genomic input DNA 
and > 23 x 105 sequence reads for each sample.  All significant (P value < 0.005 Fisher’s Exact 
Test) indel frequencies are shown.  Each on- and off-target sample was sequenced once with > 
10,000 sequences analyzed per on-target sample and an average of 76,260 sequences analyzed 
per off-target sample.  
Cas9 nickase
!!
fCas9!
wild-type Cas9!
a! b!
0.01 
0.1 
1 
10 
100 
tar
ge
t s
ite
  
off
-ta
rge
t #
1 
off
-ta
rge
t #
2 
off
-ta
rge
t #
3 
off
-ta
rge
t #
4 
in
de
l m
od
ifc
at
io
n 
fre
qu
en
cy
 (%
) 
EMX 
Cas9 nickase
!!
fCas9!
wild-type Cas9!
0.01 
0.1 
1 
10 
100 
tar
ge
t s
ite
  
off
-ta
rge
t #
1 
off
-ta
rge
t #
2 
off
-ta
rge
t #
3 
off
-ta
rge
t #
4 
in
de
l m
od
ifc
at
io
n 
fre
qu
en
cy
 (%
) 
VEGF 
c!
Cas9 nickase
!!
fCas9!
wild-type Cas9!
0.01 
0.1 
1 
10 
100 
tar
ge
t s
ite
  
off
-ta
rge
t #
1 
off
-ta
rge
t #
2 
off
-ta
rge
t #
3 
in
de
l m
od
ifc
at
io
n 
fre
qu
en
cy
 (%
) 
CLTA 
0.01 
0.1 
trial 1 trial 2 
in
de
l m
od
ifi
ca
tio
n 
fre
qu
en
cy
 (%
) 
VEGF off-
target site 1 
Cas9 nickase!!
fCas9!
d!
! 152!
a 
Nuclease type: wt Cas9 wt Cas9 
Cas9  
nickase fCas9 wt Cas9 
Cas9  
nickase fCas9 
gRNA pair target: CLTA CLTA CLTA CLTA GFP GFP GFP 
Total expression 
plasmids (ng): 1000 125 1000 1000 1000 1000 1000 
CLTA Sites 
       CLT2_On 
       Indels 3528 1423 3400 575 3 13 5 
Total 10000 10000 10000 10000 10000 10000 10000 
Modified (%) 35.280 14.230 34.000 5.750 0.030 0.130 0.050 
P-value  <1.0E-300 <1.0E-300 <1.0E-300 1.4E-163 
   On:off specificity 1 1 
 
1 
   
        CLT2_Off1 
       Indels 316 44 2 2 1 3 3 
Total 60620 64755 71537 63079 93883 91306 82055 
Modified (%) 0.521 0.068 0.003 0.003 <0.002 0.003 0.004 
P-value  1.3E-126 2.1E-16     
   On:off specificity 68 209 
 
>2850 
   
        CLT2_Off2 
       Indels 11 5 3 1 1 1 2 
Total 72596 51093 59632 35541 69114 64412 39978 
Modified (%) 0.015 0.010 0.005 0.003 <0.002 <0.002 0.005 
P-value  6.5E-03       
   On:off specificity 2328 1454 
 
>2850 
   
        CLT2_Off3 
       Indels 11 10 0 0 1 1 1 
Total 52382 44212 54072 48668 55670 58707 54341 
Modified (%) 0.021 0.023 <0.002 <0.002 <0.002 <0.002 <0.002 
P-value  2.7E-03 3.5E-03     
   On:off specificity 1680 629  >2850    
Table 3.3 (Continued).  Cellular modification induced by wild-type Cas9, Cas9 nickase, and 
fCas9 at on-target and off-target genomic sites.'
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b 
Nuclease type: wt Cas9 wt Cas9 
Cas9  
nickase fCas9 wt Cas9 
Cas9  
nickase fCas9 
gRNA pair: EMX EMX EMX EMX GFP GFP GFP 
Total expression 
plasmids (ng): 1000 125 1000 1000 1000 1000 1000 
EMX Site 
       EMX_On 
       Indels 5111 2683 2267 522 0 0 2 
Total 10000 10000 10000 10000 10000 10000 10000 
Modified (%) 51.110 26.830 22.670 5.220 <0.002 <0.002 0.020 
P-value  <1.0E-300 <1.0E-300 <1.0E-300 1.0E-154 
   On:off specificity 1 1 1 1 
   
        EMX_Off1 
       Indels 386 122 7 1 4 9 7 
Total 109787 83420 124564 88424 102817 90020 96526 
Modified (%) 0.352 0.146 0.006 <0.002 0.004 0.010 0.007 
P-value  1.3E-103 2.8E-37     
   On:off specificity 145 183 >11222 >2584 
   
        EMX_Off2 
       Indels 74 58 3 6 3 0 4 
Total 98568 94108 105747 78871 81717 79469 79193 
Modified (%) 0.075 0.062 0.003 0.008 0.004 <0.002 0.005 
P-value  3.2E-16 1.4E-12     
   On:off specificity 681 435 >11222 >2584 
   
        EMX_Off3 
       Indels 736 178 20 14 12 11 17 
Total 72888 65139 82348 59593 74341 73408 75080 
Modified (%) 1.010 0.273 0.024 0.023 0.016 0.015 0.023 
P-value  2.5E-202 3.1E-44     
   On:off specificity 51 98 >11222 >2584 
   
        EMX_Off4 
       Indels 4149 620 3 3 6 7 5 
Total 107537 91695 91368 91605 111736 119643 128088 
Modified (%) 3.858 0.676 0.003 0.003 0.005 0.006 0.004 
P-value  <1.0E-300 1.9E-202     
   On:off specificity 13 40 >11222 >2584    
Table 3.3 (Continued).  Cellular modification induced by wild-type Cas9, Cas9 nickase, and 
fCas9 at on-target and off-target genomic sites.'
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c 
Nuclease type: wt Cas9 wt Cas9 
Cas9  
nickase fCas9 wt Cas9 
Cas9  
nickase fCas9 
gRNA pair: VEGF VEGF VEGF VEGF GFP GFP GFP 
Total expression 
plasmids (ng): 1000 125 1000 1000 1000 1000 1000 
VEGF Sites 
       VEG_On 
       Indels 5253 2454 1230 1041 8 0 1 
Total 10000 10000 10000 10000 10000 10000 10000 
Modified (%) 52.530 24.540 12.300 10.410 0.080 <0.002 0.010 
P-value  <1.0E-300 <1.0E-300 <1.0E-300 6.6E-286 
   On:off specificity 1 1 1 1 
   
        VEG_Off1 
       Indels 2950 603 22 0 0 4 1 
Total 82198 71163 90434 77557 74765 79738 74109 
Modified (%) 3.589 0.847 0.024 <0.002 <0.002 0.005 <0.002 
P-value  <1.0E-300 3.2E-188 2.5E-06   
   On:off specificity 15 29 506 >5150 
   
        VEG_Off2 
       Indels 863 72 3 3 0 2 1 
Total 102501 49836 119702 65107 54247 65753 61556 
Modified (%) 0.842 0.144 0.003 0.005 <0.002 0.003 <0.002 
P-value  3.5E-159 9.6E-24     
   On:off specificity 62 170 >6090 >5150 
   
        VEG_Off3 
       Indels 260 33 3 2 3 1 0 
Total 91277 83124 90063 84385 62126 68165 69811 
Modified (%) 0.285 0.040 0.003 0.002 0.005 <0.002 <0.002 
P-value  6.8E-54 1.0E-05     
   On:off specificity 184 618 >6090 >5150 
   
        VEG_Off4 
       Indels 1305 149 3 2 3 2 4 
Total 59827 41203 65964 57828 60906 61219 62162 
Modified (%) 2.181 0.362 0.005 0.003 0.005 0.003 0.006 
P-value  <1.0E-300 2.7E-54     
   On:off specificity 24 68 >6090 >5150    
Table 3.3 (Continued).  Cellular modification induced by wild-type Cas9, Cas9 nickase, and 
fCas9 at on-target and off-target genomic sites.'
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d 
Nuclease type: 
Cas9  
nickase fCas9 
Cas9  
nickase fCas9 
gRNA pair: VEGF VEGF GFP GFP 
Total expression 
plasmids (ng): 1000 1000 1000 1000 
VEGF Sites 
    VEG_On 
    Indels 2717 2122 10 13 
Total 10000 10000 10000 10000 
Modified (%) 27.170 21.220 0.100 0.130 
P-value  <1.0E-300 <1.0E-300 
  On:off specificity 1 1 
  
     VEG_Off1 
    Indels 67 30 3 2 
Total 302573 233567 204454 190240 
Modified (%) 0.022 0.013 
  P-value  5.9E-12 2.5E-06 
  On:off specificity 1227 1652 
  Table 3.3 (Continued).  Cellular modification induced by wild-type Cas9, Cas9 nickase, 
and fCas9 at on-target and off-target genomic sites.  (a) Results from sequencing CLTA on-
target and previously reported genomic off-target sites amplified from 150 ng genomic DNA 
isolated from human cells treated with a plasmid expressing either wild-type Cas9, Cas9 
nickase, or fCas9 and a single plasmid expressing two gRNAs targeting the CLTA on-target site 
(gRNA C3 and gRNA C4).  As a negative control, transfection and sequencing were performed 
as above, but using two gRNAs targeting the GFP gene on-target site (gRNA G1, G2 or G3 and 
gRNA G4, G5, G6 or G7.  Indels: the number of observed sequences containing insertions or 
deletions consistent with any of the three Cas9 nuclease-induced cleavage.  Total: total number 
of sequence counts while only the first 10,000 sequences were analyzed for the on-target site 
sequences.  Modified: number of indels divided by total number of sequences as percentages.  
Upper limits of potential modification were calculated for sites with no observed indels by 
assuming there is less than one indel then dividing by the total sequence count to arrive at an 
upper limit modification percentage, or taking the theoretical limit of detection (1/49,500), 
whichever value was larger.  P-values: For wild-type Cas9 nuclease, Cas9 nickase or fCas9 
nuclease, P-values were calculated as previously reported18 using a two-sided Fisher’s exact test 
between each sample treated with two gRNAs targeting the CLTA on-target site and the control 
sample treated with two gRNAs targeting the GFP on-target site.  P-values of < 0.0045 were 
considered significant and shown based on conservative multiple comparison correction using 
the Bonferroni method.  On:off specificity is the ratio of on-target to off-target genomic 
modification frequency for each site.  (b) Experimental and analytic methods as in (a) applied to 
EMX target sites using a single plasmid expressing two gRNAs targeting the EMX on-target site 
(gRNA E1 and gRNA E2).  (c) Experimental and analytic methods as in (a) applied to VEGF 
target sites using a single plasmid expressing two gRNAs targeting the VEGF on-target site 
(gRNA V1 and gRNA v2).   
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The detailed inspection of fCas9-modified VEGF on-target sequences (Figure 13.17) 
revealed a prevalence of deletions ranging from two to dozens of base pairs consistent with 
cleavage occurring in the DNA spacer between the two target binding sites, similar to the effects 
of FokI nuclease domains fused to zinc finger or TALE DNA-binding domains.31   
a  
 
Figure 3.17 (Continued).  Modifications induced by Cas9 nuclease, Cas9 nickases, or fCas9 
nucleases at endogenous loci.  
Wild%type*Cas9*nuclease*modifications*of*VEGF*on%target*site:**
4747*gctgtttgggaggtcagaaatagggggtCCAGGAGCAAACTCCCCCCACCCcctttccaaagcccATTCCCTCTTTAGCCAGAGCCGGggtgtgcagacggcagtc*(ref)*
4577*gctgtttgggaggtcagaaatagggggtccagga%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%agccggggtgtgcagacggcagtc*
**58*gctgtttgggaggtcagaaatagggggtccaggagcaaactccccccaccccctttccaaagcccattccctctttagc%%%%%%cggggtgtgcagacggcagtc*
**54*gctgtttgggaggtcagaaatagggggtccaggag%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%agccggggtgtgcagacggcagtc*
**43*gctgtttgggaggtcagaaatag%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%ccggggtgtgcagacggcagtc*
**33*gctgtttgggaggtcagaaatagggggtccaggagc%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%cggggtgtgcagacggcagtc*
**23*gctgtttgggaggtcagaaatagggggtccag%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%ccggggtgtgcagacggcagtc*
**22*gctgtttgggaggtcagaaatagggggtccaggagcaaactccccccaccccctttccaaagcccattccctctttagccag%%%%%%ggtgtgcagacggcagtc*
**18*gctgtttgggaggtcagaaatagggggtccagga%%%%%%%%%%%%%%%%%%%t%%%%%%%%%%%%%%%%%%%%%%%%%%%%agccggggtgtgcagacggcagtc*
*
Cas9*nickase*modifications*of*VEGF*on%target*site:**
8770*gctgtttgggaggtcagaaatagggggtCCAGGAGCAAACTCCCCCCACCCcctttccaaagcccATTCCCTCTTTAGCCAGAGCCGGggtgtgcagacggcagtc*(ref)*
**78*gctgtttgggaggtcagaaatagggggtccag%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%acggcagtc*
**60*gctgtttgggaggtcagaaatagggggtccaggagcaaactccccccaccccctttccaaagcc%%%%%%%%%%%%%%%%%%%%%%ggggtgtgcagacggcagtc*
**58*gctgtttgggaggtcagaaatagggggtcca%%%%%%%%%%%%%%%%%%%%%%%%%%%%aagcccattccctctttagccagagccggggtgtgcagacggcagtc*
**56*gctgtttgggaggtcagaaatagggggt%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%gtgcagacggcagtc*
**49*gctgtttgggaggtcagaaatagggggtccag%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%ccggggtgtgcagacggcagtc*
**37*gctgtttgggaggtcagaaatagggggtccagg%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%gtgtgcagacggcagtc*
**36*gctgtttgggaggtcagaaatagggggtccaggagc%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%cggggtgtgcagacggcagtc*
**27*gctgtttgggaggtcagaaatag%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%ccggggtgtgcagacggcagtc*
*
fCas9*nuclease*modifications*of*VEGF*on%target*site:**
8959*gctgtttgggaggtcagaaatagggggtCCAGGAGCAAACTCCCCCCACCCcctttccaaagcccATTCCCTCTTTAGCCAGAGCCGGggtgtgcagacggcagtc*(ref)*
*125*gctgtttgggaggtcagaaatagggggtccaggagcaaactcccccca%%%%%%%%%%%%agcccattccctctttagccagagccggggtgtgcagacggcagtc*
*121*gctgtttgggaggtcagaaatagggggtccaggagcaaactccccccaccccctt%%%%%%%%%%%ttccctctttagccagagccggggtgtgcagacggcagtc*
**77*gctgtttgggaggtcagaaatagggggtccaggagcaaactccccccaccccct%%%%%%%%%%%%ttccctctttagccagagccggggtgtgcagacggcagtc*
**73*gctgtttgggaggtcagaaatagggggtccaggagcaaactcccccca%%%%%%%%%%%%%gcccattccctctttagccagagccggggtgtgcagacggcagtc*
**48*gctgtttgggaggtcagaaatagggggtccaggagcaaactccccccaccccc%%%%%%%%%%%%attccctctttagccagagccggggtgtgcagacggcagtc*
**44*gctgtttgggaggtcagaaatagggggtccaggagcaaactccccccacccccttt%%%%%%%%%%%%%%%%%%%%agccagagccggggtgtgcagacggcagtc*
**24*gctgtttgggaggtcagaaatagggggtccaggagcaaactccccccacccccttt%%aaagcccattccctctttagccagagccggggtgtgcagacggcagtc*
**22*gctgtttgggaggtcagaaatagggggtccaggagcaaactccccc%%%%%%%%%%%%%aagcccattccctctttagccagagccggggtgtgcagacggcagtc*
**
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b 
Figure 3.17 (Continued).  Modifications induced by Cas9 nuclease, Cas9 nickases, or fCas9 
nucleases at endogenous loci.  (a) Examples of modified sequences at the VEGF on-target site 
with wild-type Cas9 nuclease, Cas9 nickases, or fCas9 nucleases and a single plasmid expressing 
two gRNAs targeting the VEGF on-target site (gRNA V1 and gRNA V2).  For each example 
shown, the unmodified genomic site is the first sequence, followed by the top eight sequences 
containing deletions.  The numbers before each sequence indicate sequencing counts. The gRNA 
target sites are bold and capitalized.  (b) Identical analysis as in (a) for VEGF off-target site 
1VEG_Off1.  (c) Potential binding mode of two gRNAs to VEGF off-target site 1.  The top 
strand is bound in a canonical mode, while the bottom strand binds the second gRNA, gRNA V2, 
through gRNA:DNA base pairing that includes G:U base pairs. 
 
 In contrast, genomic off-target DNA cleavage was observed for wild-type Cas9 at all 11 
sites assayed.  Using the detection limit of the assay as an upper bound for off-target fCas9 
activity, we calculated that fCas9 has a much lower off-target modification rate than wild-type 
Cas9 nuclease.  At the 11 off-target sites modified by wild-type Cas9 nuclease, fCas9 resulted in 
on-target:off-target modification ratios at least 140-fold higher than that of wild-type Cas9 
(Figure 13.16 and Table 3.3).   
 Consistent with previous reports,5,14,15 Cas9 nickase also induced substantially fewer off-
target modification events (1/11 off-target sites modified at a detectable rate) compared to wild-
type Cas9.  An initial high-throughput sequencing assay revealed significant (P value < 10-3, 
Fisher’s Exact Test) modification induced by Cas9 nickases in 0.024% of sequences at VEGF 
off-target site 1.  This genomic off-target site was not modified by fCas9 despite similar VEGF 
on-target modification efficiencies of 12.3% for Cas9 nickase and 10.4% for (Figure 13.16 and 
Table 3.3).   Because Cas9 nickase-induced modification levels were within an order of 
!
Wild&type!Cas9!nuclease!modifications!of!VEG_Off1:!
!79248!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccCCAGGAGCAAACTCCCtCCAtCCCacaaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!(ref)!
!!!800!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccagg&&caaactccctccatcccacaaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!239!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacacccca&&&&&&&&&&&&&&&&&tcccacaaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!155!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccag&&&caaactccctccatcccacaaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!90!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacacccca&&&&&&&&&&&&&&&&&&&&&&caaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!71!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacac&&&&&&&&&&&&&tccctccatcccacaaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!54!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacacccc&&&&&&&&&&&&&&tccatcccacaaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!53!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccagga&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&tgat!
!!!!47!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgac&&&&&&&&&&&&&&&tccctccatcccacaaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!
Cas9!nickase!modifications!of!VEG_Off1:!
302573!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccCCAGGAGCAAACTCCCtCCAtCCCacaaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!(ref)!
!!!!28!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccagga&&&&&c&&&&&&&&&&&&&&&&atccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!13!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgac&&&&&&&&&&&&&&&tccctccatcccacaaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!11!cattcaacagatacttactgaatgctaatgtctcagacaggacattctga&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&tccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!!4!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccagg&&ca&&&tc&&tg&atg&&acaaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!!2!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccaggagcaaactccctccatcccacaaatccgtccttagatgtgca—cccaacctcctaagaaatagaaggatgat!
!!!!!1!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccaggagcaaactccctccatcccacaaatccgtcctt&&atgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!!1!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccagga&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&tgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!!1!cattcaacagatacttactgaatgctaatgtctcagacaggacattctga&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&aatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!
fCas9!nuclease!modifications!of!VEG_Off1:!
233567!!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccCCAGGAGCAAACTCCCtCCAtCCCacaaatccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!(ref)!
!!!!!6!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccaggagcaaactccctcc&&&&&&&&&&&&&gtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!!5!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccaggagcaaactccctc&&&&&&&&&&&tccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!!4!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccaggagcaaactccctccat&&&&&&&&tccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!!3!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccaggagcaaactccctccatcccacaaatccgtccttagatgtgca&&cccaacctcctaagaaatagaaggatgat!
!!!!!3!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccaggagcaaactccctcc&&&&&&&&&&tccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!!2!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccaggagcaaactccctcc&&&&&&&&&atccgtccttagatgtgcacacccaacctcctaagaaatagaaggatgat!
!!!!!1!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccaggagcaaactccctccatcccacaaatccgtccttagatgtgcacaccc&&&&tcctaagaaatagaaggatgat!
!!!!!1!cattcaacagatacttactgaatgctaatgtctcagacaggacattctgacaccccaggagcaaactccctccatcccacaaatccgtcc&&agatgtgcacacccaacctcctaagaaatagaaggatgat!
!
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magnitude of the limit of detection and fCas9 modification levels were undetected, we repeated 
the experiment with a larger input DNA samples and a greater number of sequence reads (150 
versus 600 ng genomic DNA and > 8 x 105 versus > 23 x 105 reads for the initial and repeated 
experiments, respectively) to detect off-target cleavage at this site by Cas9 nickase or fCas9.   
From this deeper interrogation, we observed Cas9 nickase and fCas9 to both significantly modify 
(P value < 10-5, Fisher’s Exact Test) VEGF off-target site 1 (Figure 13.16 and Table 3.3).  For 
both experiments interrogating the modification rates at VEGF off-target site 1, fCas9 exhibited a 
greater on-target:off-target DNA modification ratio than that of Cas9 nickase (> 5,150 and 1,650 
for fCas9, versus 510 and 1,230 for Cas9 nickase, Figure 3g). 
On either side of VEGF off-target site 1 there exist no other sites with six or fewer 
mutations from either of the two half-sites of the VEGF on-target sequence.  We speculate that 
the first 11 bases of one gRNA (V2) might hybridize to the single-stranded DNA freed by 
canonical Cas9:gRNA binding within VEGF off-target site 1 (Figure 3.18).   
 
Figure 3.18.  Model for dimeric cleavage at VEGF off-target site 1.  Potential binding model of 
two gRNAs to VEGF off-target site 1.  The top strand is bound in a canonical mode, while the 
bottom strand binds the second gRNA, gRNA V2, through gRNA:DNA base pairing that includes 
G:U base pairs. 
 
!
!TCCTCGTTTGAGGGAGGTAGGG!
5’(AUUCCCUCUUU!AGCCAGAGC!
3’!PAM!
AGGAGCAAACTCCCTCCATCCC!
CCTCGTTTGAGGGGGGTGGGG(5’!
5’!
3’!
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Through this gRNA:DNA hybridization it is possible that a second Cas9 nickase or fCas9 could 
be recruited to modify this off-target site at a very low, but detectable level.  Judicious gRNA 
pair design could eliminate this potential mode of off-target DNA cleavage, as VEGF off-target 
site 1 is highly unusual in its ability to form 11 consecutive potential base pairs with the second 
gRNA of a pair.  In general, fCas9 was unable to modify the genomic off-target sites tested 
because of the absence of any adjacent second binding site required to dimerize and activate the 
FokI nuclease domain. 
 The optimized FokI-dCas9 fusion architecture developed in this work modified all five 
genomic loci targeted, demonstrating the generality of using fCas9 to induce genomic 
modification in human cells, although modification with fCas9 was somewhat less efficient than 
with wild-type Cas9.  The use of fCas9 is straightforward, requiring only that PAM sequences be 
present with an appropriate spacing and orientation, and using the same gRNAs as wild-type 
Cas9 or Cas9 nickases.  The observed low off-target:on-target modification ratios of fCas9, 
> 140-fold lower than that of wild-type Cas9, likely arises from the distinct mode of action of 
dimeric FokI, in which DNA cleavage proceeds only if two DNA sites are occupied 
simultaneously by two FokI domains at a specified distance (here, ~15 bp or ~25 bp apart) and in 
a specific half-site orientation.  The resulting unusually low off-target activity of fCas9 may 
enable applications of Cas9:gRNA-based technologies that require a very high degree of target 
specificity, such as ex vivo or in vivo therapeutic modification of human cells.   This work also 
provides a foundation for future studies to characterize in greater detail and further improve the 
DNA cleavage activity and specificity of fCas9 in vitro and in vivo.   
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3.4  Methods used to study FokI-dCas9 fusions 
 
Oligonucleotides and PCR 
 PCR was performed with 0.4 µL of 2 U/µL Phusion Hot Start Flex DNA polymerase 
(NEB) in 50 µL with 1x HF Buffer, 0.2 mM dNTP mix (0.2 mM dATP, 0.2 mM dCTP, 0.2 mM 
dGTP, 0.2 mM dTTP) (NEB), 0.5 µM of each primer and a program of: 98 ˚C, 1 min; 35 cycles 
of [98 ˚C, 15 s; 65 ˚C, 15 s; 72 ˚C, 30 s] unless otherwise noted.   All oligonucleotides were 
purchased from Integrated DNA Technologies (IDT).  Oligonucleotide sequences are listed in 
Table 3.4. 
dCas9-NLS-FokI primers: sequence 
Cas9_Exp_CNF_Fok1+Plas-
Fwd CGGCGAGATAAACTTTTAA TGACCGGTCATCATCACCA 
Cas9_Exp_CNF_Cas9coD10-
Rev CCAACGGAATTAGTGCCGATAGCTAAACCAATAGAATACTTTTTATC 
Cas9_Exp_CNF_Cas9coD10-
Fwd GATAAAAAGTATTCTATTGGTTTAGCTATCGGCACTAATTCCGTTGG 
Cas9_Exp_CNF_Cas9coH850-
Rev TTCAAAAAGGATTGGGGTACAATGGCATCGACGTCGTAATCAGATAAAC 
Cas9_Exp_CNF_Cas9coH850-
Fwd GTTTATCTGATTACGACGTCGATGCCATTGTACCCCAATCCTTTTTGAA 
Cas9_Exp_CNF_(Cas9)NLS+G
GS-Fok-Rev TTGGGATCCAGAACCTCCTCCTGCAGCCTTGTCATCG 
Cas9_Exp_CNF_(Cas9)NLS+G
GS3-Fok-Rev TTGGGATCCAGAACCTCC GCTGCCGCCACTTCCACCTGA TCCTGCAGCCTTGTCATCG 
Cas9_Exp_CNF_(Cas9)NLS+G
GS-Fok-Fwd CGATGACAAGGCTGCAGGAGGAGGTTCTGGATCCCAA 
Cas9_Exp_CNF_(Cas9)NLS+G
GS3-Fok-Fwd CGATGACAAGGCTGCAGGA TCAGGTGGAAGTGGCGGCAGC GGAGGTTCTGGATCCCAA 
Cas9_Exp_CNF_Fok1+Plas-
Rev TGGTGATGATGACCGGTCA TTAAAAGTTTATCTCGCCG 
NLS-dCas9-FokI primers: 
 Cas9_Exp_NCF_Fok1+Plas-
Fwd CGGCGAGATAAACTTTTAA TGACCGGTCATCATCACCA 
Cas9_Exp_NCF_PlasS+FLAG(
NLS-Fok1-Rev TAGGGAGAGCCGCCACCATGGACTACAAAGACCATGACGG 
Cas9_Exp_NCF_NLS 
+Cas9coD10-Rev TAAACCAATAGAATACTTTTTATC CATAGGTACCCCGCGGTGAATG 
Cas9_Exp_NCF_Cas9coD10-
Fwd GATAAAAAGTATTCTATTGGTTTAGCTATCGGCACTAATTCCGTTGG 
Cas9_Exp_NCF_Cas9coH850-
Rev TTCAAAAAGGATTGGGGTACAATGGCATCGACGTCGTAATCAGATAAAC 
Cas9_Exp_NCF_Cas9coH850-
Fwd GTTTATCTGATTACGACGTCGATGCCATTGTACCCCAATCCTTTTTGAA 
Cas9_Exp_NCF_Cas9End+GG
S-Fok-Rev TTGGGATCCAGAACCTCCGTCACCCCCAAGCTGTG 
Cas9_Exp_NCF_Cas9End+GG
S3-Fok-Rev TTGGGATCCAGAACCTCC GCTGCCGCCACTTCCACCTGA GTCACCCCCAAGCTGTG 
Cas9_Exp_NCF_Cas9End+GG
S-Fok-Fwd CACAGCTTGGGGGTGACGGAGGTTCTGGATCCCAA 
Cas9_Exp_NCF_Cas9End+GG
S3-Fok-Fwd CACAGCTTGGGGGTGAC TCAGGTGGAAGTGGCGGCAGC GGAGGTTCTGGATCCCAA 
Cas9_Exp_NCF_Fok1+Plas-
Rev TGGTGATGATGACCGGTCA TTAAAAGTTTATCTCGCCG 
FokI-dCas9-NLS primers: 
 Cas9_Exp_FCN_PlasS+Fok-
Fwd TAGGGAGAGCCGCCACCATGGGATCCCAACTAGTCAAAAG 
Table 3.4 (Continued).  Oligonucleotides used in this study.   
 
! 161!
Cas9_Exp_FCN_Fok1GGS+Ca
s-Rev ACCAATAGAATACTTTTTATCCATGCTGCCACCAAAGTTTATCTC 
Cas9_Exp_FCN_Fok1GGS3+C
as-Rev ACCAATAGAATACTTTTTATCCATGCTGCCGCCACTTCCACCTG 
Cas9_Exp_FCN_Cas9coD10-
Fwd GATAAAAAGTATTCTATTGGTTTAGCTATCGGCACTAATTCCGTTGG 
Cas9_Exp_FCN_Cas9coH850-
Rev CCAACGGAATTAGTGCCGATAGCTAAACCAATAGAATACTTTTTATC 
Cas9_Exp_FCN_Cas9coH850-
Fwd GTTTATCTGATTACGACGTCGATGCCATTGTACCCCAATCCTTTTTGAA 
Cas9_Exp_FCN_Cas9End+Pla
smidEn-Rev TGGTGATGATGACCGGTCA GTCACCCCCAAGCTGTG 
Cas9_Exp_FCN_Cas9End+Pla
smidEn-Fwd CACAGCTTGGGGGTGAC TGACCGGTCATCATCACCA 
Cas9_Exp_FCN_PlasS+Fok-
Rev CTTTTGACTAGTTGGGATCCCATGGTGGCGGCTCTCCCTA 
gRNA_G1-top ACACCCCTCGAACTTCACCTCGGCGG 
gRNA_G2-top ACACCGTCGCCCTCGAACTTCACCTG 
gRNA_G3-top ACACCCAGCTCGATGCGGTTCACCAG 
gRNA_G4-top ACACCGGTGAACCGCATCGAGCTGAG 
gRNA_G5-top ACACCGCTGAAGGGCATCGACTTCAG 
gRNA_G6-top ACACCGGCATCGACTTCAAGGAGGAG 
gRNA_G7-top ACACCCAAGGAGGACGGCAACATCCG 
gRNA_G8-top ACACCACCATCTTCTTCAAGGACGAG 
gRNA_G9-top ACACCCAACTACAAGACCCGCGCCGG 
gRNA_G10-top ACACCCCGCGCCGAGGTGAAGTTCGG 
gRNA_G11-top ACACCGAAGTTCGAGGGCGACACCCG 
gRNA_G12-top ACACCTTCGAACTTCACCTCGGCGCG 
gRNA_G13-top ACACCTCAGCTCGATGCGGTTCACCG 
gRNA_G14-top ACACCCGATGCCCTTCAGCTCGATGG 
gRNA_G1-bottom AAAACCGCCGAGGTGAAGTTCGAGGG 
gRNA_G2-bottom AAAACAGGTGAAGTTCGAGGGCGACG 
gRNA_G3-bottom AAAACTGGTGAACCGCATCGAGCTGG 
gRNA_G4-bottom AAAACTCAGCTCGATGCGGTTCACCG 
gRNA_G5-bottom AAAACTGAAGTCGATGCCCTTCAGCG 
gRNA_G6-bottom AAAACTCCTCCTTGAAGTCGATGCCG 
gRNA_G7-bottom AAAACGGATGTTGCCGTCCTCCTTGG 
gRNA_G8-bottom AAAACTCGTCCTTGAAGAAGATGGTG 
gRNA_G9-bottom AAAACCGGCGCGGGTCTTGTAGTTGG 
gRNA_G10-bottom AAAACCGAACTTCACCTCGGCGCGGG 
gRNA_G11-bottom AAAACGGGTGTCGCCCTCGAACTTCG 
gRNA_G12-bottom AAAACGCGCCGAGGTGAAGTTCGAAG 
gRNA_G13-bottom AAAACGGTGAACCGCATCGAGCTGAG 
gRNA_G14-bottom AAAACCATCGAGCTGAAGGGCATCGG 
gRNA_C1-top ACACCTGGCCTGCTTGCTAGACTTGG 
gRNA_C3-top ACACCGCAGATGTAGTGTTTCCACAG 
gRNA_H1-top ACACCCTTGCCCCACAGGGCAGTAAG 
gRNA_E1-top ACACCGAGTCCGAGCAGAAGAAGAAG 
gRNA_V1-top ACACCGGGTGGGGGGAGTTTGCTCCG 
Table 3.4 (Continued).  Oligonucleotides used in this study. 
! 162!
gRNA_C1-bottom AAAACCAAGTCTAGCAAGCAGGCCAG 
gRNA_C3-bottom AAAACTGTGGAAACACTACATCTGCG 
gRNA_H1-bottom AAAACTTCTTCTTCTGCTCGGACTCG 
gRNA_E1-bottom AAAACTTACTGCCCTGTGGGGCAAGG 
gRNA_V1-bottom AAAACGGAGCAAACTCCCCCCACCCG 
PCR_Pla-fwd  AGG AAA GAA CAT GTG AGC AAA AG 
PCR_Pla-rev CAGCGAGTCAGTGAGCGA 
PCR_gRNA-fwd1 CTGTACAAAAAAGCAGGCTTTA 
PCR_gRNA-rev1 AACGTAGGTCTCTACCGCTGTACAAAAAAGCAGGCTTTA 
PCR_gRNA-rev2  
AAAAAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAG
CTCTAAAAC 
PCR_gRNA_G1 TTGCTATTTCTAGCTCTAAAACCGCCGAGGTGAAGTTCGAGGGGTGTTTCGTCCTTTCCA 
PCR_gRNA_G2 TTGCTATTTCTAGCTCTAAAACAGGTGAAGTTCGAGGGCGACGGTGTTTCGTCCTTTCCA 
PCR_gRNA_G3 TTGCTATTTCTAGCTCTAAAACTGGTGAACCGCATCGAGCTGGGTGTTTCGTCCTTTCCA 
PCR_gRNA_G4 TTGCTATTTCTAGCTCTAAAACTCAGCTCGATGCGGTTCACCGGTGTTTCGTCCTTTCCA 
PCR_gRNA_G5 TTGCTATTTCTAGCTCTAAAACTGAAGTCGATGCCCTTCAGCGGTGTTTCGTCCTTTCCA 
PCR_gRNA_G6 TTGCTATTTCTAGCTCTAAAACTCCTCCTTGAAGTCGATGCCGGTGTTTCGTCCTTTCCA 
PCR_gRNA_G7 TTGCTATTTCTAGCTCTAAAACGGATGTTGCCGTCCTCCTTGGGTGTTTCGTCCTTTCCA 
PCR_gRNA_C2 TTGCTATTTCTAGCTCTAAAACGCTTGAGGGAGATGAGGACTGGTGTTTCGTCCTTTCCA 
PCR_gRNA_C4 TTGCTATTTCTAGCTCTAAAACATGACTGTGAAGAGCTTCACGGTGTTTCGTCCTTTCCA 
PCR_gRNA_E2 TTGCTATTTCTAGCTCTAAAACGAGGACAAAGTACAAACGGCGGTGTTTCGTCCTTTCCA 
PCR_gRNA_E3 TTGCTATTTCTAGCTCTAAAACGAACCGGAGGACAAAGTACAGGTGTTTCGTCCTTTCCA 
PCR_gRNA_H2 TTGCTATTTCTAGCTCTAAAACCACCACCAACTTCATCCACGGGTGTTTCGTCCTTTCCA 
PCR_gRNA_H3 TTGCTATTTCTAGCTCTAAAACGGGCCTCACCACCAACTTCAGGTGTTTCGTCCTTTCCA 
PCR_gRNA_H4 TTGCTATTTCTAGCTCTAAAACGCCCAGGGCCTCACCACCAAGGTGTTTCGTCCTTTCCA 
PCR_gRNA_H5 TTGCTATTTCTAGCTCTAAAACACCTGCCCAGGGCCTCACCAGGTGTTTCGTCCTTTCCA 
PCR_gRNA_H6 TTGCTATTTCTAGCTCTAAAACTGATACCAACCTGCCCAGGGGGTGTTTCGTCCTTTCCA 
PCR_gRNA_H7 TTGCTATTTCTAGCTCTAAAACTAAACCTGTCTTGTAACCTTGGTGTTTCGTCCTTTCCA 
PCR_gRNA_V2 TTGCTATTTCTAGCTCTAAAACGCTCTGGCTAAAGAGGGAATGGTGTTTCGTCCTTTCCA 
PCR_gRNA_V3 TTGCTATTTCTAGCTCTAAAACCGGCTCTGGCTAAAGAGGGAGGTGTTTCGTCCTTTCCA 
PCR_gRNA_V4 TTGCTATTTCTAGCTCTAAAACTCTGCACACCCCGGCTCTGGGGTGTTTCGTCCTTTCCA 
Survey_GFP-fwd TACGGCAAGCTGACCCTGAA 
Survey_GFP-rev GTCCATGCCGAGAGTGATCC 
Survye_CLTA-fwd GCCAGGGGCTGTTATCTTGG 
Survye_CLTA-rev ATGCACAGAAGCACAGGTTGA 
Survey_EMX-fwd CTGTGTCCTCTTCCTGCCCT 
Survey_EMX-rev CTCTCCGAGGAGAAGGCCAA 
Survey_HBB-fwd GGTAGACCACCAGCAGCCTA 
Survey_HBB-rev CAGTGCCAGAAGAGCCAAGG 
Survey_VEGF-fwd CCACACAGCTTCCCGTTCTC 
Survey_VEGF-rev GAGAGCCGTTCCCTCTTTGC 
Table 3.4 (Continued).  Oligonucleotides used in this study.   
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HTS_EXM_ON-fwd CCTCCCCATTGGCCTGCTTC 
HTS_EXM_Off1-fwd TCGTCCTGCTCTCACTTAGAC 
HTS_EXM_Off2-fwd TTTTGTGGCTTGGCCCCAGT 
HTS_EXM_Off3-fwd TGCAGTCTCATGACTTGGCCT 
HTS_EXM_Off4-fwd TTCTGAGGGCTGCTACCTGT 
HTS_VEFG_ON-fwd ACATGAAGCAACTCCAGTCCCA 
HTS_EXM_Off1-fwd AGCAGACCCACTGAGTCAACTG 
HTS_EXM_Off2-fwd CCCGCCACAGTCGTGTCAT 
HTS_EXM_Off3-fwd CGCCCCGGTACAAGGTGA 
HTS_EXM_Off4-fwd GTACCGTACATTGTAGGATGTTT 
HTS_CLTA2_ON-fwd CCTCATCTCCCTCAAGCAGGC 
HTS_CLTA2_Off1-fwd ATTCTGCTCTTGAGGTTATTTGT 
HTS_CLTA2_Off2-fwd CACCTCTGCCTCAAGAGCAGAAAA 
HTS_CLTA2_Off3-fwd TGTGTGTGTGTGTGTGTAGGACT 
HTS_EXM_ON-rev TCATCTGTGCCCCTCCCTCC 
HTS_EXM_Off-rev CGAGAAGGAGGTGCAGGAG 
HTS_EXM_Off-rev CGGGAGCTGTTCAGAGGCTG 
HTS_EXM_Off-rev CTCACCTGGGCGAGAAAGGT 
HTS_EXM_Off-rev AAAACTCAAAGAAATGCCCAATCA 
HTS_VEFG_ON-rev AGACGCTGCTCGCTCCATTC 
HTS_EXM_Off1-rev ACAGGCATGAATCACTGCACCT 
HTS_EXM_Off2-rev GCGGCAACTTCAGACAACCGA 
HTS_EXM_Off3-rev GACCCAGGGGCACCAGTT 
HTS_EXM_Off4-rev CTGCCTTCATTGCTTAAAAGTGGAT 
HTS_CLTA2_ON-rev ACAGTTGAAGGAAGGAAACATGC 
HTS_CLTA2_Off1-rev GCTGCATTTGCCCATTTCCA 
HTS_CLTA2_Off2-rev GTTGGGGGAGGAGGAGCTTAT 
HTS_CLTA2_Off3-rev CTAAGAGCTATAAGGGCAAATGACT 
Table 3.4 (Continued).  Oligonucleotides used in this study.  All oligonucleotides were 
purchased from Integrated DNA Technologies. ‘/5Phos/’ indicates 5’ phosphorylated 
oligonucleotides.  
 
 
Construction of FokI-dCas9, Cas9 Nickase and gRNA Expression Plasmids 
 The human codon-optimized streptococcus pyogenes Cas9 nuclease with NLS and 
3xFLAG tag (Addgene plasmid 43861)12 was used as the wild-type Cas9 expression plasmid.  
PCR (72 °C, 3 min) products of wild-type Cas9 expression plasmid as template with Cas9_Exp 
primers listed in Table 3.4 were assembled with Gibson Assembly Cloning Kit (New England 
Biolabs) to construct Cas9 and FokI-dCas9 variants.  Expression plasmids encoding a single 
gRNA construct (gRNA G1 through G13) were cloned as previously described.  Briefly, gRNA 
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oligonucleotides listed in Table 3.4 containing the 20-bp protospacer target sequence were 
annealed and the resulting 4-bp overhangs were ligated into BsmBI-digested gRNA expression 
plasmid.   gRNA expression plasmids encoding expression of two separate gRNA constructs 
from separate promoters on a single plasmid were cloned in a two-step process.  First, one gRNA 
(gRNA E1, V1, C1, C3, H1, G1, G2 or G3) was cloned as above and used as template for PCR 
(72 °C, 3 min) with PCR_Pla-fwd and PCR_Pla-rev primers, 1 µl DpnI (NEB) was added, and 
the reaction was incubated at 37 °C for 30 min and then subjected to QIAquick PCR Purification 
Kit (Qiagen) for the “1st gRNA + vector DNA”.   PCR (72 °C, 3 min) of 100 pg of BsmBI-
digested gRNA expression plasmid as template with PCR_gRNA-fwd1, PCR_gRNA-rev1, 
PCR_gRNA-rev2 and appropriate PCR_gRNA primer listed in Table 3.4 was DpnI treated and 
purified as above for the “2nd gRNA instert DNA”.  ~200 ng of “1st gRNA + vector DNA” and 
~200 ng of “2nd gRNA instert DNA” were blunt-end ligated in 1× T4 DNA Ligase Buffer, 1 µl of 
T4 DNA Ligase (400 U/µl, NEB) in a total volume of 20 µl at room temperature (~21 °C) for 15 
min.  For all cloning, 1 µl of ligation or assembly reaction was transformed into Mach1 
chemically competent cells (Life Technologies).  Protein and DNA sequences are listed in Table 
3.4.  FokI-dCas9 expression plasmids will be available from Addgene. 
 
Modification of Genomic GFP 
 HEK293-GFP stable cells (GenTarget) were used as a cell line constitutively expressing an 
Emerald GFP gene (GFP) integrated on the genome.  Cells were maintained in Dulbecco's 
modified Eagle medium (DMEM, Life Technologies) supplemented with 10% (vol/vol) fetal 
bovine serum (FBS, Life Technologies) and penicillin/streptomycin (1x, Amresco).  5 × 
104 HEK293-GFP cells were plated on 48-well collagen coated Biocoat plates (Becton 
Dickinson).  One day following plating, cells at ~75% confluence were transfected with 
Lipofecatmine 2000 (Life Technologies) according to the manufacturer’s protocol.  Briefly, 1.5 
µL of Lipofecatmine 2000 was used to transfect 950 ng of total plasmid (Cas9 expression 
plasmid plus gRNA expression plasmids).  700 ng of Cas9 expression plasmid, 125 ng of one 
gRNA expression plasmid and 125 ng of the paired gRNA expression plasmid with the pairs of 
targeted gRNAs.  Separate wells were transfected with 1 µg of a near-infrared iRFP670 
(Addgene plasmid 45457)32 as a transfection control.  3.5 days following transfection, cells were 
trypsinized and resuspended in DMEM supplemented with 10% FBS and analyzed on a C6 flow 
! 165!
cytometer (Accuri) with a 488 nm laser excitation and 520 nm filter with a 20 nm band pass.  For 
each sample, transfections and flow cytometry measurements were performed once. 
 
T7 Endonuclease I Surveyor Assays of Genomic Modifications 
 HEK293-GFP stable cells were transfected with Cas9 expression and gRNA expression 
plasmids as described above.  A single plasmid encoding two separate gRNAs was transfected.  
For experiments titrating the total amount of expression plasmids (Cas9 expression + gRNA 
expression plasmid), 700/250, 350/125, 175/62.5, 88/31 ng of Cas9 expression plasmid/ng of 
gRNA expression plasmid were combined with inert carrier plasmid, pUC19 (NEB), as 
necessary to reach a total of 950 ng transfected plasmid DNA.  
Genomic DNA was isolated from cells 2 days after transfection using a genomic DNA isolation 
kit, DNAdvance Kit (Agencourt).  Briefly, cells in a 48-well plate were incubated with 40 µL of 
tryspin for 5 min at 37 °C. 160 uL of DNAdvance lysis solution was added and the solution 
incubated for 2 hr at 55 °C and the subsequent steps in the Agencourt DNAdvance kit protocol 
were followed.  40 ng of isolated genomic DNA was used as template to PCR amplify the 
targeted genomic loci with flanking Survey primer pairs specified in the Table 3.4. PCR 
products were purified with a QIAquick PCR Purification Kit (Qiagen) and quantified with 
Quant-iT™ PicoGreen ® dsDNA Kit (Life Technologies).  250ng of purified PCR DNA was 
combined with 2 µL of NEBuffer 2 (NEB) in a total volume of 19 µL and denatured then re-
annealed with thermocycling at 95 ˚C for 5 min, 95 to 85 ˚C at 2 ˚C/s; 85 to 20 ˚C at 0.2 ˚C/s.   
The re-annealed DNA was incubated with 1 µl of T7 Endonuclease I (10 U/µl, NEB) at 37 °C 
for 15 min.  10 µL of 50% glycerol was added to the T7 Endonuclease reaction and 12 µL was 
analyzed on a 5% TBE 18-well Criterion PAGE gel (Bio-Rad) electrophoresed for 30 min at 150 
V, then stained with 1x SYBR Gold (Life Technologies) for 30 min.  Cas9-induced cleavage 
bands and the uncleaved band were visualized on an AlphaImager HP (Alpha Innotech) and 
quantified using ImageJ software.33  The peak intensities of the cleaved bands were divided by 
the total intensity of all bands (uncleaved + cleaved bands) to determine the fraction cleaved 
which was used to estimate gene modification levels as previously described.28  For each sample, 
transfections and subsequent modification measurements were performed in triplicate on 
different days. 
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High-throughput Sequencing of Genomic Modifications 
 HEK293-GFP stable cells were transfected with Cas9 expression and gRNA expression 
plasmids, 700 ng of Cas9 expression plasmid plus 250 ng of a single plasmid expression a pair of 
gRNAs were transfected (high levels) and for just Cas9 nuclease, 88 ng of Cas9 expression 
plasmid plus 31 ng of a single plasmid expression a pair of gRNAs were transfected (low levels).  
Genomic DNA was isolated as above and pooled from three biological replicates.  150 ng or 600 
ng of pooled genomic DNA was used as template to amplify by PCR the on-target and off-target 
genomic sites with flanking HTS primer pairs specified in the Table 3.4.  Relative amounts of 
crude PCR products were quantified by gel electrophoresis and samples treated with different 
gRNA pairs or Cas9 nuclease types were separately pooled in equimolar concentrations before 
purification with the QIAquick PCR Purification Kit (Qiagen). ~500 ng of pooled DNA was run 
a 5% TBE 18-well Criterion PAGE gel (BioRad) for 30 min at 200 V and DNAs of length ~125 
bp to ~300 bp were isolated and purified by QIAquick PCR Purification Kit (Qiagen).  Purified 
DNA was PCR amplified with primers containing sequencing adaptors, purified and sequenced 
on a MiSeq high-throughput DNA sequencer (Illumina) as described previously.10  
 
Data Analysis  
 Illumina sequencing reads were filtered and parsed with scripts written in Unix Bash as 
outlined in Table 3.4.  DNA sequences will be deposited in NCBI’s Sequencing Reads Archive 
(SRA) and source code can be found in Supplementary Software.  Sample sizes for sequencing 
experiments were maximized (within practical experimental considerations) to ensure greatest 
power to detect effects.  Statistical analyses for Cas9-modified genomic sites were performed as 
previously described34 with multiple comparison correction using the Bonferroni method.  
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